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Abstract 
Postoperative insulin resistance (POIR) is a hallmark feature in patients having major 
abdominal surgery. Surgical stress may induce changes in metabolic pathways that perturb 
glucose homeostasis, resulting in stress hyperglycaemia. The studies described in the 
present thesis set out to examine the evidence behind (1) ƚŚĞ  ‘ŶŚĂŶĐĞĚZĞĐŽǀĞƌǇĨƚĞƌ
^ƵƌŐĞƌǇ ? ƉĂƚŚǁĂǇ(2) preoperative carbohydrate drinks, in attenuating the surgical stress 
response and (3) to investigate the mechanistic basis of metabolic response to surgery and 
the development of postoperative insulin resistance in patients having major abdominal 
surgery.  
Meta-analysis of randomised studies in patients having major abdominal surgery showed 
that ERAS pathway was associated with a significant reduction in length of hospital stay 
and postoperative complications. Meta-analysis of randomised studies using preoperative 
CHO was also associated with reduced length of stay and decreased POIR in support of 
reduced fasting times and preoperative carbohydrate drinks (CHO), before surgery.  
The study in patients having major abdominal surgery showed that surgical trauma was 
associated with increased skeletal muscle interleukin-6 and pyruvate dehydrogenase 
kinase isoform-4 (PDK4) mRNA and protein expression. Increased PDK4 was associated 
with a concomitant reduction in pyruvate dehydrogenase complex (PDC) activity that 
controls the rate of muscle carbohydrate oxidation in mitochondria, and contributed to 
impaired glucose tolerance and decreased mitochondrial ATP production postoperatively.  
One hypothesis is that by maximising the contribution of carbohydrate derived oxidative 
ATP regeneration by activating the PDC with the synthetic PDK4 inhibitor dichloroacetate 
(DCA) and/or by increasing muscle glucose uptake using preoperative oral carbohydrates 
(CHO) may reverse the changes in carbohydrate oxidation seen postoperatively. The results 
from the study showed that administration of either CHO or CHO with DCA attenuates the 
impairment of CHO oxidation and the development of POIR, induced by surgical stress. 
Furthermore, DCA increased mitochondrial CHO oxidation above that achieved by CHO 
alone, which waned by 48 hours after surgery. 
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 ?/ƚ ?ƐŶŽƚƐƚƌĞƐƐƚŚĂƚŬŝůůƐƵƐ ?ŝƚŝƐŽƵƌƌĞĂĐƚŝŽŶƚŽŝƚ ? ?Hans Selye  
For most patients, undergoing major surgery can be a stressful and an overwhelming 
event. The stress response to surgery is characterised by autonomic, hormonal, and 
ŵĞƚĂďŽůŝĐĐŚĂŶŐĞƐƚŚĂƚĨŽůůŽǁŝŶũƵƌǇŽƌƚƌĂƵŵĂ ?dŚĞ ‘ƐƵƌŐŝĐĂůƐƚƌĞƐƐƌĞƐƉŽŶƐĞ ?ŵĂŶŝĨĞƐƚƐ
itself in the postoperative period, as a syndrome of hypermetabolism, a hyperdynamic 
cardiovascular state and inflammation (Bone et al, 1992). Besides the surgical stress and 
the consequent changes in carbohydrate and protein metabolism, the patients have to 
deal with the fear, fatigue and pain of undergoing surgery, which have a major impact on 
recovery and delays return to their pre-surgical functional state. Moreover, perioperative 
care is not standardised with existing variations in clinical practice between different 
hospitals, professionals and countries, which ĐŽŵƉůŝĐĂƚĞ ƚŚĞ ƉĂƚŝĞŶƚ ?Ɛ ũŽƵƌŶĞǇ ƚŚƌŽƵŐŚ
surgery.  
Post-operative insulin resistance (POIR), a state in which the peripheral tissues are 
rendered less responsive to the glucose-lowering, antilipolytic and anabolic properties of 
the insulin, is central to the metabolic response following surgery. The resultant 
hyperglycaemia secondary to the surgical stress labelled ĂƐ  ‘ƐƚƌĞƐƐ ŚǇƉĞƌŐůǇĐaĞŵŝĂ ?
(Thorell et al., 1999b), contributes to increased postoperative morbidity, length of stay 
and prolonged recovery (Thorell et al., 1999b, van den Berghe et al., 2001, Jackson et al., 
2012). Evidence from studies in burns injury (Gore et al., 2001), trauma (Laird et al., 2004, 
Sung et al., 2005, Jeschke et al., 2004), and critically ill patients (Bochicchio et al., 2005, 
Pittas et al., 2004), show a causal relationship between hyperglycaemia and increased 
morbidity and mortality. By maintaining euglycaemia, significant clinical benefits of 
reduction in mortality by 43%, intensive care stay, ventilator support and reduced risk of 
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infections by 36%, have been reported in this group of patients (Van den Berghe et al., 
2006, Finfer et al., 2009). However, the underlying mechanisms that contribute to POIR, 
are less well defined in patients having major surgery.  
POIR could be attributed partly, to the metabolic response to surgery, described by 
Cuthbertson (Cuthbertson, 1932). The metabolic response to surgery is a complex, 
integrated series of events that occur, both, locally at the site of injury and within the 
body. The mechanism has probably evolved to mobilise substrates needed for organ 
function and tissue repair and to aid recovery. However, additional factors such as 
magnitude of surgery and infection can modify the metabolic response and could 
potentially lead to a catabolic state and further organ damage. Therefore, a major goal of 
modern surgery is to minimise this surgical stress induced alterations to physiological 
functions and to restore the body to its pre-injury state in order to shorten recovery 
times. 
In an attempt to attenuate the surgical stress response in patients having surgery, the 
 ‘ŶŚĂŶĐĞĚ ZĞĐŽǀĞƌǇ ĨƚĞƌ ^ƵƌŐĞƌǇ ? (ERAS) Society published an evidence based 
consensus protocol in 2009 (Lassen et al., 2009a). The protocol combined several 
perioperative treatment strategies such as preoperative carbohydrate drinks, avoidance 
of prolonged fasting, etc. that were individually evaluated in randomised controlled 
studies and reported clinical benefits of reduced complications and length of hospital 
stay.  
Therefore, measures to reduce surgical stress and the mechanisms underlying the 
development of POIR are of major clinical interest to improve clinical outcomes and to 
enhance recovery after surgery.  
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In this introductory chapter, the principles of the ERAS protocol that is reported to 
enhance recovery in surgical patients will be reviewed. Subsequently, the effect of 
surgical stress and the metabolic response to injury along with the changes in insulin 
signalling mechanisms that are involved in the development of POIR will be discussed 
which will lead to the development of the hypothesis and aims of this present research 
work.  
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1.1 Enhanced Recovery After Surgery (ERAS)  
Over the last few decades, surgical care has improved immensely with advancement of 
knowledge, and in systems of care delivery to ensure that optimal treatment is provided 
to the critically ill surgical patient. The ERAS protocol was designed to address the 
ĂĨŽƌĞŵĞŶƚŝŽŶĞĚƉĞƌŝŽƉĞƌĂƚŝǀĞŝƐƐƵĞƐĂŶĚĐŽŵďŝŶĞƐƚŚĞƉƌŝŶĐŝƉůĞƐŽĨ ‘ŵƵůƚŝŵŽĚĂůƐƵƌŐŝĐĂů
ĐĂƌĞ ? ? ŽƌŝŐŝŶĂůůǇ ƉŝŽŶĞĞƌĞĚ ďǇ ,Ğnrik Kehlet (Kehlet, 1997). ERAS comprises a series of 
perioperative interventions such as reduced fasting and preoperative carbohydrate 
drinks, epidural anaesthesia, early enteral nutrition, etc., (Fig 1.1 & Tables 1,2,3) that 
when implemented together could lead to a major reduction in the risk of complications, 
length of hospital stay and development of POIR (Thorell et al., 1999b). Studies, including 
randomised controlled trials that reported clinical benefits of these interventions such as 
reduced risk of postoperative complications and length of hospital stay, were examined 
and the validity of these perioperative interventions were appraised with the efforts of 
ƚŚĞ  ‘Z^ ŐƌŽƵƉ ? ?  ?ůĂƚĞƌ ŬŶŽǁŶ ĂƐ ƚŚĞ Z^ ƐŽĐŝĞƚǇ ? ? ǁŚŝĐŚ ƉƵďůŝƐŚĞĚ the common 
consensus guidelines in 2005 (Fearon et al., 2005). From accumulating evidence from 
several randomised controlled trials of the benefits of individual elements of 
perioperative care, the ERAS society published an updated evidence-based consensus 
protocol in 2009, which marked a paradigm shift in perioperative care, when ERAS 
protocols were originally used in colorectal surgery, extended to gynaecological, 
orthopaedic and urological surgery, subsequently (Lassen et al., 2009a).  
Thus, the ERAS protocol comprises a multidisciplinary, evidence-based approach to 
perioperative care, that is designed to attenuate the stress response to major surgery, to 
facilitate the maintenance of preoperative body compositions and organ functions and in 
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doing so, achieve early recovery. The principles of ERAS rest on the concepts of patient 
ĞĚƵĐĂƚŝŽŶ ? ‘ƉƌĞ-ŚĂďŝůŝƚĂƚŝŽŶ ?of patients including information and counselling, metabolic 
preparation with pre-operative carbohydrate treatment and nutritional supplements; 
intra-operative strategies to minimise surgical stress such as thoracic epidural analgesia, 
minimally invasive or careful choice of operative technique, goal-directed fluid therapy, 
post-operative rehabilitation such as early enteral feeding, early mobilisation, avoidance 
of opioids, attainment of pre-agreed milestones and discharge criteria (Fig 1.1). In this 
regard, it was suggested that the ERAS elements such as avoidance of pre-operative 
fasting and allowing patients carbohydrate drinks up to 2 hours before surgery reduces 
the surgical stress response and enabled the patient to undergo surgery in a 
 ‘ŵĞƚĂďŽůŝĐĂůůǇĨĞĚ ?ƐƚĂƚĞ ? 
 
Figure 1.1: Philosophy of ERAS [Varadhan et al. Crit Care Clin 26 (2010) 527 W547]. The principle 
objectives of ERAS protocol are, to modulate inflammation and the immune response, 
attenuating the hypermetabolic response to surgery, optimizing glucose control, and providing 
nutritional support to enhance recovery. 
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1.2. Components of ERAS 
Most of the ERAS interventions in Figure 1.2 are derived from existing high quality 
evidence, whilst the other less studied elements are put together from common 
consensus opinion or from a traditional-care setting. The rationale for incorporating 
these elements in the ERAS pathway and the summary of recommendations for 
ŝŶĚŝǀŝĚƵĂů ĞůĞŵĞŶƚƐ ?ǁŝƚŚ ƚŚĞ ŐƌĂĚĞƐ ŽĨĞǀŝĚĞŶĐĞ ĂĐĐŽƌĚŝŶŐ ƚŽ ƚŚĞ  ‘Centre for Evidence 
ĂƐĞĚDĞĚŝĐŝŶĞ ? ?KǆĨŽƌĚ ?ŶŐůĂŶĚ ?ĂƌĞŝůůƵƐƚƌĂƚĞĚŝŶdĂďůĞƐ ? W3.  
 
Figure 1.2: Philosophy of ERAS [Varadhan et al. Crit Care Clin 26 (2010) 527 W547] (Adapted from 
Enhanced recovery after surgery: A consensus review of clinical care for patients undergoing 
colonic resection. Fearon et al. Clinical Nutrition (2005) 24, 466-477) 
Table 1.1 shows ERAS elements that are instituted in the preoperative period, whereas 
Tables 1.2 and 1.3 illustrate the elements that form the ERAS pathway in the intra- and 
postoperative periods, respectively.  
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Table 1.1: Summary of recommendations: Preoperative interventions of ERAS 
 
Preoperative 
elements 
Rationale Recommendations 
(Note: * indicates that 
recommendation is an ERAS-
consensus statement based 
on available evidence) 
 
Le
v
e
l 
o
f 
e
v
id
e
n
ce
 
Preadmission 
information and 
counselling 
Preadmission counselling ensures a clear understanding of 
the intended perioperative care to be received with 
emphasis on attaining specific pre-set targets, would help 
in alleviating the stress responses to surgery (Blazeby et 
al., 2009, Egbert et al., 1964, Disbrow et al., 1993, Klafta 
and Roizen, 1996, Mahomed et al., 2002) 
Oral & written patient Information 
regarding hospitalization, pain relief, 
achieving postoperative targets such 
as early nutrition, mobilization and 
discharge 
* 
No bowel 
preparation 
Bowel preparation leads to dehydration and changes in 
fluid & electrolyte balance (Holte et al., 2004). No change 
(Guenaga, 2005) or rather an increased risk of 
complications such as prolonged postoperative ileus as 
well as increased risk of anastomotic leakage from 
mechanical bowel preparation (Platell and Hall, 1998, Ram 
et al., 2005, Jung et al., 2007, Slim et al., 2004) 
Patients undergoing elective colonic 
resection above peritoneal reflection 
should not receive routine oral bowel 
preparation. May be considered in 
low rectal resection where a 
diverting stoma is planned (Platell et 
al., 2006)  
A 
Preoperative 
fasting & 
Preoperative 
carbohydrate 
loading 
27-45% of hospitalized patients are malnourished (Naber 
et al., 1997, Schutz and Pirlich, 2006). This increased risk 
may be due to the combined effects of tissue wasting, 
impaired immune function, impaired healing and organ 
dysfunction (Arora and Rochester, 1982, Giner et al., 1996) 
Preoperative carbohydrate loading reduces the incidence 
of complications (Svanfeldt et al., 2007, Kaska et al., 2006) 
and facilitate accelerated recovery through early return of 
gut function and shorter hospital stay leading to an 
improved perioperative well-being (Noblett et al., 2006b, 
Nygren et al., 2001, Yuill et al., 2005) 
The consensus guidelines from a 
Cochrane review (Brady et al., 2003) 
and guidelines from anaesthetic 
societies recommend clear fluids 
until 2 hours before induction of 
anaesthesia and a 6 hour fast for 
solid food (Lassen et al., 2009a) 
 
A 
No long acting 
sedatives/ 
premedication 
Long acting sedatives, hypnotics and opioids (pre-emptive 
analgesia) were thought to reduce anxiety and stress 
related to surgery, but these effects are far outweighed by 
the risk of prolonged recovery due to inability to drink or 
mobilize postoperatively. No effect on postoperative pain 
relief by starting analgesic treatment before the 
operation(Moiniche et al., 2002). Short acting anxiolytics 
have not shown prolonged recovery or length of stay 
(Smith and Pittaway, 2000, Smith and Pittaway, 2003) 
Medications causing long term 
sedation should be avoided; Short 
acting medications given to facilitate 
insertion of epidural catheter are 
acceptable 
A 
Antimicrobial 
Prophylaxis 
Prophylactic antibiotics minimize infectious complications 
in colorectal surgery (Song and Glenny, 1998)  
 
A single dose, one hour prior to skin 
incision and further doses for 
procedures lasting more than 3 hours 
(Song and Glenny, 1998) 
A 
Thromboembolic 
prophylaxis 
Increased risk of thromboembolic complications in certain 
high risk patients undergoing major abdominal surgery is 
associated with prolonged hospitalization and recovery 
Subcutaneous low-dose 
unfractionated heparin or 
subcutaneous low-molecular-weight 
heparin(Wille-Jorgensen et al., 2001, 
McLeod et al., 2001) 
A 
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Table 1.2: Summary of recommendations: Intraoperative interventions of ERAS 
 Intra-operative 
elements 
Rationale Recommendations 
Note: * indicates that 
recommendation is an 
ERAS-consensus 
statement based on 
available evidence 
Le
v
e
l 
o
f 
e
v
id
e
n
ce
 
Standard anaesthetic 
protocol / Mid-
thoracic epidural 
with local 
anaesthetic/opioid 
Rational use of short acting agents to facilitate 
proactive recovery postoperatively. Preoperative 
commencement of mid-thoracic epidural blocks 
stress hormone release and attenuates 
postoperative insulin resistance (Lassen et al., 
2009a). Helps in achieving analgesia and 
sympathetic blockade and in preventing gut 
paralysis (Miedema and Johnson, 2003) 
Avoid long acting opioids; Mid-
thoracic epidural commenced 
preoperatively, containing local 
anaesthetic in combination with 
a low-dose opioid. Consider 
short acting inhalational 
anaesthesia as an alternative to 
total intravenous anaesthesia  
A 
Laparoscopic / 
minimally invasive 
surgery 
Decreased inflammatory response, insulin 
resistance, improved pulmonary function, early 
return of bowel function, mobilization, less pain, 
reduced incidence of complications, readmissions 
and length of stay (Lin et al., 2009, Vlug et al., 2009, 
Zerey et al., 2006) 
Laparoscopic assisted colorectal 
surgery is recommended in 
dedicated specialist centres, 
with outcomes comparable to 
open surgery 
A 
Maintenance of 
normothermia 
Reduced wound infections, cardiac complications, 
bleeding and transfusion requirements (Frank et al., 
1997, Kurz et al., 1996, Nesher et al., 2003, Schmied 
et al., 1996, Scott and Buckland, 2006) 
Routine use of upper body-
forced-air heating cover; 
prevention of hypothermia by 
warm intravenous fluids 
A 
Perioperative fluid 
management 
Sodium and fluid overload delays return of GI 
function, prolongs hospital stay, increased side-
effects and complications (Lobo et al., 2002a, Lobo 
et al., 2002b, Nisanevich et al., 2005). 
Fluid restriction, avoiding 
hypovolemia, sodium and fluid 
overload. Goal directed fluid 
therapy in high-risk cases. 
A 
Selective use of 
drains 
Routine use of drains does not reduce the incidence 
or severity of anastomotic leak (Jesus et al., 2004, 
Urbach et al., 1999).  
No drains after routine colonic 
resections above peritoneal 
reflections; short term (< 24 
hours) drainage after low 
anterior resections 
A 
Urinary drainage  Increased risk of urinary tract infections following 
prolonged use (Wald et al., 2008). Reduced 
incidence of complications (Basse et al., 2000b) 
Suprapubic catheter for rectal 
surgery; Early removal of 
catheters following colonic 
surgery 
A 
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Postoperative 
elements 
Rationale Recommendations 
Le
v
e
l 
o
f 
e
v
id
e
n
ce
 
No routine use of 
nasogastric tube 
Facilitates earlier return of bowel function. Not 
associated with increased risk of complications or 
length of stay(Nelson et al., 2007, Yang et al., 
2008) 
Nasogastric tubes should not 
be used routinely in the 
postoperative period. Used in 
selected cases of 
postoperative ileus, or unless 
severe PONV 
A 
Aggressive treatment of 
postoperative nausea 
and vomiting (PONV) 
Facilitates early oral feeding. Symptoms related to 
postoperative ileus and opioids can be more 
stressful than postoperative pain. Female gender, 
non-smoking status, history of motion sickness or 
PONV and postoperative opioids confer high risk 
Individuals at moderate risk 
(>2 factors) should receive 
prophylactically with 
dexamethosone sodium 
phosphate at induction or 
serotonin receptor antagonist 
at the end of surgery (Carlisle 
and Stevenson, 2006, 
Wallenborn et al., 2006) 
A 
Prevention of 
postoperative ileus 
Surgical stress, opioids and bowel handling, fluid 
overload predispose to ileus and impairs GI 
function leading to delayed discharge. Oral 
magnesium oxide promotes postoperative bowel 
function (Basse et al., 2000a, Basse et al., 2001) 
Mid-thoracic epidural 
analgesia, avoidance of fluid 
overload and laparoscopic 
approach, where possible is 
recommended. A low dose 
postoperative laxative such 
as magnesium oxide may also 
be considered 
 
Postoperative analgesia 
/ Mid-thoracic epidural 
analgesia 
TEDA results in better pain relief and earlier return 
of bowel function compared with patient 
controlled analgesia (Block et al., 2003, Marret et 
al., 2007, Taqi et al., 2007, Turunen et al., 2009). 
Ineffective pain control, analgesia with oral or 
intravenous opiates, lack of mobility, loss of 
appetite contributes to the delayed 
gastrointestinal recovery (Bisgaard and Kehlet, 
2002). TEDA also results in attenuated stress 
response, insulin resistance, reduced incidence of 
respiratory and cardiovascular complications 
(Kehlet and Wilmore, 2002) 
Continuous epidural mid-
thoracic low-dose local 
anaesthetic and opioid 
combinations for 
approximately 48 hours, 
following elective colonic 
surgery and approximately 
72-96 hours following pelvic 
surgery. 
Acetominophen 
(paracetomol) for baseline 
analgesia (4g/d) 
postoperatively. Boluses for 
breakthrough pain. NSAIDS 
started following removal of 
epidural (multimodal 
analgesia). Remove catheter 
if present 
A 
Early oral nutrition Less gut permeability, early return of bowel 
function, reduced length of stay and complications 
(Bisgaard and Kehlet, 2002, Lewis et al., 2009, 
Lassen et al., 2008, Maessen et al., 2009) 
Oral diet, day of surgery with 
nutritional supplements 
(200ml, energy dense, 2-3 
times daily) until normal food 
intake is achieved. Continued 
for several weeks in 
nutritionally depleted 
patients 
A 
Early mobilization Decreases insulin resistance, risk of 
thromboembolism and pulmonary dysfunction. 
Increases muscle strength and facilitates early 
discharge 
Encourage independence and 
mobilization for at least 2 
hours on the day of surgery 
(e.g. turning, sitting in bed) 
and 6 hours thereafter (e.g. 
walking) 
* 
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        Table 1.3: Summary of recommendations: Postoperative elements of ERAS 
For the purpose of this thesis, the ERAS interventions such as avoidance prolonged 
fasting and preoperative carbohydrate drinks in patients having surgery will be reviewed. 
The principles of ERAS emphasise avoidance of prolonged fasting, as prolonged fasting of 
both solids and liquids and the metabolic stress from surgery, leads to fluid deficits 
(Noblett et al., 2006b) and POIR. ERAS guidelines permit fluids and solids up to two and 
six hours prior to surgery, respectively, to ensure that patients are in a  ‘ŵĞƚĂďŽůŝĐĂůůǇĨĞĚ ?
state (Thorell et al., 1999b). The traditional practice and belief that fasting from midnight 
ensures an empty stomach and thereby reduces the risk of pulmonary aspiration in 
elective surgical patients, has no scientific evidence behind this dogma. A Cochrane 
review of surgical patients showed that fasting from midnight does not reduce gastric 
content nor raises the pH of gastric fluid compared with patients allowed clear fluids until 
2 hours before anaesthesia (Brady et al., 2003). Recommendations from anaesthetic 
societies report that shortened fluid fast until 2 hours before surgery as well as a 6 hour 
fast for solid food, does not result in increased risk of pulmonary aspiration, differences 
in gastric pH, volume or increased morbidity even in high risk patients (Smith et al., 
2011a, Ljungqvist and Soreide, 2003, Soreide et al., 1997, Warner et al., 1993, ASA 
practice guidelinesHolness and Sugden, 1999). 
Discharge criteria ĚĚƌĞƐƐŝŶŐƉĂƚŝĞŶƚƐ ?ƐƉĞĐŝĂl needs and anticipating 
problems delaying discharge facilitates early 
recovery and does not increase readmission rates 
(Andersen et al., 2007) 
Criteria for discharge: 
Mobilized to preoperative 
level, pain control on oral 
analgesic, return of gut 
function and no 
complications in need of 
hospital care  
* 
Systematic audit  Documenting defined outcomes following 
implementation of ERAS programs ensures 
standard of care and identifies areas for 
improvement  
A systematic audit should be 
performed to allow direct 
comparison across 
institutions 
* 
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Similarly, there are no conclusive data to support the fact that patients with diabetes 
have delayed emptying for fluids and when given along with normal diabetic medication, 
gastric emptying of a carbohydrate drink was shown to be normal. Many studies show 
that carbohydrate treatment results in a better-maintained lean body mass (Yuill et al., 
2005) and muscle strength (Henriksen et al., 2003, Noblett et al., 2006b), less 
postoperative losses of nitrogen and protein (Crowe et al., 1984, Svanfeldt et al., 2007), 
accelerated recovery (Nygren et al., 2001, Noblett et al., 2006a) 
Evidence shows that there is an up-regulation of skeletal muscle PDK4 mRNA expression 
after 48 hours of starvation, associated with a 42% reduction in insulin sensitivity and 
provision of carbohydrate derived pyruvate was associated with reduced muscle 
pyruvate dehydrogenase kinase (PDK4) mRNA and protein expressions and increased 
liver glycogen content (Awad et al., 2010). Raised PDK4 mRNA expression in muscle has 
been shown to inhibit pyruvate dehydrogenase complex activity, which is the rate-
limiting step in carbohydrate oxidation (described in detail in section 1.5.2). This suggests 
that muscle PDK4 would be a prime target in carbohydrate oxidation and that CHO 
favours oxidative glucose disposal in skeletal muscle by its effect on PDK4.  
Dysregulation of protein kinase B (Akt1) signalling was implicated in insulin resistance 
which causes inhibition of FOXO transcription factors which in turn regulates PDK4 
activity by phosphorylation. A study in patients by Wang et al investigated whether 
altered insulin dependent activation of the phosphatidyl-inositol 3 kinase (PI3K)/Akt 
signalling pathway would contribute to the development of POIR (Wang et al., 2010). 
POIR and subjective wellbeing were significantly better in the CHO group than in the 
fasting/placebo group. At the end of surgery, muscle protein tyrosine kinase activities, as 
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well as PI3K and PKB levels were significantly increased in the CHO group. The 
PI3K/Akt/FOXO signalling pathway is discussed in detail in section 1.5. 
Despite the initial reluctance and difficulties in implementation of ERAS principles, many 
randomised controlled trials (RCT) were undertaken, implementing some or most of the 
ERAS interventions in surgical patients and comparing their clinical outcomes against 
those treated in the traditional way. Some studies showed clinical benefits of reduced 
length of hospital stay, complications and early recovery, whilst others reported mixed 
results. This was thought to be a problem with either implementation or adherence to 
the ERAS protocol and differences in practice amongst various surgical units (Kehlet, 
2009).  
In an attempt to analyse and validate the effect of the perioperative interventions on 
clinical outcomes of patients treated using ERAS principles, a systematic review and 
meta-analysis of randomised controlled trials of ERAS in patients having abdominal 
surgery was performed. RCTs that studied the effects of preoperative carbohydrate 
drinks in surgical patients with particular reference to the development of POIR, were 
also systematically reviewed. The results of both the systematic reviews are presented in 
subsequent chapters, in this thesis (Chapter 3 and Chapter 4).  
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1.2 Postoperative insulin resistance 
The teƌŵ  ‘/ŶƐƵůŝŶ ƌĞƐŝƐƚĂŶĐĞ ? ƌĞĨĞƌƐ ƚŽa blunting of the stimulatory effect of insulin on 
tissue glucose uptake. The development of surgical induced insulin resistance syndrome 
(elevated blood glucose and fatty-acid concentrations, reduced muscle glucose uptake, 
and increased liver glucose production), which occurs concurrently with increased oxygen 
consumption, hyper-lactatemia and protein catabolism, has been a consistent feature in 
the postoperative period, following major surgical interventions, thereby delaying 
recovery (Ljungqvist et al., 2005, Van den Berghe et al., 2003). However, the 
pathogenesiƐŽĨ  ‘ƐƚƌĞƐƐŚǇƉĞƌŐůǇĐĂĞŵŝĂ ? ?very ŵƵĐŚ ůŝŬĞƚŚĞƉĂƚŝĞŶƚ ?Ɛcondition, is likely 
to be dynamic, change over time and normalises when the counter-regulatory hormonal 
surge and pro-inflammatory response abates during recovery (Clement et al., 2004, 
Meduri et al., 2009).  
 
POIR, as indicated by a decrease in insulin sensitivity, refers to the ability of insulin to 
support glucose homeostasis, by promoting glucose uptake in insulin-sensitive tissues or 
organs (or whole body glucose uptake) is measured by the average rate of exogenous 
glucose infusion after reaching a steady state level during a hyperinsulinaemic 
euglycaemic clamp study, to maintain euglycaemia for 30 min, (M-value). It is more 
pronounced in the 1-2 days following surgery, which then takes several days to recover 
to basal levels (Fig 1.3). (Ljungqvist et al., 2005, Van den Berghe et al., 2003, Cerra, 1987).  
There is also a strong correlation between the magnitude of surgery and the degree of 
insulin sensitivity. By measuring insulin sensitivity both preoperatively and 24 hours after 
elective surgery in otherwise healthy individuals, it was found that insulin sensitivity was 
reduced by approximately 50% after uncomplicated electi
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(Thorell et al., 1994). A 50-60% decrease in insulin sensitivity has been shown to be 
associated with major abdominal surgery (Fig 1.4) and surgery using minimally invasive 
techniques such as laparoscopic cholecystectomy showed with a significantly less 
pronounced reduction in insulin sensitivity compared with open surgery (Thorell et al., 
1999b, Ljungqvist, Thorell et al., 1993, Thorell et al., 1996c). Moreover, the relative 
reduction in insulin sensitivity was found to be constant, after a given operation, with a 
coefficient of variation of 12.3% or less (Thorell et al., 1993).  
It has also been reported that the degree of POIR, along with other surgical factors such 
as type of surgery and perioperative blood loss significantly best predicted the length of 
hospital stay, with a predictive value of 71% (Thorell et al., 1999b). Another study in 
diabetic and non-diabetic patients undergoing cardiac surgery, reported that insulin 
resistance is associated with 5-fold increase in the risk of complications, risk of severe 
infection by more than 10-fold and a decrease in insulin sensitivity by 50% (Sato et al.). 
Therefore, it is clear that interventions that attenuate the development of insulin 
resistance in the perioperative setting and during critical illness may have a major effect 
on recovery. 
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Figure 1.4: Percentage reduction in insulin sensitivity and magnitude of operation. 
 
 
Figure 1.3: Degree of insulin insulin sensitivity in the postoperative period, as 
measured by Hyperinsulinaemic euglycaemic clamp. 
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1.3. Metabolic response to Surgery 
1.3.1 Metabolic response: Evolution of concept 
Sir David Paton Cuthbertson, in his series of experiments in the late 1920s, established 
the associations of increased nitrogen loss, breakdown of lean tissue (particularly skeletal 
muscle), fever and increased oxygen consumption to the post-traumatic catabolic state. 
In his study of calcium metabolism, he investigated the effects of bed rest on healthy 
volunteers and in individuals with non-inflammatory dysfunction of the knee joint and 
found that bed rest caused a slight increase in the excretion of nitrogen, potassium, 
sulphur and creatine, which returned to baseline levels with time. Interestingly, his 
subsequent experiments on patients with long bone fractures, showed much greater 
losses in the above parameters than those associated with bed rest alone. This negative 
nitrogen balance was maximal from day 2 to day 8 after injury and lasted for up to 1 
month (Cuthbertson, 1929, Cuthbertson, 1930, Cuthbertson, 1932). Studies that followed 
linked the activation of the hypothalamic-pituitary-adrenal axis (HPA) and the release of 
stress hormones to the systemic metabolic response (Hume, 1953, Egdahl, 1959, Goodall 
et al., 1957). Hume and Egdahl, described the adrenal cortical response to limb injury in 
dogs caused by trauma or burns, which produced an immediate and sustained increase 
of adrenal hormones. However, the response was abated if the sciatic nerve or spinal 
cord were transected, demonstrating the importance of afferent nerve signals to mediate 
the HPA response. The effect of stress hormones such as cortisol, glucagon and 
epinephrine infusion in healthy volunteers over a 74-hour period to achieve 
concentrations similar to patients undergoing surgery compared with saline infusion, 
showed a significant hypermetabolism, negative nitrogen balance, glucose intolerance, 
33 
 
insulin resistance and leucocytosis, pointing to the role of stress hormones in the 
metabolic response to surgery (Bessey et al., 1984). Similarly, evidence from patients 
with burns showed a strong association between the hypermetabolic response of burn 
injury and the secretion of catecholamines (Wilmore et al., 1974). A positive correlation 
between the injury severity and the plasma concentration of catecholamines and 
dopamine, secondary to an increased sympathetic activity has also been reported in 
some studies (Ljungqvist, 2009, Frayn et al., 1985). The importance of neuronal pathways 
in eliciting the stress response was reported in a study by Brandt et al, in which they 
studied the effects of epidural anaesthesia on patients undergoing elective abdominal 
surgery. They showed that the neuraxial blockade attenuated the activation of the HPA 
axis, dampened reflex neurogenic responses to the liver and intestinal tract and 
postoperative pain. This was associated with a reduction in the secretion of catabolic 
hormones, reduced hyperglycaemia and attenuated negative nitrogen balance (Brandt et 
al., 1978). Furthermore, a study in patients undergoing upper abdominal surgery, showed 
that epidural blockade of catecholamine release also reduced the degree of POIR (Uchida 
et al., 1988). Therefore, inhibition of the endocrine-metabolic response to surgery by 
neurogenic blockade may reduce the morbidity precipitated in high-risk patients by the 
catabolic response to surgery. 
Thus, it is evident that the metabolic response to surgery is initiated by the neurogenic 
stimuli from the site of injury, which plays a crucial part in the metabolic response to 
surgery and that stress hormones play a vital role in the propagation of the response. 
However, the cellular and molecular mechanisms that lead to changes in substrate 
utilisation and POIR in patients undergoing surgery, have not been well defined. 
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1.3.2 The ebb and flow phase of metabolic response  
The metabolic response to critical illness is associated with global hyper-metabolism, 
insulin resistance, alterations in substrate utilisation and a negative nitrogen balance. In 
the following paragraphs, the physiological events that take place during the metabolic 
response secondary to surgical stress and how it may contribute to the development of 
POIR will be reviewed.  
The metabolic response to surgical stress is classified into a relatively short-lived hypo-
ŵĞƚĂďŽůŝĐ  ‘Ğďď ? ƉŚĂƐĞ ? ĨŽůůŽǁĞĚ ďǇ ƚŚĞ ŚǇƉĞr-ŵĞƚĂďŽůŝĐ Žƌ  ‘ĨůŽǁ ? ƉŚĂƐĞ, as described 
below. 
dŚĞ  ?Ğďď ? ƉŚĂƐĞ: dŚĞ  ‘Ğďď ? ƉŚĂƐĞ ĐŽƌƌĞƐƉŽŶĚƐ ƚŽ ƚŚĞ ƉĞƌŝŽĚ ŽĨ ƌĞĚƵĐĞĚ ĞŶĞƌŐǇ
expenditure, hypovolaemia and an increased sympathetico-adrenal activity associated 
with an outpouring of counter-regulatory hormones immediately after injury and lasts for 
12  W 24 h (Frayn et al., 1985). The patient is in the state of traumatic shock and with 
adequate resuscitation, the metabolic changes are considered to be reversible. However, 
if the metabolic response is severe enough to initiate an inflammatory process, it can 
trigger a cascade of events that lead to further injury in other organs. The post-traumatic 
 ‘Ɛƚress hyperglycaĞŵŝĂ ?ǁŚŝĐŚ ŝƐƉƌĞƐĞŶƚŝŶƚŚĞ ‘Ğďď ?ƉŚĂƐĞŝƐƐĂŝĚƚŽďĞŝŶŝƚŝĂůůǇƚŚĞƌĞƐƵůƚ
of enhanced hepatic glycogenolysis (Stoner et al., 1979) and later a consequence of 
increased glucose production coupled with reduced peripheral utilisation(Wolfe et al., 
1977). Stress hyperglycaemia is stimulated by increased sympathetic activity, combined 
with increase in glucagon and suppression of insulin levels (Allison et al., 1968, Ryan, 
1976, Barton, 1985). The insulin level is considered to be low in this phase, relative to the 
degree of hyperglycaemia (Barton, 1985). Catecholamines also interfere with the normal 
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feedback control of insulin and glucagon secretion by circulating glucose levels and 
contribute to the development of stress hyperglycaemia (Halter et al., 1984). It has also 
been reported that raised cortisol in the postoperative period is a predictor of 
postoperative insulin resistance in non-diabetic patients after cardiac surgery (Lehrke et 
al., 2008). 
dŚĞ  ?ĨůŽǁ ? ƉŚĂƐĞ ? dŚĞ  ‘Ğďď ? ƉŚĂƐĞ ŝƐ ĨŽůůŽǁĞĚ ƵƐƵĂůůǇ ďǇ Ă ƉĞƌŝŽĚ ŽĨ ŚĂĞŵŽĚǇŶĂŵŝĐ
instability which can last about 3 days, and may require fluid resuscitation with colloids 
and inotropes. Subsequently, the patient progresses on ƚŽ ƚŚĞ ŵŽƌĞ ƉƌŽůŽŶŐĞĚ  ‘ĨůŽǁ ?
phase which peaks around 3-5 days and abates by 7-10 days and merges into the 
anabolic or the recovery phase (Mizock, 2001). The flow phase is reported to be 
characterised by a high metabolic rate with an increased energy expenditure, breakdown 
of protein and fat, negative nitrogen balance, weight loss, and rising insulin levels (Frayn, 
1986), and as a consequence there is increased glucose production (the important 
gluconeogenic precursors being alanine and glutamine) possibly due to the action of 
counter-regulatory hormones such as catecholamines, glucocorticoids and glucagon (Hill, 
1988). It has been reported that nearly one-ĨŝĨƚŚŽĨƚŚĞďŽĚǇ ?ƐƐƚŽƌĞŽĨƉƌŽƚĞŝŶŝƐůŽƐƚŽǀĞƌ
the first 3 weeks, most during the first 10 days, predominantly from the skeletal muscle 
(about 65%) which leads to problems with respiratory function and subsequent weaning 
from ventilators (Windsor and Hill, 1988a). 
Another consequence of the hyper-metabolic phase is an increased turnover of free fatty 
acid and glycerol from adipose tissue probably due to increased catecholamine activity, 
and an increased lactate production from muscle glycogenolysis and metabolism in the 
hypoxic injured tissues (Wilmore et al., 1980, Frayn, 1985), that is subsequently utilized 
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ďǇƚŚĞůŝǀĞƌĨŽƌŐůƵĐŽŶĞŽŐĞŶĞƐŝƐ ŝŶƚŚĞ ‘ŽƌŝĐǇĐůĞ ? ?ĨŽƌŵĂŝŶƚĂŝŶŝŶŐƚŚĞĞŶĞƌŐǇƐƵƉƉůǇ ŝŶ
the traumatised patient (Shaw and Wolfe, 1989). The ultimate goal of this acute phase is 
to meet the metabolic needs of the elevated energy expenditure, increase availability of 
amino acids for gluconeogenesis, to promote wound healing, increase immune cell 
replication and acute phase proteins synthesis in the liver and to conserve fluid for the 
repair process.  
Following acute stress conditions such as surgery, trauma, burns and sepsis, protein 
catabolism predominantly from the skeletal muscle, is accelerated and the protein 
synthetic response to feeding is impaired, resulting in reduced muscle mass and strength, 
impaired immune response, reduced gut function, increased clinical complications and 
mortality or prolonged convalescence (Christensen et al., 1982, Windsor and Hill, 1988b, 
Iapichino et al., 1981, Wolfe et al., 1983, Wolfe et al., 1989).  
Many studies have shown that the post-traumatic state is accompanied by loss of body 
protein and negative nitrogen balance (Rennie et al., 1984, O'Keefe et al., 1974, 
Wernerman et al., 1986). A study in patients having open cholecystectomy in which 
protein synthesis was determined from the total concentration size and distribution of 
ribosomes, has demonstrated depressed muscle protein synthesis even after 30 days 
following surgery (Petersson et al., 1990). In patients having major surgical procedures 
and critically injured patients, loss of one-ĨŝĨƚŚŽĨƚŚĞďŽĚǇ ?ƐƐƚŽƌĞŽĨƉƌŽƚĞŝŶĐŽƵůĚŽĐĐƵƌ
in the first three weeks, with most loss in the first 10 days, mainly from skeletal muscle 
(Vary, 1998). This leads to prolonged convalescence, problems with respiratory function 
and weaning from ventilators, resulting in morbidity and mortality (Monk et al., 1996, 
Windsor and Hill, 1988a) .  
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Thus, it is evident that the metabolic response is characterised by well-coordinated 
autonomic, hormonal, and metabolic responses that follow injury or trauma. This 
manifests as a syndrome consisting of hypermetabolism, a hyperdynamic cardiovascular 
state and clinical features of fever or hypothermia, tachycardia and lecukocytosis. 
Importantly, depending on the intensity of stress and patient factors such as fluid status, 
infection etc., it is associated with increased oxygen consumption, hyperglycemia, 
hyperlactatemia and protein catabolism which can affect patient recovery (Cerra, 1987). 
The main features of the ebb and flow phases are represented in the table 1.4. 
 
Table 1.4: The ebb and flow phases of Cuthbertson (adapted from Hill et al, British Journal of 
Surgery, 1998; 85, 884-890) 
 
 Ebb phase Flow phase 
Metabolism Hypometabolic Hypermetabolic 
Oxygen consumption Decreased Increased 
Core temperature Low Raised 
Energy expenditure Decreased Increased 
Cardiac output Decreased Increased 
Tissue perfusion Poor Normal 
Extremities Cold and clammy Warm and pink 
Nitrogen loss Normal Increased 
Glucose production Normal Increased 
Blood glucose Increased Increased 
Lactate Increased Normal 
Free fatty acids Increased Increased 
Catecholamines and cortisol Increased Increased 
Insulin Decreased Increased 
Glucagon Raised Raised or normal glucagon 
Cytokine production Normal Increased 
Insulin resistance Increased Increased 
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Figure 1.5: Metabolic response to trauma: reflex stimuli from site of surgical trauma, alerts the 
central nervous system, mainly the neurons of the paraventricular nucleus of the hypothalamus, 
that stimulates the production of corticotropin-releasing hormone and activate the 
hypothalamic-pituitary-adrenal axis (HPA) and the brain stem to stimulate peripheral autonomic 
ŶĞƌǀŽƵƐ ƐǇƐƚĞŵ ƌĞƐƉŽŶƐĞƐ ? dŚŝƐ ŝŶƚĞŐƌĂƚĞĚ  ‘ƐƚƌĞƐƐ ? ƌĞƐƉŽŶƐĞ ? ĐŽŶƚƌŽůƐ ƉƌŝŵĂƌǇ ďŽĚŝůǇ ĨƵŶĐƚŝŽŶƐ
such as arousal, cardiovascular tone, respiration, altered gastrointestinal function and 
intermediate metabolism. 
 
Liver 
Gluconeogenesis, 
Glycogenolysis 
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1.4. Postoperative insulin resistance (POIR) 
Postoperative insulin resistance is central to the metabolic response to surgery. The key 
feature of the  ?ŚǇƉĞƌŵĞƚĂďŽůŝĐ ? stress response involves increased endogenous hepatic 
glucose production while insulin-stimulated peripheral glucose uptake is reduced (Baron 
et al., 1988). However, it is not fully understood how the metabolic signalling pathways 
that regulate whole body glucose and fat metabolism are perturbed as a result of surgical 
stress and contribute to the development of POIR. 
Skeletal muscle plays an important role for the regulation of glucose metabolism. It 
contributes to more than 30% of resting metabolic rate and 80% of whole body glucose 
uptake(de Lange et al., 2007). Insulin is the most important hormone of metabolic 
regulation through its integrated action on carbohydrate, lipid and protein metabolism. It 
stimulates glucose uptake in insulin-sensitive tissues such as liver, muscle and adipose 
tissue and suppresses the endogenous glucose production in the liver. In the liver and 
muscle, insulin promotes glycogen synthesis by activating the enzyme glycogen synthase, 
increase synthesis and uptake of fatty acids (FA), by activation of acetyl-CoA carboxylase 
and inhibition of FA release by inactivation of hormone-sensitive lipase. Conversely, 
catecholamines, cortisol, glucagon and growth hormone, raise blood glucose by 
enhanced glycogenolysis and gluconeogenesis.  
Glucose is transported through cell membranes by facilitated carrier-mediated diffusion, 
by the glucose transporters (GLUT1, GLUT2 and GLUT4) that differentially regulate 
glucose uptake in various tissues (Shepherd and Kahn, 1999, Pessin and Bell, 1992). 
GLUT4 is the major isoform in insulin-sensitive tissues such as skeletal muscle, cardiac 
muscle and adipose tissue. Upon stimulation by insulin binding to its receptor, GLUT4 is 
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translocated to the cell-membrane to permit the movement of glucose down a 
concentration gradient across cell membranes, a rate-limiting step in glucose uptake in 
these insulin sensitive tissues (Pessin and Saltiel, 2000).  
Plasma insulin levels vary rapidly in response to fluctuations in glucose levels. Under 
normal physiological conditions, the increased concentration of glucose in the portal 
ďůŽŽĚ ƐƚŝŵƵůĂƚĞƐ ŝŶƐƵůŝŶ ƌĞůĞĂƐĞ ĨƌŽŵ ƚŚĞ ɴ-cells of pancreatic islets and suppresses 
ƐĞĐƌĞƚŝŽŶŽĨŐůƵĐĂŐŽŶĨƌŽŵƚŚĞɲ-cells. Conversely, in the fasting or post-absorptive state, 
the stored metabolic reserves of glycogen, triacylglycerol and protein are released at 
times of increased metabolic demand, in response to the hormone, glucagon, resulting in 
increased liver glycogenolysis and gluconeogenesis, in liver and kidney.  
However, the effect of surgery on insulin levels, glucose uptake and oxidation shows 
mixed results. Many studies in patients undergoing surgery have highlighted important 
cellular events in carbohydrate metabolism that may lead to postoperative muscle insulin 
resistance and hyperglycaemia.  
Thorell et al, measured insulin sensitivity in patients undergoing open cholecystectomy 
using a euglycaemic, hyperinsulinaemic clamp and reported that the postoperative 
insulin resistance was associated with a significantly higher plasma concentrations of 
glucose, noradrenaline and glucagon whilst the levels for insulin, growth hormone, 
cortisol and adrenaline were unaltered (Thorell et al., 1994). Other studies in patients 
undergoing major elective surgery reported that postoperative hyperglycaemia (Brandi et 
al., 1990, Crowe et al., 1984), was associated with increased insulin requirements to 
maintain euglycaemia (Brandi et al., 1990) and a raise in counter-regulatory hormones, 
whole body protein oxidation and energy expenditure (Brandi et al., 1990). Wright et al 
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also noted that glucose utilisation was significantly depressed during and after operation 
along with suppression of insulin secretion during operation together with increased 
plasma cortisol levels and an increased urinary catecholamine excretion(Wright et al., 
1974). 
Brandi et al, in their study of insulin resistance in patients undergoing major elective 
surgery, reported that patients were hyperglycaemic (7.3 ± 0.6 versus 4.2 ± 0.3 mmol/l 
glucose pre-surgery, mean ± SEM, P <0.01) with normal insulin concentrations (73 ± 15 
versus 64 ± 18 pmol/l). Furthermore, eight times more insulin was needed than before 
surgery, (14.14 ± 1.15 versus 1.78 ± 0.29 pmol min-1 kg-1, P less than 0.001) to maintain 
euglycaemia(Brandi et al., 1990). Another study by the same author, using a three-step 
iso-glycaemic insulin clamp combined with indirect calorimetry, [6-3H]glucose infusion 
and the forearm technique, also reported impaired whole-body glucose disposal by 33-
60%, in patients 6 -8 hours after undergoing major abdominal surgery whilst the hepatic 
glucose production at baseline was less suppressed by insulin (Brandi et al., 1993). 
Forearm glucose extraction was markedly depressed at all insulin levels and forearm 
lactate release was in excess of concurrent glucose uptake, suggesting ongoing 
glycogenolysis despite insulin. This was associated with increased cortisol, lactate and 
total lipolysis (plasma free fatty acid and glycerol levels).  
Other studies investigating serum insulin changes in surgical patients, have reported 
lower insulin levels at the start of surgery compared with intraoperative and 
postoperative periods (Crowe et al., 1984, Nygren et al., 1998b, Aarimaa et al., 1974), 
and impaired insulin response both intra-operatively (Wright et al., 1974, Barton, 1985) 
and soon after surgery (Stenberg et al., 1984, Aarimaa et al., 1974).  
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Crowe et al studied the effect of glucose infusion commenced either the night before 
operation with that of glucose infusion commenced postoperatively in patients having 
abdominal surgery. The values of intra-operative plasma glucose concentrations were 
increased compared with the levels at the time of induction of anaesthesia while plasma 
insulin concentrations only showed a mild increase (insulin levels in mU/l: at induction of 
anaesthesia: 5±2; mean intraoperative: 7±3; on day-1 postop: 17±5; day-3 postop: 11±3).  
Wright et al, also investigated the changes in glucose utilisation and insulin secretion 
during surgery in patients having inguinal herniorraphy, vagotomy and pyloroplasty and 
aorto-femoral bypass (Wright et al., 1974) and reported that glucose utilisation was 
significantly depressed during and after operation, to a degree which increased with the 
severity of operation. Suppression of insulin secretion was observed during operation 
together with increased plasma cortisol levels and an increased urinary catecholamine 
excretion. Similarly, Stenberg et al, also found the increase of insulin in response to 
glucose was significantly (p<0.001) reduced 2 hours after laparotomy as compared to 
control subjects (Stenberg et al., 1984).  
Using isotope labelling techniques, Shaw et al, demonstrated a decreased glucose 
oxidation in septic and trauma patients (Shaw and Wolfe, 1985, Shaw et al., 1985, Jahoor 
et al., 1986). They studied the metabolic response in severely-ill patients suffering from 
blunt trauma, and compared the data with normal controls. Whilst the glucose uptake 
was increased in patients (21 ± 2 mmol/kg/minute vs. 14 ± 1 mmol/kg/minute), the 
trauma patients had an impaired capacity to directly oxidize plasma glucose (23 ± 4% vs 
36 ± 2%). However, a study in septic, non-diabetic patients which investigated the effect 
of two levels of insulinaemia (250 mIU/l in step 1 and 1250 mIU/l in step 2) in the 
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presence of a euglycaemic clamp on glucose metabolism, showed both glucose uptake 
and oxidation were not significantly different when compared with controls. 
A study in septic rats also reported hyperlactatemia and reduced activity of the pyruvate 
dehydrogenase complex which regulates an important rate-limiting step in carbohydrate 
oxidation (Vary, 1996). 
A study investigating the effects of cardiac surgery on the development of POIR, in non-
diabetic patients highlighted that postoperative serum cortisol level was a better 
predictor for inflammatory insulin resistance, followed by IL-6, leptin and adiponectin. 
The study reported a slow rise in serum cortisol, resistin and leptin which peaked at 22 
hours after surgery (Lehrke et al., 2008). They also reported that the comparable pattern 
of regulatory proteins in chronic environment of obesity and in acute inflammation 
suggests similar causative mechanisms of insulin resistance. 
Thus it is clear that the antagonistic actions of counter-regulatory hormones such as 
glucagon, cortisol and catecholamines impair the metabolic actions of insulin and may 
contribute to the acute insulin resistance in the immediate postoperative period(Krentz, 
1996). Therefore, it is suggested from the aforementioned studies, that a failure of 
cellular glucose utilisation along with the changes in insulin response, is an important 
event in the metabolic response to injury that may lead to the stress induced 
hyperglycaemia, noticed in patients undergoing major abdominal surgery.  
1.4.1 Role of cytokines 
Surgery is associated with a pronounced inflammatory response with the release of pro-
inflammatory cytokines. Cytokine-mediated inflammatory response could be one of the 
molecular triggers for the metabolic response to surgery. Studies show that the cytokines 
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produced locally at the site of surgical trauma act locally on the wound and also on 
distant organs such as the liver, gut and skeletal muscle. The cytokines stimulate 
important mediators such as platelet activating factor, oxygen free radicals, nitric oxide 
and arachidonic acid metabolites, which act both directly on the cells and indirectly by 
altering regional blood flow (Hebert et al., 1995, Bulkley, 1993). IL-6 mediated 
inflammatory response is thought to be responsible for the fever and metabolic changes 
in the acute phase of illness that has been consistently found in sepsis, trauma and 
postoperative states and a marked IL-6 response is found to correlate with the severity of 
illness. Furthermore, the effects of TNF on the hemodynamic changes and tissue injury in 
septic shock, and causing endothelial damage, inducing disseminated intravascular 
coagulation, multiple organ failure and death has also been reported (Martin et al., 1997, 
Tang, 1996, Bach et al., Svoboda et al., 1994, Tompkins, 1997, Bach et al., 1997). A study 
on the systemic cytokine response to trauma in patients having aortic surgery, reported 
an increase in IL-6 levels that peaked at 4-48 hours after surgery, was significantly higher 
and also preceded the clinical onset of major complications (Baigrie et al., 1992). It has 
also been shown that the metabolic pathways involved in insulin-mediated glycogen 
synthesis are more sensitive to the inhibitory effects of cytokines such as interleukin (IL-
6) and tumour necrosis factor (TNF) and counter-regulatory hormones (Baron et al., 
1988). A recent review identified the role of IL- ?ĂƐĂ ‘ŵǇŽŬŝŶĞ ?, produced in the skeletal 
muscle and responsible for the metabolic regulation and changes in insulin signalling (Pal 
et al., 2014). Cytokines along with counter-regulatory hormones such as catecholamines 
and glucocorticoids can induce insulin resistance by inhibition of insulin binding to 
insulin-receptor and subsequent GLUT4 translocation (Chiasson et al., 1981, Mizock, 
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2001). Furthermore, a study reported that non-insulin mediated glucose uptake in tissues 
such as lung, liver, spleen and wounds are also modulated by TNF and IL-1 by stimulation 
of GLUT1 synthesis, plasma membrane concentration and activity (Dimitriadis et al., 
1997). 
Cytokines are also reported to influence skeletal muscle catabolism by modulating 
protein synthesis and degradation and inhibit regulatory actions of anabolic hormones 
(Vary, 1998). TNF, when infused into animals induced a net catabolic state by mediating 
increased catabolism at the level of specific tissues, by activating the HPA axis and 
causing anorexia (Flores et al., 1989, Mealy et al., 1990). Flores et al estimated the rates 
of protein synthesis and degradation in muscle and liver tissues in intact rats treated with 
several doses of recombinant IL 1 and/or TNF. They reported that rats exposed 
systemically to sub-lethal doses of TNF responded with increasing muscle and decreasing 
liver proteolysis, similar to that observed in inflammation and in cancer.  
 
Cytokines other than IL-6 and TNF-ɲ ? ƐƵĐŚ ĂƐ ƉůĂƐŵŝŶŽŐĞŶ ĂĐƚŝǀĂƚŽƌ ŝŶŚŝďŝƚŽƌ  ? ?
angiotension and leptin are also secreted by adipose tissue, which may also contribute to 
insulin resistance. Whilst TNF-ɲ ? ĂŶĚ />-6 is reported to impair insulin signalling and 
increase lipolysis , angiotensinogen and leptin are associated with increased insulin 
resistance (Devaraj et al., 2004).  
 
Thus, it is possible that the development of POIR in surgical patients could be partly 
attributed to the metabolic response to surgery. The surgical stress induced 
inflammatory response mediated by the interaction of pro-inflammatory cytokines and 
counter-regulatory hormones regulated by central nervous system, may interfere with 
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the normal carbohydrate metabolism especially in the liver and skeletal muscle that may 
lead to POIR and stress hyperglycaemia seen in patients having major abdominal surgery.  
 
1.4.2 Role of preoperative fasting in surgical patients 
 
Traditionally, patients having surgery fast between 12-18 hours whilst awaiting surgery 
which may contribute to insulin resistance (Svanfeldt et al., 2005). A period of brief 
fasting or hypo-caloric nutrition has been associated with reduction in insulin sensitivity 
(Nygren et al., 1997b, Nygren et al., 1997a, Svanfeldt et al., 2003).  
In the post-absorptive or fasted state, it is reported that insulin-independent tissues such 
as brain and splanchnic organs account for the majority of whole-body glucose disposal 
(50% and 25% respectively), whilst the insulin dependent tissues such as skeletal muscle 
account for the reminder of glucose utilisation (25%). During fasting, plasma glucose 
concentration is about 5 mmol/l and insulin concentration is about 60 pmol/l. Liver 
releases glucose from its stored energy reserves by glycogenolysis (65-75%) and 
subsequently by gluconeogenesis (25-35%) to maintain whole body glucose homeostasis. 
Liver glycogen reserves are sufficient for only a period of 24 hours, gluconeogenesis 
proceeds at the expense of muscle protein. It has been reported that the initial period of 
starvation (2-3 days) is accompanied by mobilisation of amino acids from skeletal muscle 
to support the augmented rate of hepatic gluconeogenesis and that increased protein 
breakdown rather than depressed protein synthesis may contribute to gluconeogenesis 
(Magnusson et al., 1990). Therefore, if the patients do not return to enteral feeding after 
surgery, they enter the period of starvation where the process of gluconeogenesis is 
augmented, the important precursors being lactate, alanine and glycerol, which initiates 
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the catabolic process (Nygren, 2006). This metabolic adaptation also leads to increased 
circulating fatty acids (FFA) from lipolysis to be used as a metabolic fuel in muscle, 
secondary to the effects of increased adrenergic stimulation and decreased insulin levels. 
Increased oxidation of FFA and the production of ketone bodies, which is used as fuel in 
tissues such as brain, can minimise further protein breakdown (Nygren, 2006). Therefore, 
it is evident that fasting which contributes to the metabolic stress in patients having 
surgery, is strongly associated with the development of POIR. Avoidance of fasting or 
reduced fasting times before surgery, can therefore attenuate the development of POIR 
and improve glucose and protein metabolism. The role of surgical stress on the metabolic 
response and POIR is summarised below. 
 
Figure 1.6: Surgical stress and the metabolic response 
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1.5 Molecular mechanisms 
1.5.1 PI3K/Akt1/FOXO signalling pathway 
 
Under normal conditions, stimulation with growth factors, such as insulin-like growth 
factor-1 (IGF-1), and hormones, such as insulin, leads to the activation of the 
phosphatidylinositol-3 kinase (PI3K)/Akt signalling cascade. Phosphorylation of Forkhead 
box O (FOXO) by Akt1 leads to their exclusion from the nucleus, and a reduction in the 
expression of key genes involved in the regulation of carbohydrate oxidation [pyruvate 
dehydrogenase kinase 4 (PDK4)]. This results in increased pyruvate dehydrogenase 
complex activity. Activated PDC is important for the conversion of carbohydrate-derived 
pyruvate into acetyl-CoA which is the rate limiting step for carbohydrate oxidation. 
Skeletal muscle plays an important role in the insulin-mediated glucose disposal in 
humans (DeFronzo et al., 1981). Insulin binding to its receptor stimulates activation of 
receptor tyrosine kinase, which phosphorylates multiple intracellular substrates including 
insulin receptor substrate (IRS1). IRS1 activation of the PI3 kinase is responsible for 
insulin signalling mediated glucose homeostasis. Insulin mediated glucose entry into 
skeletal muscle, is facilitated by PI3 kinase stimulated translocation of insulin-responsive 
glucose transporter (GLUT4) to the plasma membrane by phosphorylating the protein 
kinase B (Akt) (Chow et al., 2010). Therefore, any alteration in this important signalling 
mechanism may contribute to the development of POIR, seen in patients having major 
abdominal surgery. 
The insulin-like growth factor-1 (IGF-1)/phosphatidyl-inositol-3 kinase (PI3K)/Akt1 
pathway, through inhibition of FOXO transcription factors play an important role in the 
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regulation of muscle carbohydrate metabolism and protein synthesis. In the following 
section, the components of this pathway and their potential role in the development of 
POIR will be discussed. 
Forkhead Box O (FoxO) proteins belong to the mammalian forkhead transcription factors 
ŝŶ ƚŚĞ  ‘K ? ĐůĂƐƐ ? &ŽǆK ? ? &ŽǆK ? ? &ŽǆK ? ĂŶĚ &ŽǆK ? ? dŚĞǇ ƉůĂǇ Ă ƐŝŐŶŝĨŝĐĂŶƚ ƌŽůĞ ĚƵring 
normal cellular function as well as during progressive disease and govern diverse 
functions of differentiation, proliferation, survival and longevity during multiple cellular 
environments that can involve oxidative stress. They are expressed in tissues of the 
reproductive system of males and females, skeletal muscle, the cardiovascular system, 
lung, liver, pancreas, spleen, thymus and the nervous system (Castrillon et al., 2003, 
Furuyama et al., 2000, Furuyama et al., 2002, Hoekman et al., 2006, Maiese et al., 2008, 
Modur et al., 2002). FoxOs are also expressed in skeletal muscle and their expression 
levels are changed in response to energy metabolism. Expression levels of FoxO1 and 
FoxO3a were increased in skeletal muscle by starvation and glucocorticoid treatment 
(Furuyama et al., 2003). Dexamethasone treatment in chronically instrumented, 
lipopolysaccharide LPS infused male Sprague-Dawley rats, inhibited the cytokine-
mediated inhibition of Akt/FOXO signalling in the induction of muscle atrophy and 
impairment of muscle carbohydrate oxidation and also reduced the LPS-mediated 
increase in cathepsin-L mRNA expression and enzyme activity by 43%. Furthermore, 
dexamethasone-suppressed LPS-induced pyruvate dehydrogenase kinase 4 (PDK4) mRNA 
upregulation by ׽50% (P <0.01), and prevented LPS-mediated muscle glycogen 
breakdown and lactate accumulation (Crossland et al., 2010).  
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Akt and regulation of FoxO transcription factors 
In regards to the inhibition of FoxO protein activity, the serine-threonine kinase protein 
kinase-b (Akt) is a primary mediator of phosphorylation of FoxO. FoxOs are mainly 
regulated via reversible changes in subcellular localization by Akt dependent 
phosphorylation. Several serine/threonine kinases, including the Akt family of protein 
kinases and the related SGK (serum and glucocorticoid inducible kinase) are activated by 
phosphoinositide kinase (PI3K) upon stimulation and activation by insulin or other growth 
factors via their binding to their tyrosine kinase receptors. Akt dependent 
phosphorylation of FOXO transcription factors at the N-terminal site, creates a binding 
motif for 14-3-3 proteins and also interferes with the DNA binding domain of FOXO that 
facilitates the translocation of FOXO from the nucleus into the cytoplasm(Van Der Heide 
et al., 2004). Akt activity and cytoplasmic localization are necessary for FoxO1 
ubiquitination and subsequent proteosome-dependent degradation (Huang et al., 2005). 
The nuclear exclusion and cytoplasmic translocation of FoxO also inhibits transcription of 
the muscle specific ubiquitin ligases, MAFbx and MuRF1 that causes skeletal muscle 
atrophy.  
The protein kinase Akt, is an upstream activator of protein synthesis and has been shown 
to have growth-promoting effects in muscle. Other factors that are downstream of Akt, 
such as mTOR and p70s6 kinase are regulated by Akt and are involved in muscle protein 
synthesis (Rommel et al., 2001). Decreased phosphorylation of both mTOR and p70S6 
kinase is shown to be consistent with decreased translation rate and muscle unloading 
(Bodine et al., 2001b) and overexpression of Akt is associated with attenuation of 
denervation-induced atrophy in rodents by 70% (Hornberger et al., 2001).  
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Furthermore, it has been reported that Akt signalling also mediates other cellular 
functions such as modulation of glycolysis through the regulation of phosphofructokinase 
and regulation of protein synthesis such as activation of mTOR and p70skk and inhibition 
of glycogen synthase kinase 3 (GSK3). An interesting study in myotubes transfected with 
Akt, showed that Akt inhibited the Dexamethasone induced dephosphorylation of FOXOs 
and consequently blocked the induction of atrogin-1 (MAFbx), demonstrating that the 
activity of AKT 1 is sufficient to inactivate FOXOs and reduce atrogin-1 (MAFbx) 
expression (Nader, 2005) . 
Myostatin, a member of the Transforming Growth Factor-ɴĨĂŵŝůǇ ?ŚĂƐďĞĞŶĂƐƐŽĐŝĂƚĞĚ
with muscle wasting in conditions such as immobilization (Carlson et al., 1999), HIV 
infection (Gonzalez-Cadavid et al., 1998) and chronic muscle disuse (Reardon et al., 
2001). Myostatin has also been shown to inhibit muscle carbohydrate oxidation 
(McPherron and Lee, 2002) and inhibits protein synthesis via the Akt/mammalian target 
of rapamycin (mTOR)/p70S6k signalling pathway (Trendelenburg et al., 2009). Myostatin 
overexpression in myoblasts induces muscle wasting by directly inhibiting 
phosphorylation of Akt, thereby increasing activity of FOXO transcription factors and its 
expression of downstream targets. FoxO1, in addition to activation of the ubiquitin 
ligases, could also enhance muscle atrophy through inhibition of myogenesis resulting 
from enhanced myostatin expression (Allen and Unterman, 2007).  
Surgical patients are prone for oxidative stress resulting from free radical injury from 
ischemic tissues. Oxidative stress may result in the release of reactive oxygen species 
(ROS) is reported to be associated with mitochondrial DNA mutations in tissue injury and 
aging. Both, cellular survival and longevity are intimately dependent on exposure to 
52 
 
oxidative stress and induction of apoptotic pathways (Chong et al., 2005, Yui and 
Matsuura, 2006). It has been reported that Akt can prevent cellular apoptosis and is 
usually cyto-protective, such as during free radical exposure (Chong et al., 2003, 
Matsuzaki et al., 1999), hyperglycaemia (Anitha et al., 2006), hypoxia and oxidative stress 
(Kang et al., 2003a, Kang et al., 2003b).  
A critical component of muscle metabolism during fasting or other catabolic states is a 
switch from oxidation of carbohydrates as the major energy source to fatty acids. FoxO1 
is involved in this adaptive response (Bastie et al., 2005). In calorie restriction (CR) or 
starvation, FoxOs are in the nucleus, and therefore active transcriptionally, and are 
associated with increased hepatic glucose production, decreased insulin secretion, and 
degradation of skeletal muscle for supplying substrates for glucose production.  
FOXO transcription factors are also involved in the inhibition of muscle carbohydrate 
oxidation, via increased pyruvate dehydrogenase kinase-4 (PDK4) transcription 
(Furuyama et al., 2003) as a result of impaired stimulation of PI3K and Akt1 (Kim et al., 
2006). PDK4 phosphorylates and inactivates the pyruvate dehydrogenase complex (PDC), 
which promotes pyruvate entry into mitochondria and thereby regulates carbohydrate 
oxidation. Insulin and IGF-1 can suppress FoxO protein activity through activation of Akt 
(Guo et al., 1999, Nakae et al., 1999). In terms of protein synthesis, IGF-1 is also involved 
in myoblast differentiation through PI3K/Akt (Tureckova et al., 2001). Inactivation of IGF 
signaling by targeted mutagenesis of IGF1 receptor leads to muscle hypoplasia (Liu et al., 
1993), whereas overexpression of IGF1 results in enlarged myofibers (Coleman et al., 
1995). FOXO proteins can stimulate the insulin-like growth factor-binding protein-1 
promoter by binding to the insulin-responsive sequence.  
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Studies on animal models and healthy volunteers have also shown a strong association of 
insulin signalling and the role of FOXO transcription factors, in causing insulin resistance 
and skeletal muscle wasting. Specifically, using an animal-endotoxaemia model, the study 
by Crossland et al, has shown that an inhibition of PI3K/Akt1 signaling, and activation of 
the Forkhead Box O (FOXO) family of transcription factors that lie downstream of 
PI3K/Akt1, occurs concomitantly with muscle atrophy and the impairment of muscle 
carbohydrate oxidation (Crossland et al., 2008). Importantly, these events were 
accompanied by marked upregulation of FOXO gene targets, i.e. muscle atrophy F-box 
(MAFbx), muscle RING finger 1 (MuRF1) and pyruvate dehydrogenase kinase-4 (PDK4), 
which strongly suggests a role for Akt/FOXO signaling in the simultaneous induction of 
muscle atrophy and impairment of muscle carbohydrate oxidation during endotoxaemia 
(fig 1.7A and 1.7 B).  
In keeping with this premise, activation of FOXO, as a result of impaired Akt signaling, has 
been implicated in the induction of muscle atrophy, via upregulation of E3-ubiquitin 
ligases MAFbx and MuRF1 (Stitt et al., 2004), which are considered to be key regulators 
of muscle protein breakdown (Bodine et al., 2001a).  
Impaired Akt/FOXO signaling has also been implicated in muscle insulin resistance, 
through FOXO-mediated up-regulation of PDK4 and reduction in the mitochondrial 
pyruvate dehydrogenase complex (PDC) activity which controls the rate of 
carbohydrate/pyruvate oxidation (Kim et al., 2006). An increase in muscle PDK4 
expression down-regulates the activity of PDC, leading to an impairment of muscle 
carbohydrate oxidation (Crossland et al., 2008). Based on the above evidence, we 
contend that the systemic inflammatory response secondary to surgical trauma could be 
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responsible for the concomitant activation of muscle protein breakdown and induction of 
muscle insulin resistance.  
LPS study in rodents
A
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Fig 1.7 A: Stimulation with growth factors, such as insulin-like growth factor-1 (IGF-1), and hormones, such 
as insulin, leads to the activation of the phosphatidylinositol-3 kinase (PI3K)/Akt signalling cascade. 
Phosphorylation of Forkhead box O (FOXO) by Akt1 leads to their exclusion from the nucleus, and a 
reduction in the expression of key genes involved in the regulation of carbohydrate oxidation pyruvate 
dehydrogenase kinase-4 (PDK4). (Figure adapted from Crossland et al, J Physiol 586.22 (2008) pp 5589-
5600) 
Fig 1.7 B: LPS-induced endotoxaemia: Akt1 is in a predominantly dephosphorylated / inactive state, 
possibly due to elevated cytokine levels, such as tumour necrosis factor-ɲ ?dE&-ɲ ? ?dŚŝƐĞŶĂďůĞƐ&KyK
factors to up-regulate PDK4 causing inhibition of the pyruvate dehydrogenase complex (PDC). Inhibiting the 
activity of PDC by phosphorylation of the complex, prevents the conversion of carbohydrate-derived 
pyruvate into acetyl-CoA which is the rate limiting step for carbohydrate oxidation. (Figure adapted from 
Crossland et al, J Physiol 586.22 (2008) pp 5589-5600). 
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1.5.2 Role of Pyruvate Dehydrogenase Complex and Pyruvate dehydrogenase kinase in 
POIR 
PDC is a multi-enzyme complex located on the inner mitochondrial membrane and 
controls the rate limiting step in carbohydrate oxidation, the conversion of pyruvate into 
mitochondrial acetyl-CoA by oxidative decarboxylation of pyruvate. PDC activation and 
acetyl-CoA availability limit oxygen dependent mitochondrial ATP formation. Therefore 
the impairment of PDC activation has an important role in muscle metabolism, as it 
represents the only entry point for carbohydrates, (derived from circulating glucose or 
intramuscular glycogen) into the mitochondria for complete oxidation (Pilegaard and 
Neufer, 2004). The activation status of the PDC is controlled by a covalent modification 
(via phosphorylation-dephosphorylation), involving competing pyruvate dehydrogenase 
kinase (PDK) and phosphatase (PDP) reactions. The resulting inter-conversion cycle 
determines the amount of PDC existing in non-phosphorylated (active) form, i.e. PDCa. 
Phosphorylation of specific serine residues within the enzyme pyruvate dehydrogenase, 
catalysed by PDK, renders it inactive, whereas dephosphorylation and activation of PDC is 
catalysed by pyruvate dehydrogenase phosphatase (Wieland, 1983). The PDK family 
comprises of four isoforms (PDK1-4), of which PDK2 and PDK4 mRNA are most abundant 
in human skeletal muscle (Bowker-Kinley et al., 1998, Spriet et al., 2004).  
It is reported that an increase in free fatty acids (FFA) during energy deficit may be an 
important regulator of PDK4 expression in resting skeletal muscle (Holness et al., 2003), 
which explains up-regulation of PDK4 mRNA in response to prolonged fasting (Wolfe et 
al., 1987, Dobbins et al., 1998), obesity (Wolfe and Peters, 1987), and in pathologies such 
as insulin resistance (Baldeweg et al., 2000) and type-2 diabetes (Reaven et al., 1988). A 
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study investigating the dose-response relationship between elevated FFA levels and 
impaired insulin-mediated glucose disposal in normal glucose-tolerant subjects showed 
inhibition of insulin stimulated glucose uptake inversely correlates with the increased FFA 
levels produced by the lipid infusion (Belfort et al., 2005). This study also showed that an 
increase of plasma FFA levels disrupts insulin signalling by inhibiting insulin receptor 
tyrosine phosphorylation, insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, 
PI3-kinase activity and AKT serine phosphorylation (Belfort et al., 2005).  
Fasting, in addition to exercise, increases the expression of lipoprotein lipase, the enzyme 
that hydrolyses plasma triglycerides into fatty acids and glycerol for uptake by the muscle 
cell (Goldberg, 1996, Greiwe et al., 2000, Rauramaa et al., 1980). FoxO1 levels under 
numerous conditions parallel lipoprotein lipase expression, and overexpression of FoxO1 
in C1C2 myocytes increases lipoprotein lipase (Kamei et al., 2003). Chronic exposure to 
elevated levels of free fatty acids can increase reactive oxygen species production in cells 
and can lead to mitochondrial DNA damage and impaired pancreatic ß-cell function 
(Rachek et al., 2006). Smaller skeletal muscle mitochondria and a decrease in the levels of 
mitochondrial proteins and mitochondrial DNA in adipocytes have been associated with 
the development of insulin resistance. Furthermore, Insulin resistance has also been 
associated with elevation in fat accumulation and altered mitochondrial oxidative and 
phosphorylation activity in the elderly (Choo et al., 2006, Kelley et al., 2002, Petersen et 
al., 2003, Pospisilik et al., 2007). However, the mechanisms by which FFAs up-regulate 
PDK4 expression and inhibit PDC-controlled CHO oxidation in surgical patients, has not 
been investigated previously. Thus it would be interesting to study the link between an 
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overnight fast on circulating FFA in surgical patients and whether it is associated with the 
development of muscle insulin resistance. 
1.5.3 Role of Mitochondria  
Mitochondria play a key role in cell-ƐƵƌǀŝǀĂů ? ŐĞŶĞƌĂƚĞƐ ƚŚĞ ŵĂũŽƌŝƚǇ ŽĨ ĐĞůů ?Ɛ ƐƵƉƉůǇ ŽĨ
adenosine triphosphate (ATP) synthesis through aerobic respiration and oxidation of 
substrates such as glucose, pyruvate and NADH. Studies report changes in markers of 
mitochondrial metabolism associated with depressed oxidative function and impaired 
switching to carbohydrate substrate from fasted to fed state in insulin resistant states. 
Mitochondria convert the products of carbohydrate, protein and fat metabolism to CO2 
and water using the enzymes of the electron transport chain namely, NADH 
dehydrogenase (Complex I), succinate dehydrogenase (Complex II), cytochrome C 
(Complex III) and cytochrome c oxidase (Complex IV). Electrons from NADH + H+ and 
FADH2, are transported from matrix to the Complexes I and II of the electron transport 
chain (ETC), creating an electro-chemical gradient and in the process, synthesize ATP 
within the mitochondrial matrix. The important contributor to the ETC, is the oxidation of 
acetyl-CoA in the tricyclic acid cycle (Johannsen and Ravussin, 2009). 
Therefore, it would be interesting to study if surgical stress induces changes in 
mitochondrial function and contribute to decreased energy production in the form of 
ATP. 
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1.6 Hypothesis  
 
Stress induced hyperglycaemia is common in patients having major surgery and the 
development of POIR and hyperglycaemia has been associated with poor postoperative 
outcomes. Minimising the effects of insulin resistance and managing perioperative 
changes in metabolism has been shown to be improve outcomes in surgical care. In this 
context, ERAS principles may help to attenuate the undesirable consequences of the 
metabolic response to critical illness and enhance anabolic activity during recovery. 
Evidence from studies using the ERAS pathway report that perioperative interventions 
such as reduced fasting times, preoperative carbohydrate treatment and early enteral 
nutrition are associated with improved postoperative outcomes. However, the 
mechanisms that link insulin resistance to surgical stress remain to be determined and 
how these perioperative interventions attenuate the effect of surgical stress remains to 
be largely explored.  
Previous studies in surgical patients looking at the gene expression changes in skeletal 
muscle during surgery suggested a possible role for inflammation in the development of 
insulin resistance (Witasp et al., 2009b). Studies have reported increases in plasma 
concentrations of stress hormones after surgery (Thorell et al., 1993, Thorell et al., 1994), 
and plasma concentrations of pro-inflammatory cytokines have been shown to positively 
correlate with the degree of insulin resistance after surgery (Baigrie et al., 1992, Shenkin 
et al., 1989). These studies suggest the possible role of inflammation and surgical stress 
in the development of POIR. 
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A recent randomised study on the molecular mechanisms underlying the protective 
effects of preoperative feeding using an oral nutrition supplement (ONS) containing 
carbohydrates, glutamine and antioxidants has shown a significant decrease in muscle 
PDK4 mRNA, and PDK4 protein expression in the ONS group (Awad et al., 2010). Whilst 
these perioperative interventions to improve muscle insulin sensitivity in patients having 
major abdominal surgery seem promising, they require further evaluation of the 
molecular mechanisms involved, to confirm their efficacy for perioperative risk reduction 
and to optimise treatment of patients having surgery.  
 
Figure.1.7 showing the potential role of surgical stress induced changes in 
Akt/FOXO/PDK4 signalling in causing postoperative muscle insulin resistance 
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One possible hypothesis for the development of POIR and hence the theme of this 
present research is as follows: 
Inflammatory states such as those induced by surgical stress following major abdominal 
surgery result in systemic release of cytokines and bacterial products, possibly secondary 
to bacterial translocation. Therefore it is possible that the changes in the systemic 
inflammatory response over time, occurring as a result of inflammation and/or infection 
caused by surgical stress, may trigger changes in insulin signalling and important 
downstream targets such as PDK4 and PDC activity resulting in the development of 
skeletal muscle insulin resistance (fig. 1.7) 
 
The reduction in Akt1 activity may lead to the activation of FOXO family of transcription 
factors leading to an increased transcription of MAFbx, MuRF and PDK-4 causing muscle 
protein breakdown and decreased carbohydrate oxidation (through PDC inhibition), 
respectively. The effect of surgical stress on Akt/ Foxo /PDK4 mediated protein 
degradation and insulin resistance has not been studied in human skeletal muscle 
previously. Therefore, the aims of this thesis were to test the aforementioned hypothesis 
by examining the components of these signalling pathways, in the blood and muscle 
biopsy specimens in patients undergoing major elective open abdominal surgery.  
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1.7 Aims  
 
The aims of this this thesis were three-fold,  
(1) To examine the evidence behind the principles of ERAS pathway and the effect of 
preoperative carbohydrate drinks on postoperative outcomes, in patients undergoing 
major abdominal surgery using a systematic review and meta-analytical approach  
(2) To study the molecular basis of the metabolic response to surgery underlying the 
development of postoperative muscle insulin resistance with particular emphasis on 
changes in insulin signalling and mitochondrial function. Specifically, to investigate 
whether alterations in the insulin mediated, Akt/FOXO and PDK4 signaling pathway 
underlies the development of insulin resistance following surgical stress and whether 
these changes in the signaling mechanisms are associated with increased inflammatory 
gene expression in skeletal muscle and  
(3) To study the effect of interventional strategies such as preoperative carbohydrate 
drinks and dichloroacetate in attenuating the development of POIR and the resultant 
changes in the underlying molecular mechanisms, in patients undergoing major 
abdominal surgery. 
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Chapter 2  
 Analytical Methods 
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2.1 Human Volunteers 
Patients who were having major abdominal surgery were contacted and given detailed 
information about the studies. Those who expressed interest in the study were invited 
for a screening visit after an overnight fast (from 22.00 on the night prior to experimental 
day). On arrival, patients completed a general health questionnaire and when considered 
to satisfy the eligibility criteria, a written informed consent was obtained for the patients 
to be included in the studies. Data were collected for demographics, height, weight, 
blood pressure, nutrition status, clinical diagnosis and surgical procedure planned, 
following which serial blood samples were taken and an oral glucose tolerance test 
(OGTT) was performed during the screening visit. The OGTT was repeated again on the 
second day after surgery, to assess postoperative insulin resistance. The studies were 
approved by the Cambridgeshire Medical Research Committee and NHS Ethics 
ŽŵŵŝƚƚĞĞĂŶĚƉĞƌĨŽƌŵĞĚĂƚEŽƚƚŝŶŐŚĂŵhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂůƐYƵĞĞŶ ?ƐDĞĚŝĐĂůĞŶƚƌĞ. 
2.2 Blood sampling and analysis 
Patients were asked to rest in a semi-reclined position on a bed while the hand was 
placed into a heated box for 15 minutes at approximately 55°C, for collection of 
arterialised blood samples(Gallen and Macdonald, 1990), from either the antecubital or 
cephalic veins using a retrograde cannula (21 g Venflon) and subsequently transferred 
into EDTA tubes, and immediately placed on ice. The line was kept patent using a slow 
0.9% saline infusion, for the duration of the study. On the day of surgery, the samples 
were collected about 30 minutes preoperatively and also immediately postoperatively 
after skin closure. Blood samples were also obtained from the patients on the morning of 
the second day after surgery, following an overnight fast. The serum was separated out 
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in a cold centrifuge at 3,000 ƌƉŵĨŽƌ ? ?ŵŝŶƵƚĞƐĂŶĚŝŵŵĞĚŝĂƚĞůǇĨƌŽǌĞŶĂƚAL ? ?° C until 
further analysis. 
2.2.1 Blood glucose 
Blood glucose was collected from patients who participated in the studies (chapters 5 
and 6), and immediately introduced into an automated analyser, to measure the 
concentration of whole blood glucose.  
2.2.2 Plasma Insulin  
Plasma insulin levels were measured using an ELISA kit from Mercodia (Uppsala, 
Sweden). The enzyme-linked immunosorbent assay (ELISA) assay principle is detailed 
below (fig 2.1). 
Figure 2.1 
  
A microplate pre-coated with 
capture antibody is provided. 
Samples or standards are added and 
any analyte present is bound by the 
immobilised antibody. Unbound 
materials are washed away. 
A second HRP-labeled antibody 
(detection antibody) is added and 
binds to the captured analyte. 
Unbound detection antibody is washed 
away. 
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Principle of the procedure 
Mercodia Insulin ELISA is a solid phase two-site enzyme immunoassay. It is based on the 
direct sandwich technique in which two monoclonal antibodies are directed against 
separate antigenic determinants on the insulin molecule. During incubation insulin in the 
sample reacts with peroxidase-conjugated anti-insulin antibodies and anti-insulin 
antibodies bound to microplate wells. A simple washing step removes unbound enzyme 
ůĂďĞůůĞĚ ĂŶƚŝďŽĚǇ ? dŚĞ ďŽƵŶĚ ĐŽŶũƵŐĂƚĞ ŝƐ ĚĞƚĞĐƚĞĚ ďǇ ƌĞĂĐƚŝŽŶ ǁŝƚŚ  ? ? ? ? ? ? ? ?-
tetramethylbenzidine (TMB). The reaction is stopped by adding acid to give a colorimetric 
endpoint that is read spectrophotometrically at 450 nm.  
 
 
Tetramethylbenzidine (TMB) 
substrate solution is added to the 
wells and a blue colour develops in 
proportion to the amount of analyte 
present in the sample. Colour 
development is stopped turning the 
colour in the wells to yellow. The 
absorbance of the colour at 450 nm 
is measured. 
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2.2.3 Plasma Free Fatty Acid 
Extraction methods are widely used for the colorimetric determination of non-esterified 
fatty acids (NEFA) in serum. NEFA are converted to their copper salts that are extracted 
into an organic solvent. The salts are then complexed with a dye for purposed of 
colorimetric measurement. Alternatively, extracted NEFA are titrated with standard alkali 
to an acid base indicator endpoint. These approaches are time consuming, hazardous and 
not easily automated. Wako has made extensive studies of NEFA quantitation and has 
succeeded in developing an original enzymatic method which is available in a series of 
individual reagents. This enzymatic method is accurate, precise, simple and fast. The 
need for an extraction step has been eliminated and the method can be automated. 
The Wako enzymatic method (Wako HR series NEFA-HR2; in vitro enzymatic calorimetric 
assay, Wako Diagnostics, USA), relies upon the acylation of coenzyme A (CoA) by the fatty 
acids in the presence of added acyl-CoA synthetase (ACS). The acyl-CoA thus produced is 
oxidized by added acyl-CoA oxidase (ACOD) with generation of hydrogen peroxide, in the 
presence of peroxidase (POD) permits the oxidative condensation of 3-methy-N-ethyl-
E ?ɴ-hydroxyethyl)-aniline (MEFA) with 4-aminoantipyrine to form a purple coloured 
adduct which can be measured colorimetrically at 550 nm. 
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2.2.4 Plasma Cortisol 
Cortisol, also known as hydrocortisone, is the primary glucocorticoid produced and 
secreted by the adrenal cortex. It is found either free or bound to corticosteroid-binding 
globulin (CBG) in the blood. Cortisol is involved in glucose homeostasis, inflammation, 
hypersensitivity, immunosuppression, and disease resistance.  
The steps for plasma cortisol assay are as follows: 
·    Prepare all reagents, standard dilutions, and samples as directed in the product insert. 
·    Remove excess microplate strips from the plate frame, return them to the foil pouch 
containing the desiccant pack, and reseal. 
 
Calibrator Diluent 
 
·    Add 150 µL of Calibrator Diluent to the 
non-specific binding (NSB) wells.  
·    Add 100 µL of Calibrator Diluent to the 
zero standard (B0) wells.  
 
100 µL Standard, Control, or Sample 
 
·    Add 100 µL of Standard, control, or 
sample to the appropriate wells.  
 
50 µL Conjugate 
 
·    Add 50 µL of Conjugate to all wells.  
 
 
 
 
 
 
68 
 
50 µL Primary Antibody Solution 
 
·     
 
 
 
Add 50 µL of Primary Antibody Solution to each well (except the NSB wells). Cover with a 
plate sealer, and incubate at room temperature for 2 hours on a horizontal orbital 
microplate shaker.  
·    Aspirate each well and wash, repeating the process 3 times for a total of 4 washes.  
 
200 µL Substrate Solution 
 
·    Add 200 µL Substrate Solution to each 
well. Incubate at room temperature for 30 
minutes on the benchtop. PROTECT FROM 
LIGHT.  
 
50 µL Stop Solution 
 
· Add 50 µL of Stop Solution to each well. 
Read at 450 nm within 30 minutes. Set 
wavelength correction to 540 nm or 570 
nm. 
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2.2.5 Plasma cytokines 
Plasma TNF-ɲ, and IL-6 were measured using ELISA Quantikine Human kits from R & D 
Systems (Minneapolis, USA). The Quantikine Human TNF-alpha Immunoassay is a 3.5 or 
4.5 hour solid phase ELISA designed to measure human TNF-ɲŝŶĐĞůůĐƵůƚƵƌĞƐƵƉĞƌŶĂƚĞƐ ?
serum, and plasma. It contains E. coli-derived recombinant human TNF-alpha and 
antibodies raised against this protein. It has been shown to accurately quantitate the 
recombinant factor. Results obtained with naturally occurring TNF-ɲ ƐĂŵƉůĞƐ ƐŚŽǁĞĚ
linear curves that were parallel to the standard curves obtained using the Quantikine kit 
standards. These results indicate that this kit can be used to determine relative mass 
values for natural human TNF-ɲ ? 
The Quantikine Human IL-6 Immunoassay is a 4.5 hour solid phase ELISA designed to 
measure IL-6 in cell culture supernates, serum, and plasma. It contains recombinant 
human IL-6 and antibodies raised against recombinant human IL-6 and has been shown 
to accurately quantitate the recombinant factor. Results obtained using natural IL-6 
showed linear curves that were parallel to the standard curves obtained using the E. coli-
expressed Quantikine kit standards. These results indicate that this kit can be used to 
determine relative mass values for natural human IL-6. 
2.3 
51
Cr-EDTA gut permeability test 
For the study described in chapter 5, a 51Cr-EDTA gut permeability test using an oral 
preparation containing 1.8 MBq of 51-chromium labelled ethylene-diamine-tetra-acetate 
(51Cr-EDTA), (Department of Medical Physics, University of Nottingham, U.K.) in 100 mL 
of water was performed during the screening visit and on the 2nd postoperative day. 24 
hour urine sample was collected and a small sample of urine was counted for 
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raĚŝŽĂĐƚŝǀŝƚǇ ďǇ Ă ɶ-scintillation counter in triplicate (IGE Millennium VG camera with 
Hawkeye CT and Wallac Wizard 3 automatic gamma counter). Results were expressed as 
the percentage urinary excretion of the orally administered dose of 51Cr-EDTA. 
2.4 Muscle Sampling 
Muscle biopsies of approximately 100  W 200 mg, were taken from rectus abdominis and 
vastus lateralis muscles at the beginning and at the end of surgery, using a conchotome, 
whilst the patients were under the effect of general anaesthesia. Another biopsy from 
vastus lateralis was obtained on the second day after surgery in chapter 5, using 1% 
lignocaine local anaesthesia. The samples obtained were dissected free of connective 
tissue and fat and were immediately snap-frozen in liquid nitrogen for future analysis. 
The specimens obtained at the end of surgery were taken from the contralateral side to 
avoid false measurements due to local tissue injury.  
2.5 Muscle mRNA and protein analysis 
2.5.1 Real-time quantitative polymerase chain reaction (PCR) 
Overview of quantitative real-time PCR 
The technique of real-time PCR is a widely-used method for rapidly and accurately 
quantifying selected mRNA transcripts in a sample, and was first developed in the early 
1990s by Higuchi et al. (Higuchi et al., 1993). It is used to detect the products of PCR as 
they accumulate after each thermal cycle, without interfering with the reaction itself. 
Reverse transcription PCR (RT-PCR) enables the reverse transcription of a desired RNA 
template into single-stranded cDNA, followed by its exponential amplification. Two 
synthetic DNA oligonucleotides, designed to be complementary in sequence to opposite 
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ends of the amplicon of interest, are annealed to the DNA template, after first heating 
the reaction mixture to allow strand separation. In the presence of the four 
deoxyribonucleoside triphosphates, DNA polymerase synthesises new DNA from the two 
ƉƌŝŵĞƌƐ ŝŶ Ă  ? ? ƚŽ  ? ? ĚŝƌĞĐƚŝŽŶ  ?&ŝŐƵƌĞ  ?.2). This process is repeated, resulting in the 
exponential amplification of the amplicon product. 
 
Figure 2.2: A diagrammatic representation of the steps of the PCR reaction and the role of 
TaqMan probes in real time PCR.    
 
In real-time PCR, using a fluorogenic-labelled DNA oligonucleotide probe, the reaction 
can be monitored over time. TaqMan probes are short oligonucleotides that are 
constructed with a fluorescent reporter dye and a corresponding quencher dye at each 
end and designed to hybridise to the target strand within the boundaries of the 
amplicon. When the probe is intact, the proximity of the quencher greatly reduces the 
fluorescence emitted by the reporter dye, by a process known as Fluorescence 
Resonance Energy Transfer (FRET). During the PCR, the DNA polymerase extends the DNA 
strand from the annealed primers until it encounters the TaqMan probe downstream of 
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ƚŚĞƉƌŝŵĞƌ ?dŚĞ ? ?ĞǆŽŶƵĐůĞĂƐĞĂĐƚŝǀŝƚǇŽĨEƉŽůǇŵĞƌĂƐĞŝƐƵƐĞĚƚŽĐůĞĂǀĞƚŚĞdĂƋDĂŶ
probe to remove the nucleotides and proceed with polymerisation. This process 
physically separates the reporter dye from the quencher dye, thus increasing reporter 
dye signal. Additional reporter dye molecules are cleaved from their probes with each 
PCR cycle, resulting in an increase in fluorescence intensity, which can be detected 
spectrophotometrically. 
By measuring the increase in fluorescence emission after each thermal cycle, the kinetics 
of the PCR reaction can be monitored in real time. Generally, there are three main 
phases during amplification: the exponential, linear and plateau phase (Figure 2.3).          
Figure 2.3: Example of a real-time PCR plot showing the three main phases of the 
reaction; the exponential, linear and plateau phase. A threshold of fluorescence is set in 
the exponential phase, and the cycle number at which reporter emission of the sample 
reaches this threshold is reported as the cycle threshold (Ct) value. 
  
 
Initially, fluorescence levels are lower than can be detected, but increase with each cycle 
number, proportional to the amount of amplicon produced. It is during the exponential 
phase (when amplicon number is doubling every cycle (assuming 100% efficiency) that 
samples can be analysed, where the fluorescence detected is directly proportional to the 
quantity of cDNA in the sample. A threshold value of fluorescence is set in the 
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exponential phase of the reaction, and the cycle number at which this is reached is 
reported as the cycle threshold (Ct) value. Thus, the higher the quantity of cDNA in the 
sample at the beginning of the reaction, the sooner the threshold value of fluorescence 
will be reached.  
Relative quantification of mRNA from the Ct data is performed using the standard curve 
or the comparative Ct method (see User Bulletin No. 2 for ABI Prism 7700 Sequence 
Detection System (P/N 4303859); Applied Biosystems). The standard curve method 
involves analysis of a serially diluted standard on each plate examined. Samples are 
expressed as a fold change relative to the undiluted standard (unless the standard 
concentration is known, in which case absolute quantification of mRNA is possible). This 
method requires less optimisation than the Ct method, but relies on accurate pipetting of 
the standard and for absolute quantification, accurate determination of the standard 
concentration. The comparative Ct method relies upon an endogenous reference to 
quantify RNA rather than a standard curve. Relative quantification is based on changes in 
steady-state mRNA levels of the target gene, relative to levels of an endogenous control 
(a housekeeping gene). Relative expression of target mRNA between two groups can be 
determined by the formula: 
Relative amount of target mRNA = 2-ȴȴƚ 
tŚĞƌĞ PȴȴƚA?ȴƚtreatment group  W ȴƚcontrol group 
ĂŶĚ PȴƚA?ƚtarget gene  W Ctendogenous reference 
 ŝ ?Ğ ? ƚŚĞ ŶŽƌŵĂůŝƐĂƚŝŽŶ ŽĨ ȴƚ ŽĨ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ŐƌŽƵƉ ƚŽ ƚŚĞ ŵĞĂŶ ȴƚ ŽĨ ƚŚĞ ĐŽŶƚƌŽů
ŐƌŽƵƉ ?ǁŝƚŚȴƚďĞŝŶŐƚŚĞĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞƚŚƌĞƐŚŽůĚĐǇĐůe of the gene of interest 
and the endogenous control. The advantages of the comparative Ct method are that a 
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standard curve is not necessary for each plate, and sample-to-sample variations in RT-
PCR efficiency and pipetting errors are corrected by use of the endogenous reference. 
However, for the 2-ȴȴƚ formula to be valid, the amplification efficiency of the target and 
endogenous reference has to be approximately equal. The chosen housekeeping gene 
chosen (HMBS) is crucial to the reliability of the results. 
 Appropriate housekeeping genes chosen for use as an endogenous reference are 
generally those that are required for the maintenance of the cell, are ubiquitously 
expressed, and are transcribed at a relatively constant level. Importantly, their 
expression levels must not be affected by experimental conditions. Common 
ŚŽƵƐĞŬĞĞƉŝŶŐ ŐĞŶĞƐ ŝŶĐůƵĚĞ  ? ?^ ZE ? ɴ-actin, glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and albumin. In these studies, the housekeeping gene 
hydroxymethylbilane synthase (HMBS), also known as porphobilinogen deaminase 
(PBGD) was used as an endogenous reference for its Ct consistency through all the 
experiments. HMBS exists in two isoforms (Chretien et al., 1988); one is expressed in 
erythrocytes where it is involved in haem biosynthesis, and the other is expressed 
ubiquitously, and has been suggested to be a reliable endogenous reference for use in 
real-time PCR (Fink et al., 1999).  
2.5.2 Muscle total RNA isolation 
Total RNA was extracted from frozen wet muscle samples (20-30 mg) by homogenisation 
using a polytron homogeniser for  ? ? Ɛ ? ŝŶ  ? ? ? ʅů ŝĐĞ-cold Tri Reagent® (Sigma-Aldrich, 
WŽŽůĞ ? h< ? ĐŽŶƚĂŝŶŝŶŐ  ? ? ʅŐ ?ʅů ŐůǇĐŽŐĞŶ ƐŽůƵƚŝŽŶ  ?^ŝŐŵĂ-Aldrich, Poole, UK). The 
ŚŽŵŽŐĞŶĂƚĞǁĂƐ ŝŶĐƵďĂƚĞĚĂƚ ƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ ĨŽƌ  ?ŵŝŶ ƚŚĞŶƚƌĞĂƚĞĚǁŝƚŚĂ  ? ? ?ʅů
mixture of chloroform: isoamyl alcohol in a ratio of 49:1. Samples were shaken vigorously 
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for 30 s. Following incubation at room temperature for 2-3 min, the homogenate was 
centrifuged at 12,000 g for 15 min at 4oC. The aqueous phase, containing RNA separated 
from contaminating protein, was collected, and RNA was precipitated using ice-cold 
isopropanol (Sigma-Aldrich, Poole, UK) at 1:1 water phase:alcohol. Samples were kept at 
-20o C overnight to increase precipitation yield and subsequently pelleted by 
centrifugation (12,000 g, 15 min). The RNA-containing pellets were left to dry at room 
ƚĞŵƉĞƌĂƚƵƌĞ ĨŽƌ  ? ŵŝŶ ĂŶĚ ǁĂƐŚĞĚ ŝŶ  ? ? ? ʅů ŽĨ  ? ?A? ĞƚŚĂŶŽů ? ďĞĨŽƌĞ ďĞŝŶŐ ƌĞƐƉƵŶ Ăƚ
10,000 g for 10 min. The pellets were air-dried to remove ethanol and resuspended in 35 
ʅů ŽĨ ZEĂƐĞ-free water. Total RNA was quantified through spectrophotometric 
measurement at 260 nm and 280 nm, and RNA quality determined by the 260:280 nm 
ratio. 
2.5.3 cDNA synthesis (reverse transcription) 
Extracted total RNA samples were diluted with RNase-ĨƌĞĞǁĂƚĞƌƚŽ ? ? ?ʅŐ ?ʅůĂŶĚƌĞǀĞƌƐĞ
trĂŶƐĐƌŝƉƚŝŽŶǁĂƐĐĂƌƌŝĞĚŽƵƚƵƐŝŶŐ ?ʅŐZE ?dŽƚĂůZEǁĂƐĨŝƌƐƚŝŶĐƵďĂƚĞĚĂƚ ? ?o C for 5 
ŵŝŶŽŶĂƚŚĞƌŵŽĐǇĐůĞƌ ?ƉƉĞŶĚŽƌĨ ?ŝŶƚŚĞƉƌĞƐĞŶĐĞŽĨ ?ʅůƌĂŶĚŽŵƉƌŝŵĞƌƐ ? ? ? ?ʅŐ ?ŵů ?
Promega, Madison, USA), to denature secondary structures and allow primers to anneal. 
ZĞǀĞƌƐĞƚƌĂŶƐĐƌŝƉƚŝŽŶǁĂƐƉĞƌĨŽƌŵĞĚƵƐŝŶŐ ?ʅůDĂůŽŶĞǇŵƵƌŝŶĞůĞƵŬĂĞŵŝĂǀŝƌƵƐ ?DD>s ?
ƌĞǀĞƌƐĞ ƚƌĂŶƐĐƌŝƉƚĂƐĞ  ? ? ? ? h ?ʅů ? ?  ? ʅů ŽĨ DD>s ƌĞǀĞƌƐĞ ƚƌĂŶƐĐƌŝƉƚĂƐĞ ďƵĨĨĞƌ ?  ? ? ? ʅů ŽĨ
ZEĂƐĞŝŶŚŝďŝƚŽƌ ? ? ?h ?ʅů ?ĂŶĚ ? ? ? ?ʅůŽĨĂƉŽŽůĞĚŶƵĐůĞŽƚŝĚĞŵŝǆ ?ĐŽŶƚĂŝŶŝŶŐĚdP, dGTP, 
dCTP and dUTP at a concentration of 10 mM each (all from Promega). Samples were 
ŵĂĚĞ ƵƉ ƚŽ  ? ? ʅů ƵƐŝŶŐ ZEĂƐĞ-free water, and incubated at room temperature for 10 
min, followed by 1 hr at 42oC for the reverse transcription reaction to occur, and finally 
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15 min at 70oC to inactivate the reverse transcriptase enzyme. Newly synthesised cDNA 
samples were subsequently diluted 4-fold with RNase-free water and stored at -80o C. 
 
2.5.4 Real-time Quantitative PCR 
The housekeeping gene PBGD (Porphobilinogen deaminase) is amplified for 
normalization of the data. 
A PCR reaction mixture was set up in a 96-well PCR plate, with 2 µl cDNA template, in a 
total reaction volume of 25 µl, consisting 1.25 µl primer/probe mix, 12.5 µl PCR Master 
Mix (Eurogentec, Qiagen) and 8.75 µl RNase-free water. Reactions for all samples as well 
as a non-ƚĞŵƉůĂƚĞĐŽŶƚƌŽůĂŶĚ  ‘Zd-ŵŝŶƵƐ ?ǁĂƐƉĞƌĨŽƌŵĞĚ ŝŶĚƵƉůŝĐĂƚĞŽŶƚŚĞ/WƌŝƐŵ
7000 Sequence Detection System (Applied Biosystems). Parameters for PCR includes 1 
cycle of 50o C for 2 min, 1 cycle of 95o C for 10 min followed by 40 cycles of 95o C for 15 s 
and 60o C for 1 min. For FOXO1, a slightly different template was used for Taqman: 1 
cycle of 50o C for 2 min, 1 cycle of 95o C for 15 min then 45 cycles of 76o C for 30 s, 94o C 
for 15 s and 56o C for 30 s. 
RT-PCR involves reverse transcription of an RNA template into single-stranded cDNA, 
followed by its exponential amplification in a PCR reaction. Reverse transcription 
followed by PCR is an effective method of detecting and quantifying mRNA in a sample. 
Sensitivity, reproducibility and specificity are key factors for successful RT-PCR in the 
analysis of gene expression. Relative quantification is based on changes in steady-state 
mRNA levels of the target gene, relative to levels of an endogenous control (a 
housekeeping gene). Ŷ  ‘Zd-ŵŝŶƵƐ ? ĐŽŶƚƌŽů ŝƐ ŝŶĐůƵĚĞĚ ŝŶ ƚŚĞ WZ ƌĞĂĐƚŝŽŶ ? ƚŽ ĐŽŶĨŝƌŵ
that no contaminating DNA is present. 
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During PCR, fluorescence is detected for each temperature cycle, which at the start is 
lower than can be detected, and increases with each cycle number to eventually cross a 
threshold fluorescence value. The cycle number where this occurs is defined as Ct, and 
this always takes place during the exponential phase of amplification. The number of 
copies of amplicon should double with every cycle, and the fluorescence detected is 
directly proportional to the quantity of cDNA in the sample. The higher amount of cDNA 
in the sample at the beginning of the reaction, the fewer number of cycles it takes to 
reach the threshold fluorescence value, therefore the lower the Ct value. The amount of 
amplified target is directly proportional to the amount of starting material only during 
the exponential phase of the reaction. Relative expression between two groups can be 
determined by: 2-ȴȴƚ ? ǁŚĞƌĞ ȴȴƚ A?  ?ƚƚĂƌŐĞƚ- CtPBGD)LPS - (Cttarget - 
ƚW' ?ŽŶƚƌŽůĂŶĚŝƐƚŚĞŶŽƌŵĂůŝǌĂƚŝŽŶŽĨȴƚŽĨƚŚĞƐĂŵƉůĞƚŽƚŚĞĂǀĞƌĂŐĞȴƚŽĨƚŚĞ
ĐŽŶƚƌŽůŐƌŽƵƉ ?ǁŝƚŚȴƚďĞŝŶŐƚŚĞĚŝĨĨĞƌĞŶĐĞďĞƚǁĞĞŶƚŚĞĂǀĞƌĂŐĞƚŚƌĞƐŚŽůĚĐǇĐůĞŽĨƚŚĞ
endogenous control and gene of interest.  
dŚĞȴȴƚŵĞƚŚŽĚǁĂƐƵƐĞĚƚŽĚĞƚĞƌŵŝŶĞƚŚĞƌĞůĂƚŝǀĞƋƵĂŶƚŝĨŝĐĂƚŝŽŶŽĨŐĞŶĞĞǆƉƌĞƐƐŝŽŶŝŶ
the studies. ƚǀĂůƵĞƐ ĨŽƌƐĂŵƉůĞĚƵƉůŝĐĂƚĞƐǁĞƌĞĂǀĞƌĂŐĞĚĂŶĚƚŚĞȴƚĚĞƚĞƌŵŝŶĞĚďǇ
subtraction of the average Ct value for the housekeeping gene, PBGD. This was done for 
treated and control samples. ȴȴƚǁĂƐĐĂůĐƵůĂƚĞĚƵƐŝŶŐ ?ƚŽƚŚĞƉŽǁĞƌŽĨƚŚĞĚŝĨĨĞƌĞŶĐĞ
ŝŶȴƚďĞƚǁĞĞŶƐĂŵƉůĞƐ ?ŽƌƚŚĞȴƚŽĨƚƌĞĂƚĞĚƐĂŵƉůĞƐŵŝŶƵƐƚŚĞŵĞĂŶȴƚŽĨĐŽŶƚƌŽůƐ ?
and fold changes in mRNA expression for each gene from samples obtained before and 
after surgery was calculated using the expression 2-ȴȴƚ ?  
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2.5.5 Taqman analysis 
Taqman primer and probe (FAM) sets are obtained from Applied Biosystems (Foster City, 
California, USA). Primer/probe sequences are not available due to protection of 
intellectual property rights, but are designed to span across exon/exon boundaries, thus 
ensuring the exclusion of genomic DNA as a template in the PCR reaction. Previous work 
(Constantin et al., 2010) validated the primer and probe sets, which is achieved by 
performing RT-PCR with a series of 2-fold cDNA template dilutions to generate standard 
curves of Ct against log relative concentration. Given that all primer/probe sets amplified 
cDNA with equal efficiency (data not shown), the comparative Ct method is used for the 
relative quantification of gene expression. Specificity was assured by using TaqMan 
probes that spanned only over exon-exon boundary within each unique transcript. A 
minus RT reaction was amplified regularly along with the transcripts of interest to 
identify the presence of genomic DNA, if any. The size of amplicon generated was 
determined by electrophoresing the PCR products on 3% agarose and comparing it to the 
theoretical size. Sensitivity of the gene expression assays were determined by serial 
dilation curves of a known amount of cDNA. As a thumb rule 5 ng of cDNA could elicit 
reliable amplification curves (Ct around 35) of low expressed transcripts. 
Reactions for all samples as well as a non-ƚĞŵƉůĂƚĞĐŽŶƚƌŽůĂŶĚ ‘Zd-ŵŝŶƵƐ ?are performed 
in duplicate on the ABI Prism 7700 Sequence Detection System (Applied Biosystems). A 
PCR reaction mixture is set up in a 96-ǁĞůůƌĞĂĐƚŝŽŶƉůĂƚĞ ?ǁŝƚŚ ?ʅůŽĨĐEƚĞŵƉůĂƚĞŝŶ
ĞĂĐŚǁĞůů ?ŝŶĂƚŽƚĂůƌĞĂĐƚŝŽŶǀŽůƵŵĞŽĨ ? ?ʅů ?ĐŽŶƐŝƐƚŝŶŐ ? ? ? ?ʅůŽĨƉƌŝŵĞƌ ?ƉƌŽďĞŵŝǆ ? ? ? ? ?
ʅůŽĨWZhŶŝǀĞƌƐĂůDĂƐƚĞƌDŝǆ ?ƵƌŽŐĞŶƚĞĐ ?ĂŶĚ ? ? ? ?ʅůŽĨZEĂƐĞ-free water. Parameters 
for the PCR reaction include 50o C for 2 min, 95oC for 10 min followed by 40 cycles of 95o 
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C for 15 s and 60o ĨŽƌ ?ŵŝŶ ?dŚĞƚǀĂůƵĞƐĨŽƌĞĂĐŚĚƵƉůŝĐĂƚĞĂƌĞĂǀĞƌĂŐĞĚĂŶĚƚŚĞȴƚ
calculated by the subtraction of the corresponding mean Ct value for the normalization 
gene HMBS. Data from all treatment groups are normalised to the average of the saline 
control group. 
2.6 Western blotting 
2.6.1 Overview of Western blotting protocol 
Western blotting is a routine technique used for the analysis of protein expression and 
phosphorylation status that was first introduced by Towbin et al. in 1979 (Towbin et al., 
1979). The technique involves the use of specific antibodies to identify proteins that have 
been separated according to their size by gel electrophoresis. After separation, proteins 
are transferred to a membrane, which replicates the pattern of proteins on the gel, 
allowing their detection on the membrane surface. It is the specificity of the interactions 
between antibody and antigen that enables the target protein to be detected within the 
sample. 
 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a standard 
method used to separate proteins according to their molecular weight. Following 
extraction from tissues, protein samples are diluted in a buffer containing SDS, an anionic 
detergent used to denature and solubilise proteins. The function of SDS is to bind to the 
polypeptide backbones so that they become negatively charged. SDS binds specifically in 
a mass ratio of 1.4:1; therefore the negative charge on the polypeptide will be roughly 
proportional to its length, ensuring that migration speed through the gel is determined 
by the molecular weight of the protein. Samples may also be treated with DTT to reduce 
disulphide bridges. Polyacrylamide gels are a neutrally charged, hydrophilic network of 
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long hydrocarbons cross-linked by methylene groups. The size of pore created in the gel 
can be controlled by the total amount of acrylamide and cross-linker present, which 
ultimately determines the separation of molecules within the gel Proteins are individually 
separated by passing a current through the separating gel in a chamber containing an 
SDS-containing migration buffer. 
Following electrophoresis, the negatively-charged proteins in the gel are transferred, by 
application of an electrical current, onto a membrane, which provides a sturdy support 
for protein detection. The most commonly used membranes are polyvinylidene fluoride 
(PVDF) and nitrocellulose. Membranes are placed next to the gel, sandwiched between 
absorbent materials and clamped between solid supports to maintain tight contact 
between the gel and membrane. Following transfer, membranes are blocked with either 
non-fat milk or BSA to prevent any non-specific background binding of antibodies to the 
membrane surface. The steps following blocking include incubation with a primary 
antibody specific for the protein of interest, washing of the membrane and incubation 
with a secondary antibody. Secondary antibodies are typically conjugated to enzymes 
that allow for signal amplification and visualisation of the protein bands. Horseradish 
peroxidase (HRP) is often used, which can be reacted with a chemiluminescent substrate, 
producing light as a byproduct. The signal intensity should correlate with the abundance 
of the protein on the membrane. 
2.6.2 Extraction of muscle proteins 
Cytosolic and nuclear proteins were extracted using a modification of the method by 
Blough et al. (1999). Approximately 30 mg of frozen wet tissue was homogenised for 30 s 
in 20 volumes of homogenisation buffer containing: 50 mM Tris-HCl, 1 mM EDTA, 1 mM 
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EGTA, 1% (v/v) IGEPAL and 0.1% (v/v) 2-mercaptoethanol (pH 7.5). To every 1 ml of 
ŚŽŵŽŐĞŶŝƐĂƚŝŽŶďƵĨĨĞƌ ? ? ?ʅůŽĨĂƉƌŽƚĞĂƐĞŝŶŚŝďŝƚŽƌĂŶĚĂƉŚŽƐƉŚĂƚĂƐĞŝŶŚŝďŝƚŽƌĐŽĐŬƚĂŝů
(Sigma-Aldrich, Poole, UK) was added. Muscle lysates were left on ice for 15 min before 
being centrifuged (10,000 g, 5 min at 4o C). The supernatant, containing cytosolic 
proteins, is stored at -80o ?dŚĞƌĞŵĂŝŶŝŶŐƉĞůůĞƚǁĂƐƌĞƐƵƐƉĞŶĚĞĚŝŶ ? ? ?ʅůŽĨĂŶŝĐĞ-cold 
buffer containing 20 mM HEPES, pH 7.9, 25% (v/v) glycerol, 500 mM NaCl, 1.5 mM MgCl2 
and 0.2 mM EDTA, pH 8.0. To this, further protease and phosphatase inhibitors are 
ĂĚĚĞĚ ? ? ?ʅů ?ŵů ? ?ĂŶĚƐĂŵƉůĞƐǁĞƌĞŝŶĐƵďĂƚĞĚŽŶŝĐĞĨŽƌ  ? ?ŵŝŶ ?ŵŝǆŝŶŐŝŶƚĞƌŵŝƚƚĞŶƚůǇ ?
Samples were spun down (3,000 g, 5 min) and the supernatant, containing nuclear 
proteins, was stored at -80o C. Extracted proteins were quantified using the Bradford 
assay (Bio-ZĂĚ ? h< ? ĂŶĚ ĚŝůƵƚĞĚ ƚŽ Ă ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ  ? ? ʅŐ ? ? ? ʅůǁŝƚŚ  ? ? ? ʅů ŽĨ  ?ǆ
NuPAGE® LDS sample buffer (InvitroŐĞŶ ?h< ?ĂŶĚ ?ʅůŽĨĨƌĞƐŚdd ? ? ?ŵŐ ?ŵů ? ?WƌĞƉĂƌĞĚ
samples were heated at 70o C for 10 min before loading. 
 2.6.3 SDS-PAGE, transfer and Western blotting 
 
Twenty-ĨŝǀĞʅŐŽĨƉƌŽƚĞŝŶǁĂƐůŽĂĚĞĚŽŶƚŽĂEƵW' ? ?-12% Bis-Tris gel (Invitrogen, UK) 
and separated by molecular weight, at a constant voltage of 200 V for 1 h, using 1x Tris-
Glycine SDS running buffer (Invitrogen, UK). A pre-stained protein marker (Bio-Rad, UK) 
was loaded onto each gel to indicate approximate band size. Following electrophoresis, 
proteins were transferred overnight at 4o C to a PVDF membrane, sandwiched within a 
cassette consisting of two sheets of blotting paper and one sponge on either side of the 
PVDF and gel (with care taken not to introduce air bubbles), and within a chamber 
containing 1x Tris-Glycine plus 20% (v/v) methanol. Following transfer, equal loading of 
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samples was confirmed by Ponceau S staining of the membrane. Membranes were 
subsequently blocked with 5% (w/v) BSA in 1% Tris-buffered saline (TBS) for 1 hr at room 
temperature, followed by an overnight incubation at 4oC with a polyclonal rabbit primary 
antibody (Cell Signaling Technology, Danvers, USA). 
 The following day, membranes were washed in TBS-Tween for 15 min (changing the 
solution every 5 min) and incubated for 1 hr with the secondary antibody, which is HRP-
conjugated donkey anti-rabbit antibody (GE Healthcare, Little Chalfont, UK). Bands were 
visualised by development with enhanced chemiluminescence (ECL) reagents (Pierce, 
UK). Reagent A and B were mixed in a 1:1 ratio and pipetted onto the membrane, 
ensuring complete coverage. After 2 min, membranes were blotted to remove the 
detection reagents, and in the dark room, blots are exposed to X-ray film and 
subsequently developed. Films were scanned and bands are quantified by densitometry 
using GeneTools software (Syngene, Frederick, USA). Values were adjusted by subtracting 
the background and normalized to an actin protein control for cytosolic proteins and 
lamin for nuclear proteins (New England BioLabs, Hitchin, UK). 
2.7 Analysis of Muscle Glycogen 
2.7.1 Extraction procedure for measurement of muscle glycogen 
Freeze dried powdered aliquots of muscle tissue were extracted according to the method 
of Harris et al (Harris et al., 1974). Freeze-dried muscle samples of 6-10 mg of dissected 
muscle fibres, devoid of all visible connective tissue and blood contamination were 
powdered in a percussion pestle and mortar and aliquot weighed (2-3 mg). The muscle 
metabolites were extracted from the powdered muscle using 0.5 M ice-cold perchloric 
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acid (PCA) containing 1 mM EDTA for 10 minutes maintained on ice. Proteins and 
unwanted cell debris were removed by centrifugation at 22,000 g for 3 minutes at 4° C 
and the resulting supernatant was neutralised with 2.2 M KHCO3 for at least 15 minutes, 
producing perchlorate and carbon dioxide. The solution was centrifuged at 22,000 g for 3 
minutes at 4° C and the supernatant (extract) removed and frozen at  W80° C prior to 
analysis. 
2.7.2 Measurement of muscle glycogen content using spectrophotometery 
Muscle glycogen concentrations were determined spectrophotometerically using the 
methods described by Harris et al (Harris et al., 1974). The contents of these metabolites 
were measured indirectly from changes in the absorbance of NADH and NADPH. Both the 
oxidised and reduced forms of these reducing agents absorb light at 260 nm, while only 
the reduced form absorbs light at 340 nm. The complete utilisation of the metabolite is 
coupled to a reaction utilising the NAD+/NADH or NADP+/NADPH systems by means of 
common intermediates (see individual assays). Metabolite concentration can then be 
calculated from the recorded changes in absorbance according to the Beer- Lambert law: 
C = DA / (e x d); where: A = absorbance; C = concentration (of metabolite, mmol L-1); e = 
molar extinction coefficient; d = light path (cm); (1mM NADH e340nm= 6.22 cm
2 mmol-1)*; 
*1mM solution of NADH gives an absorbance equal to 6.22 absorbance units at 340 nm 
Glycogen assay 
Principle: 
1:  Glu + ATP                     HK                      Glu 6-P + ADP 
2:  Glu 6-P + NAD+         G6PDH                    P-gluconolactone + NADH 
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Muscle glycogen extract was removed from  W80° C storage, fast thawed under hot water, 
vortexed and stored on ice. Glucose assay buffer containing 32 % G1 (Triethanolamine 
(100 mM), KOH (40 mM), MgAC2.4 H2O (30 mM), EDTA.Na2.2 H2O (1 mM), pH 8.2), 2 % 
ATP (0.75 mM), 2 % DTT (1 mM), 4 % NAD+ (1 mM) and 60 % distilled water, with 40 µl of 
undiluted G6PDH (Sigma-Aldrich) was prepared. Muscle extract (50 µl) or water (50 µl) or 
Standard (1.5 mmol glucose; 50 µl) were transferred into a cuvette along with 250 µl of 
glucose assay buffer and agitated to mix. Baseline absorbance was taken using a standard 
spectrophotometer at 366 nm before 5 µl of undiluted hexokinase (HK; Sigma-Aldrich) 
was added to each cuvette and agitated to mix. Absorbance changes were monitored 
until the reaction reached end point, then the concentration (mmol glucosyl units kg-1 of 
dry muscle) was determined using the following formula: 
 ((V2 x (A2  W Abl2)  W V1 x (A1  W Abl1)) / (SV x 3.4) x EF 
 Where, 
V2 = final volume in cuvette (i.e. SV + Buffer + HK enzyme (µl)) 
A2 = absorbance value at end point 
Abl2 = absorbance value of water blank at end point 
V1 = initial volume (i.e. SV + Buffer (µl)) 
A1 = absorbance value at baseline 
Abl1 = absorbance value of water blank at baseline 
SV = sample volume (µl) 
3.4 = 1 mM of NADH has absorbance value of 3.4 at 366 nm 
EF = extraction factor (volume NaOH + HCl and Citric acid buffer + AGG / muscle powder 
weight (mg)) 
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2.8 Isolation and Suspension of Mitochondria from Muscle Tissue 
2.8.1 Overview  
In order to assay mitochondrial function in skeletal muscle, mitochondria are isolated and 
re-suspended from muscle tissue immediately after extraction from the subject. Muscle 
samples were obtained using a conchotome biopsy from the superficial portion of the 
vastus lateralis, Mitochondria were isolated and resuspended immediately after 
extraction from muscle tissue. The immediacy of the procedure, and its performance on 
unfrozen tissue, reflects the necessity to maintain mitochondrial double membrane 
structure. It is crucial for mitochondria to be actively respiring for maximal ATP 
production rates to be assayed. 
2.8.2 Laboratory Protocol 
 Approximately 40 mg of muscle tissue (retained on ice) was finely diced on a cooled glass 
plate, and weighed in milligrams, to two decimal places (Mettler Toledo scales, model 
XS105). The muscle was homogenised for 3 minutes on ice, using a pestle homogeniser 
and a glass homogenisation vessel (Camlab homogeniser, model K43), in homogenisation 
buffer (pH 7.2, KCl 100mM (Sigma Aldrich, UK), KH2PO4 50 mM (Sigma Aldrich, UK), Tris 
50mM (Sigma Aldrich, UK), MgCl2 5mM (Sigma Aldrich, UK), EDTA 1mM (Sigma Aldrich, 
UK), ATP 1.8mM (Sigma Aldrich, UK)). The crude homogenate was centrifuged at 650 g 
for 3 minutes, at ~-4o C (Hettich refrigerated centrifuge, model EBA12R). The resultant 
supernatant was transferred to a clean test tube and centrifuged at 15,000 g for 3 
minutes, at ~-4o C. Following this, the supernatant was removed and discarded before 
resuspending the mitochondria-rich pellet in the original homogenisation buffer. This was 
then centrifuged at 15000 g for 3 minutes, at ~-4o C. After removal of the supernatant, 
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the pellet was resuspended in a resuspension solution (pH 7.2, HSA 0.5 mg/ml, sucrose 
240 mM, monopotassium phosphate 15mM, magnesium acetate tetrahydrate 2 mM, 
EDTA 0.5 mM). The mitochondrial suspension was then retained on ice prior to 
mitochondrial ATP production rate analysis (MAPR), or was frozen at -80o C for other 
analysis. 
2.9 Mitochondrial ATP production Rate Analysis (MAPR Analysis) 
2.9.1 Overview 
Having produced an isolated mitochondrial suspension from muscle extract, the rates of 
ATP production were determined using a luminescence technique as described by 
Wibom et al. (Wibom et al., 2002). The method used in this thesis is a more accurate 
method for the fact that it measures ATP directly as it is produced ex vivo, unlike the 
ĐůĂƐƐŝĐĂů ŵĞƚŚŽĚ ŽĨ ĚĞƚĞƌŵŝŶĂƚŝŽŶ ĞŝƚŚĞƌ ďǇ ŵĞĂƐƵƌŝŶŐ ƚŚĞ ŝƐŽůĂƚĞĚ ŵƵƐĐůĞ ?Ɛ ŽǆǇŐĞŶ
consumption or by measuring the activity of enzymes involved in the oxidative 
phosphorylation pathway. The sensitivity obtained by this method is far greater than 
measurements of oxygen consumption, as it is not affected by mitochondrial uncoupling. 
Oxygen consumption is a function of complex IV of the electron transport chain. Under 
normal conditions, the rate of oxygen consumption can be used to extrapolate the rate 
of ATP production, as both processes are directly proportional. However, mitochondria 
electron transport can become uncoupled if mitochondrial damage or membrane 
perturbation has occurred. In this scenario, oxygen consumption will still occur 
unhampered in the mitochondria, but no ATP will be produced in relation to this 
consumption and instead heat is produced. Hence, measurements of mitochondrial 
function extrapolated from oxygen consumption are prone to overestimation. Therefore, 
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direct measurement of ATP as it is produced provides an important novel insight, and 
evolves previous conclusions made with indirect measurements.  
The method measures the ATP production rate of isolated mitochondria in optimum 
conditions. It relies on the properties of a reagent purchased from BioTherma 
(BioTherma, Sweden)  W a luciferase based ATP monitoring reagent. The luciferase binds 
to ATP as it is hydrolysed and produces light (see reaction scheme in Fig 2.4)  
 
Figure 2.4: Reaction Scheme for Luciferase Based ATP Monitoring Reagent. 
 ? ?>ƵĐŝĨĞƌŝŶA?dWAP>ƵĐŝĨĞƌǇůĚĞŶǇůĂƚĞA?WWi  
2. Luciferyl Adenylate + O2APKǆǇůƵĐŝĨĞƌŝŶA?DWA?>ŝŐŚƚ 
Isolated mitochondria are introduced to the reagent, along with ADP and a substrate for 
ATP production (e.g., Pyruvate). The substrate can be chosen in order to test 
mitochondrial ability to utilise specific substrates. The substrates tested in this thesis are 
thoroughly described in chapter, but for convenience they are described in the table 
below. The increase in luminescence (due to the production of ATP) is monitored on a 
BioOrbit 1253 luminometer (Bio-Orbit, Turku, Finland). 
88 
 
2.9.2 Laboratory Protocol 
Isolated mitochondria from muscle is retained on ice, 12 cuvettes (final volume 1ml) 
were made comprising of 800µl luciferase based ATP production monitoring reagent 
(Lyophilized ATP monitoring reagent (BioTherma, Sweden), containing firefly luciferase, 
D-luciferine 0.1g/L, L-luciferine 4mg/L, bovine serum albumin 1g/L, and Na2P2O7 1 µM) 
dissolved in (sucrose 0.19M, monopotassium phosphate 19 mM, magnesium acetate 
tetrahydrate 2.5 mM, EDTA 0.7 mM pH 7), 140µl of a substrate solution (described 
below), 50 µl 0.6 mM ADP (Sigma Aldrich, UK), and (added last) 10 µl of diluted 
mitochondrial suspension. The cuvettes were then transferred to the luminometer to 
record luminescence over time. As luminescence is directly a result of the ATP content, 
luminescence steadily increased as ATP was being produced by the active and intact, 
isolated respiring mitochondria. After 3-5 minutes of activity, the cuvettes were injected 
with 10 µl of 25 µM ATP. This is equivalent to a precise injection of 250 pmoles of ATP. 
This injection triggers a burst of luminescence, which is recorded by the luminometer. 
The cuvettes are then allowed to continue for a few more minutes before terminating 
the experiment. Calculations are demonstrated below.  
2.9.3 Substrates for ATP Production 
Mitochondria are extremely versatile organelles and are capable of utilising a number of 
different substrates to produce ATP. Carbohydrates and fatty acids are the main fuels, 
ďƵƚ ŝŶ ƚŚŝƐ ƚŚĞƐŝƐ ǁĞ ŚĂǀĞ ƚĞƐƚĞĚ ŵŝƚŽĐŚŽŶĚƌŝĂ ?Ɛ ĂďŝůŝƚǇ ƚŽ ƵƐĞ Ă ŶƵŵďĞƌ ŽĨ ĚŝĨĨĞƌĞŶƚ
substrates, to evaluate specific mechanisms of inflammation-induced pathology. The 
substrates used are listed below, along with a detailed description of how they are 
utilised by skeletal muscle mitochondria. 
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Pyruvate/Malate 
Pyruvate, the end production of the cytosolic glycolytic pathway can succumb to one of 
two main fates. If possible, the mitochondrial membrane bound pyruvate dehydrogenase 
complex will convert the pyruvate to acetyl CoA and transport it into the mitochondrial 
matrix in the process. This is aerobic respiration. If the pyruvate dehydrogenase complex 
is unable to utilise pyruvate for any reason, it will be converted to lactate during an 
anaerobic reaction associated with the buildup of lactic acidosis. In this thesis, malate is 
also provided along with pyruvate as a substrate. Malate acts as a co-transporter for 
pyruvate. It is oxidised by activity of endogenous malate dehydrogenase producing 
oxaloacetate, and subsequently citrate through activity of the TCA cycle. This shifts the 
dynamic equilibrium of the TCA cycle, essentially blunting succinate being converted to 
fumarate. This temporarily halts the production of FADH2, stopping donation of electrons 
to the electron transport chain at complex II. All electron transport now begins at 
complex I, maximizing the use of pyruvate as a substrate in these experiments, thus 
promoting its active uptake. 
Glutamate/succinate 
Glutamate is a common amino acid vital to all aspects of protein synthesis. Mitochondria, 
carrying their own separate genome have intrinsic mechanisms of protein synthesis 
which require amino acid fuels, in the same way cytosolic protein synthesis does. In 
terms of metabolism, glutamate is bound by intrinsic glutamate dehydrogenase, 
ƉƌŽĚƵĐŝŶŐɲ-ketoglutarate, a component of the TCA cycle. This transamination reaction 
provides a necessary intermediate for NADH production, fuelling complex I of the 
electron transport chain. In this thesis, glutamate is provided to mitochondria 
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accompanied by both malate and succinate. The glutamate and malate substrate 
combination acts similarly to the pyruvate and malate combination, blunting FADH2 
production and limiting complex II activation. Providing glutamate and succinate together 
allows activation of both complexes I and II of the electron transport chain, as succinate 
is the precursor to the succinate dehydrogenase reaction, show in figure 2.5. 
  
Figure 2.5 Mitochondrial ATP Production Rate Analysis.  
The figure shows the multi stage graph generated by analysis of a single isolated 
mitochondria sample, utilising a single substrate combination to produce ATP within a 
cuvette. Stage 1 of the graph shows an increase in relative luminescence over time. This 
increase is representational of ATP being produced by isolated mitochondria, respiring in 
the luciferase reagent. After stage 1, a 150 pmol of ATP is injected into the cuvette. As a 
result there is an increase in luminescence. This increase can be calculated (in relative 
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luminescence units) by extrapolating the curve in stage 3, back to the point of ATP 
injection. Subsequently, this information can be used to calibrate stage 1 of the graph, 
and convert ATP production in relative luminescence units/minute, to a quantity of 
ATP/minute.  
 
2.9.3 Pyruvate dehydrogenase Complex assay 
 
PDC was measured according to Constantin-Teodosiu et al (Constantin-Teodosiu et al., 
1991). This is a radioactive assay for the determination of pyruvate dehydrogenase 
complex activity in muscle tissue has been used. The assay measures the rate of acetyl-
CoA formation from pyruvate in a reaction mixture containing NAD+ and CoASH. The 
acetyl-CoA is determined as [14C]citrate after condensation with [14C]-oxaloacetate by 
citrate synthase. The method is specific and sensitive to the picomole range of acetyl-CoA 
formed. Total pyruvate dehydrogenase complex (PDCt) activity is determined after 
activation by pretreating the muscle homogenate with Ca2+, Mg2+, dichloroacetate, 
glucose, and hexokinase. The precision of the method was determined by analyzing 4-5 
samples of the same muscle piece. The coefficient of variation for PDCa was 8% and for 
PDCt 5%.  
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Chapter 3 
 
The enhanced recovery after surgery (ERAS) pathway for patients undergoing major 
elective open colorectal surgery: A meta-analysis of randomized controlled trials 
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 3.1 Introduction 
 
Patients undergoing major open colorectal surgery traditionally undergo prolonged 
rehabilitation during the postoperative period with profound changes in endocrine, 
metabolic, neural and pulmonary function. Complication rates of 15-20% (Bokey et al., 
1995, Basse et al., 2000a), and even as high as 45-48% (Muller et al., 2009, Serclova, 
2009) have been reported after major elective open colorectal surgery undertaken in the 
setting of traditional perioperative care. This may not be surprising since many traditional 
interventions that have been shown to be outdated, and even harmful, for patients 
(Guenaga et al., 2009, Lobo et al., 2002a, Nelson et al., 2007, Rahbari et al., 2009, Awad 
et al., 2009a) are still in use. For patients without complications, a key factor for 
postoperative recovery is the return of bowel function and this is influenced by several 
perioperative factors such as preoperative fasting and bowel preparation, analgesic and 
anaesthetic techniques, magnitude and complications of surgery, fluid overload, and also 
ďǇƚŚĞƉĂƚŝĞŶƚƐ ?ĐŽ-morbidities.  
ŶŚĂŶĐĞĚ ƌĞĐŽǀĞƌǇ ĂĨƚĞƌ ƐƵƌŐĞƌǇ  ?Z^ ? Žƌ  ‘ĨĂƐƚ-ƚƌĂĐŬ ? ƐƵƌŐĞƌǇ ƉĂƚŚǁĂǇƐ ŚĂǀĞ ďĞĞŶ
developed to address these issues and to accelerate recovery by attenuating the stress 
response so that the length of hospital stay and possibly the incidence of postoperative 
complications and mortality can be reduced, with the added benefits of reducing 
healthcare costs (Kehlet and Wilmore, 2002, Lassen et al., 2009b). The important 
elements of ERAS and similar fast track programs in open colorectal surgery included in 
these studies were factors shown to improve outcomes and many of them also 
addressed traditional treatments that were proven to be outdated. These measures were 
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then amalgamated into treatment programs that included preoperative counselling, no 
bowel preparation, no premedication, symbiotics administered before surgery, no 
preoperative fasting but provision of clear carbohydrate enriched liquids until 2 h before 
surgery, standard anaesthetic techniques, thoracic epidural anaesthesia, high inspired 
oxygen concentrations, avoidance of perioperative fluid overload, maintenance of body 
temperature, short/transverse incisions, non-opioid analgesia, no routine use of drains 
and nasogastric decompression tubes, early removal of bladder catheters, standard 
laxatives and prokinetics, and early postoperative feeding and mobilization.  
/ƚŚĂƐďĞĞŶƐŚŽǁŶƚŚĂƚƚŚĞƐĞ ‘ŵƵůƚŝŵŽĚĂůƌĞŚĂďŝůŝƚĂƚŝŽŶ ?Žƌ ‘ĨĂƐƚ-ƚƌĂĐŬ ?ƐƵƌŐĞƌǇƉƌŽŐƌĂŵƐ
improve surgical outcome with decreased hospitalization, increased patient satisfaction 
and safety after discharge. A systematic review of three randomized controlled trials 
(RCTs) and three case control trials, showed some benefits of the enhanced recovery 
pathway in elective open colorectal surgery such as reduction in primary hospital stay 
and morbidity (Wind et al., 2006). Three recent meta-analyses also showed a positive 
influence of implementing the ERAS protocol in this group of patients (Gouvas et al., 
2009a, Eskicioglu et al., 2009a, Walter et al., 2009). However, the authors recommended 
the need for further RCTs as, with a maximum of 198 randomized patients included in the 
meta-analysis, the data available were too limited to draw firm conclusions. This 
multimodal approach has been the subject of interest in several other non-randomized, 
case controlled and prospective studies including a consensus review of optimal care 
recommended by the ERAS group in patients undergoing major colorectal surgery 
(Lassen et al., 2009b). 
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The purpose of the present meta-analysis of RCTs was to study the effect of ERAS 
pathway in patients undergoing major elective open colorectal surgery in reducing the 
length of primary hospital stay, and to examine the incidence of postoperative 
complications, readmission rates and mortality. 
3.2 Methods  
3.2.1 Criteria for considering studies for this review  
 
Studies comparing enhanced recovery programs with traditional perioperative care in 
patients undergoing major elective open colorectal surgery were selected from the initial 
search. RCTs documenting the individual elements of the ERAS pathway that were 
implemented, with a minimum of four elements covering the pre-, intra- and 
postoperative periods of the ERAS pathway, were subsequently included in this meta-
analysis.  
Non-randomized studies, case-controlled trials, cohorts, retrospective studies and other 
studies which did not fulfil the inclusion criteria were excluded. 
 
3.2.2 Outcome measures  
 
The primary outcome measure of this meta-analysis was length of primary hospital stay. 
Secondary outcome measures were postoperative complications (total number of 
patients with complications in each group), readmission rates and mortality. 
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3.2.3 Search methods for identification of studies  
 
Electronic searches  
Studies published between January 1966 and November 2009 were searched in Medline, 
Embase, the Science Citation Index, the Cochrane Library and CINAHL databases. The 
relevant studies were identified using the search terms colorectal surgery, colon, colonic, 
colorectal, rectum. These results were combined with multimodal, fast track, enhanced 
recovery, ERAS, accelerated, rehabilitation, convalescence, perioperative care and 
ĂŵďƵůĂƚŝŽŶ ŝŶĐŽŵďŝŶĂƚŝŽŶǁŝƚŚƚŚĞŽŽůĞĂŶŽƉĞƌĂƚŽƌƐE ?KZĂŶĚEKd ?dŚĞ  ‘ƌĞůĂƚĞĚ
ĂƌƚŝĐůĞ ?ĨƵŶĐƚŝon was used to identify any further articles that were eligible for inclusion in 
the meta-analysis. The search included publications in all languages. 
Searching other resources  
The references from relevant articles were scanned and primary authors were consulted 
for additional information as necessary. The authors of relevant papers were identified 
from authorship of trials and review articles found in the search. Bibliographies of RCTs, 
meta-analyses, and systematic reviews were hand-searched for studies that were not 
captured by the initial electronic search. Experts in the subject were consulted to ensure 
that no published or unpublished work had been missed.  
3.2.4 Data collection and analysis  
 
Two review authors inspected the citations identified from the search independently. 
The quality of the retrieved articles was assessed separately by the two review authors 
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for inclusion according to the previously defined criteria. Any disagreement was resolved 
by consensus discussions with the third member of the review team. 
3.2.5 Data extraction  
 
Data from included RCTs were extracted independently by two review authors. The 
studies were assessed for the methodological quality, study design, inclusion and 
exclusion criteria, reporting of outcome measures. Any missing data were obtained by 
contacting the author and included in the analysis.  
3.2.6 Statistical analysis  
 
The focus of this meta-analysis was on the effect of the ERAS pathway on outcome 
measures such as length of hospital stay, readmission rates, postoperative complications 
and mortality, using the standard methods recommended by the Cochrane Collaboration. 
Calculations of effect sizes for dichotomous variables are presented as risk ratio (RR) with 
95% confidence intervals (CI) and for continuous outcomes as weighted mean differences 
(WMD). Pooled analyses were performed using the random effects model with the 
Mantel WHaenszel method. The random-effects method incorporates an assumption that 
the different studies are estimating different, yet related, intervention effects and hence 
explicitly accounts for heterogeneity. Statistical heterogeneity was assessed by 
considering the I2 ƐƚĂƚŝƐƚŝĐĂůŽŶŐƐŝĚĞ ƚŚĞʖ2 'p' value. The I-squared statistic provides an 
estimate of the percentage of inconsistency thought to be due to chance.(Higgins and 
Green, 2008) The threshold values of I2 equal 25%, 50%, and 75%, representing low, 
moderate, and high heterogeneity, respectively. Thes
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RevMan 5.0 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, 
Denmark). 
 
3.3 Results 
3.3.1 Eligible Studies 
 
Six RCTs (Anderson et al., 2003, Delaney et al., 2003, Gatt et al., 2005, Khoo et al., 2007, 
Muller et al., 2009, Serclova, 2009) fulfilled the inclusion criteria for the meta-analysis 
(Figure 3.1), leading to a total of 452 patients, 226 in each group, being included (median 
number of patients in each study 67, range 25-151). The characteristics of included 
studies are presented in Table 3.1. All six studies reported appropriate randomization 
methods sealed envelope in four studies (Serclova et al., 2009, Anderson et al., 2003, 
Delaney et al., 2003, Gatt et al., 2005); random number generator in two (Muller et al., 
2009, Khoo et al., 2007). None of the RCTs were blinded. Due to the nature of these trials 
and allocation of patients to treatment groups that become self-evident following 
randomization, blinding of patient groups and observer was not always possible. 
Therefore, all except one RCT (Delaney et al., 2003) had a Jadad score (Jadad et al., 1996) 
of 3 (Table 3.2). Standard criteria were defined for inclusion, exclusion, length of hospital 
stay, complications, readmissions and discharge in these studies. There were clear 
definitions of the fast-track or enhanced recovery protocol with a minimum of 4 ERAS 
elements implemented in the intervention group. The number of ERAS elements used in 
all 6 RCTs, ranged from 4-12 with a mean of 9, as listed in Table 3.3. Five studies (Muller 
et al., 2009, Serclova et al., 2009, Anderson et al., 2003, Delaney et al., 2003, Gatt et al., 
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2005) reported a 30-day follow-up. In the study (Khoo et al., 2007) in which 14 day follow 
up was reported, 30 day follow up data were obtained from the authors. There was no 
reporting of protocol violations in three studies (Anderson et al., 2003, Gatt et al., 2005, 
Khoo et al., 2007) but these were reported in the other three studies (Muller et al., 2009, 
Serclova et al., 2009, Delaney et al., 2003). The use of epidurals in traditional care and 
ERAS groups is illustrated in Table 3. 4. 
 
100 
 
Figure 3.1: PRISMA 
 
Figure 3.1: PRISMA diagram showing selection of studies for the meta-analysis. From the 
85 studies searched, six studies which fulfilled the inclusion criteria were included for the 
meta-analysis. 
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Table 3.1.1: Characteristics of included studies  
1. Anderson et al., 2003  
Methods Consecutive series of patients, randomized into ERAS or Traditional care (TC) groups. 30 
day postoperative follow up.  
Participants Patients living independently at home and having left or right hemicolectomy. 
Interventions Preoperative factors: Written preoperative information, preassessment by surgical registrar 
or anaesthetist, prebiotics (oligofructose) and probiotics (Trevis) for 7-14 days before 
surgery, no bowel preparation, oral carbohydrate loading.  
Admitted the day before surgery, normal diet up to and including the evening meal. A drink 
containing 100 g carbohydrate (Maxijul) in 400 ml water at 2200 hours and 50 g in 400 ml 
3-4 h before the operation. Perioperative anaesthetic factors were same in both groups. 
Analgesia: Epidural sited between T7 and L1, initial bolus of 15-20 ml 0.25% bupivacaine, 
then continuous infusion until 24-36 h after surgery. PCA for control group. 
Intraoperative factors: iv cefuroxime and metronidazole in both groups; transverse incision 
in optimization group; midline or paramedian incision in control group. Nasogastric tube 
only for decompression during surgery and removed at the end. 
Postoperative factors: No nasogastric tubes or drains, free fluids on day of operation, light 
diet day 1, full diet day 2.  
Epidural infusion (0.15% bupivacaine + fentanyl 2 µg/ml), epidural catheter removed 24 -36 
h after surgery. Paracetomol 1 g qds, ibuprofen 400 mg tds, if required; parenteral 
morphine 5-10 mg (rescue analgesia); no oral opiates. 
Chest physiotherapy, walk length of ward with physiotherapist. Encouraged to mobilise 
early on the evening after surgery. 
Discharge criteria: Tolerating standard hospital diet, mobilizing safely around the ward, on 
oral analgesics. 
Outcomes Twice daily patient review by the surgical research fellow or nutrition nurse specialist. Data 
recorded before operation and post operative days 1, 7 and 30.  
Primary outcome: Length of hospital stay. 
Secondary outcomes: Hand grip strength (non dominant hand), 
Measures of physical function: FEV1 measured at time of surgery and when patient walked 
to the toilet unaided (mean distance 12.5 m), 
Return of normal gastrointestinal function as indicated by the ability to tolerate a diet of 
three light meals a day. 
Pain and fatigue scores recorded between 1100 and 2400 hours using visual analogue scale 
at rest, during mobilisation and coughing. 
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Table 3.1.2: Characteristics of included studies 
2. Delaney et al., 2003   
Methods Prospective RCT comparing a pathway of controlled rehabilitation with early ambulation 
and diet and traditional care after laparotomy and intestinal resection. A baseline visual 
analogue score, McGill pain score questionnaire (MGPQ), SF-36 and a previously validated 
quality of life questionnaire [Cleveland Clinic Global Quality of Life (CGQL)] were completed 
at randomization, discharge and postoperative days 10 and 30. Complications were 
determined prospectively and were reassessed by telephone follow-up or outpatient visit 
30 days after surgery. 
Participants All patients scheduled for elective segmental intestinal or rectal resection by laparotomy, 
including patients undergoing reoperation or pelvic surgery and those with comorbidities, 
were eligible for inclusion in the study. [5 patients (16%) in both groups had small bowel 
resections]. 
Exclusions: loop ileostomy closure and ventral hernia repair without scheduled intestinal 
resections. 
Interventions Controlled Rehabilitation with Early Ambulation and Diet (CREAD) Protocol: 
Orogastric tubes removed before extubation. 
Patient controlled anaesthesia (PCA) for both groups. Analgesia supplemented with 30 mg 
of iv ketorolac every 6 h, as needed.  
Post operative day 1, walk at least one circuit of the nursing floor (approx 60 meters) up to 
five times, sit out of bed between walks, regular incentive spirometry. 
Non-carbonated liquids, offered solid food that evening if tolerating oral fluids. 
Oral analgesia (oxycodone) on 2nd postoperative day, if either liquids or diet was tolerated, 
PCA was discontinued. 
Discharge criteria: All patients passed flatus or stool, comfortable with oral analgesia, stand 
and walk unaided. 
Outcomes Primary: Length of stay including readmissions and length of primary hospital stay. 
Secondary: Evaluate the influence of patients' age < 70 years, effect of increasing surgeons ? 
experience, effect of diverting ileostomy, complication and readmission rates. 
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Table 3.1.3: Characteristics of included studies 
3. Gatt et al., 2005 
Methods RCT comparing a ten point multimodal optimization programme with conventional 
perioperative management.  
Participants Consecutive patients undergoing major elective open colorectal surgery, living 
independently at home.  
Exclusions : Failure to obtain consent, age <18 years, pregnancy, intolerance to probiotics 
and/or prebiotics, contraindication to one or more optimization strategy, contraindications 
to early postoperative discharge prescribed medications that may independently prolong 
hospital stay (e.g. anticoagulants), advanced malignancy on preoperative assessment, 
palliative surgery, emergency surgery and failure to perform colonic or rectal resection. 
Interventions Ten point multimodal pathway: 
Preoperative: Verbal and written preoperative information; preassessment by surgical 
registrar or anaesthetist, synbiotics (probiotics and prebiotics), avoidance of mechanical 
bowel preparation, oral carbohydrate loading and 3 h preoperative fast. 
Perioperative: High inspired O2 concentrations (80%), transverse incision, no drains or 
nasogastric tubes 
Postoperative: Early fluid and diet reintroduction, aggressive structured mobilization plan. 
Epidural analgesia for both groups until 24-36 h after surgery. 
Discharge criteria: Tolerating three light meals a day, mobilizing safely and taking oral 
medications only. 
Patients in the control group received none of the optimization measures. Admitted the 
day prior to surgery, fasted from midnight and received bowel preparation. 
Outcomes Assessed twice a day and follow-up by the same researcher.  
Physiological function: Spirometry (FEV1, FVC), grip strength, Physiological and Operative 
Severity Score for the enumeration of Mortality and morbidity(POSSUM), ASA scores, 
duration of catheterization, time to mobilization and fluid balance. 
Psychological function: Cognitive function scoring, fatigue scoring, pain scoring and 
analgesic requirements. 
Gut function: Time to tolerance of fluids and diet and duration of intravenous fluids. 
Clinical outcome: Primary endpoint: length of hospital stay, complications and death, need 
for readmission, general practitioner visits. 
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Table 3.1.4: Characteristics of included studies 
4. Khoo et al., 2007 
Methods RCT of multimodal perioperative management protocol in patients undergoing elective 
open colorectal resection for cancer. 
Participants All elective patients presenting with colorectal cancer; both colonic and rectal surgery; no 
age limit. 
Exclusions: if unable to mobilize independently over 100 m at preoperative assessment, 
had contraindications to thoracic epidurals, or had pre-existing clinical depression, 
palliation or other joint operations involving other surgical specialty. 
Interventions All patients admitted morning prior to surgery, had standard bowel preparation (Fleet) and 
oral fluids up to 3 h prior to surgery. Control arm received 125 ml/h of intravenous fluids 
from 2200 hours.  
Multimodal arm: Intravenous fluids restricted to 1500 ml unless bleeding in excess of 500 
ml intraoperatively. Allowed free oral fluids immediately after the operation. Intravenous 
fluids discontinued when able to tolerate 200 ml of water over 30 minutes. Urine output 
not used to guide fluid therapy. 
NG tube inserted for all patients in the multimodal group and removed in recovery. Oral 
feeding immediately following surgery in the multimodal, with regular domperidone, 
magnesium hydroxide 8% and liquid protein/calorie supplements from admission. 
Thoracic epidural analgesia (TEDA) in 32 out of 35 patients. Patient controlled analgesia 
with morphine and cyclizine, if TEDA not possible. Epidural rate was not adjusted unless 
there were features of narcotization and discontinued 48 hours postoperatively. Regular 
oral analgesics postoperatively. 
Mobilization from night of the operation and encouraged to meet predefined mobility 
targets. Catheters removed 24 h postoperatively following colonic resection and 72 h after 
total mesorectal excision. 
Traditional Care: NG tube removed following morning unless there was > 200 ml of free 
drainage overnight. 
TEDA (34 out of 35 patients) was titrated against pain and narcotization and removed when 
the rate was <1 ml/h. Oral analgesia given as required. 
Mobilization: sat out and assisted to mobilize on 1st postoperative day, but not normally 
aggressively mobilized until discontinuation of the thoracic epidural. 
Discharge criteria: when self-caring, stoma or bowel function, mobilizing independently 
(able to ambulate to toilet/bath and 100 m unassisted) and were comfortable on oral 
analgesia. 
Outcomes Primary endpoints: Length of hospital stay, achievement of independent milestones. 
Secondary endpoints: complications, readmission rates and mortality. 
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Table 3.1.5: Characteristics of included studies 
5. Muller et al., 2009  
Methods Multicentre study involving four teaching hospitals in northern Switzerland, RCT of fast 
track programme. Factors associated with significant reduction of complications (effective 
epidural analgesia and a stringent fluid regimen) were assessed using multivariate analysis. 
Participants Patients who were older than 18 years, open elective colonic resection with a primary 
anastomosis.  
Exclusion criteria: Emergency operations, contraindications to epidural anaesthesia, 
scheduled total colectomy or rectum resection, preoperatively immobile patients. 
Interventions Both groups had thromboprophylaxis and antibiotics, no bowel preparation, patients were 
allowed to drink up to 4 hours prior to surgery. Standard anaesthetic procedures, median 
laparotomy, no nasogastric tubes or drains were used postoperatively in both the groups. 
Fast track programme: Restricted fluid regime consisting of preoperative loading with 
ZŝŶŐĞƌ ?ƐůĂĐƚĂƚĞĂƚ ?ŵů ?ŬŐ ?ŚĂŶĚ nil by mouth, with an intra-operative substitution of 5 
ml/kg/h. All fluids discontinued on 1st postoperative day, unless any medical reason to 
continue. Additional fluid or vasopressors were given when mean arterial pressure <60 mm 
Hg or urine output 0.5 ml/kg/h.  
Start drinking immediate postoperative period in fast track group. Two additional protein 
drinks were permitted for first 3 days and resume oral nutrition by day 1. Patients in the 
standard group were allowed to drink on day 2, increasing oral nutrition on day 2, with 
possible full oral nutrition by day 4. 
Early mobilization in both groups. 
Criteria for insertion of NG tube: 2 consecutive episodes of vomiting greater than 400 ml. 
Epidural with ropivacaine 0.33% or bupivacaine 0.25% was placed at T6-9 preoperatively 
and removed on 2nd postoperative day. (61 out of 76 in fast-track and 59 out of 75 patients 
in control group had epidurals). Thereafter intravenous paracetamol only. 
Discharge when fully mobile, pain controlled by oral analgesics only, tolerance of oral food 
and patients felt comfortable on discharge. Sufficient oral intake, when patients take more 
than 2/3 of daily meal. 
Outcomes Primary end point: Total complications (general and surgical) occurring until 30 days after 
surgery. (Telephone follow-up if necessary). 
Secondary end point: Median hospital stay, readmission rate, anastomotic leak.  
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Table 3.1.6: Characteristics of included studies 
6. Serclova et al., 2009 
Methods Prospective monocentric, unblinded, randomised study of patients scheduled for open 
intestinal resection.  
Participants All patients undergoing open intestinal resection between 18-70 years and with ASA score I 
-II. 
Exclusions: Patients scoring ASA III-IV, those who had pelvic radiation, having multi-organ 
resections or generalisation of cancer and pregnant women. 
Interventions Patients in the FT group were informed prior to surgery about perioperative anaesthesia 
and analgesic care. PCA (patient-controlled analgesia) pump training was conducted and 
the system of pain assessment by means of the visual analogue scale (VAS 0-10, 0 = no 
pain, 10 = maximum pain) was explained. 
Thoracic epidural T10-T12, (32 out of 52 in non-FT group and all patients in FT group). 
Bowel preparation only if rectal surgery planned. 
Normal oral intake on the day before surgery until 1400 hours and light dinner on the 
evening before surgery. Advised to increase fluid and carbohydrate cocktail intake (400-800 
ml of 12.5% carbohydrate solution, Nutricia preOp, Nutricia Ltd). Fluid intake was stopped 
2-4 h prior to surgery. 
Standard anaesthesia for FT group. Epidural anaesthesia was combined with intravenous 
paracetamol and diclofenac or metamizole. An epidural catheter was inserted in all 
patients from the FT group and in 32 patients from the non-FT group (62%).  
Perioperative fluid restriction was not part of the study protocol.  
Drains used selectively, removed 1st post op day. Catheters only if pelvic surgery, 
fistulation or procedure > 3hours. VAS monitoring hourly for first 24 h and every 4 h 
thereafter. 
Exercise in bed, encouraged to mobilise after postoperative stabilisation. Enteral feed on 
the same day. 
Discharge criteria: Oral intake higher than 2000 ml/day, normal gastrointestinal function; 
pain controlled by oral analgesics; and no signs of infection or other complications and 
content to be discharged. 
Traditional care group: Orthograde mechanical bowel preparation & fasted from midnight. 
Anaesthesia and analgesia not standardised. 
Outcomes Data regarding patient demographics, weight, BMI prior to surgery, nutritional markers, 
length and severity of surgery, postoperative weight and BMI, visual analogue score for 
pain, oral intake, diet, rehabilitation, nausea, vomiting, bowel movements and first stool 
were recorded.  
Outcomes such as complications (infectious & non-infectious), wound healing, length of 
hospital stay, readmissions, postoperative analgesia and death were studied. 
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Table 3.2: Quality assessment and study design  
RCT 
No of patients Age (years), Median (Range) 
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Jadad Score 
ERAS  
Traditional 
care  
ERAS Traditional care 
Anderson et 
al., 2003 
14 11 64 (55-68) 68 (65-75) 30 Yes No Yes 
Not 
blinded 
Yes 3 
Delaney et al., 
2003 
31 33 
50.6±16.9 
(mean±sd) 
41.9±13.3 
(mean±sd) 
30 Yes No Yes 
Not 
blinded 
No 2 
Gatt et al., 
2005 
19 20 67 (59-76) 67 (60-73) 30 Yes No Yes 
Not 
blinded 
Yes 3 
Khoo et al., 
2007 
35 35 
69.3 
(46-88) 
73 
(46-85) 
10-
14 
Yes No Yes 
Not 
blinded 
Yes 3 
Muller et al., 
2009 
76 75 
62 
(27-91) 
59 
(39-89) 
30 Yes No Yes 
Not 
blinded 
Yes 3 
Serclova et al., 
2009 
51 52 33 (20-66) 36 (18-68) 30 Yes Yes Yes 
Not 
blinded 
Yes 3 
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Table 3.3: Summary of ERAS elements included in the RCTs     
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Anderson 
et al., 2003 
9 9 9 9   9  9 9 9 9 9 9 9   
Delaney et 
al., 2003 
9          9  9 9    
Gatt et al., 
2005 
9 9 9 9   9  9 9 9 9 9 9 9   
Khoo et al., 
2007 
9     9   9  9  9 9 9  9 
Muller et 
al., 2009 
9 9  9  9   9  9 9 9 9 9   
Serclova et 
al., 2009 
9 9  9  ×   9  9 9 9 9 9   
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Table 3.4: Use of epidurals in RCTs 
3.3.2 Meta-analysis of RCTs 
Patients undergoing major open colonic/colorectal surgery and managed with a 
perioperative ERAS pathway had a primary hospital stay of 2.5 days less than those 
managed with a traditional care pathway [WMD (Random, 95% CI) -2.51(-3.54, -1.47); 
I2=55%, p<0.00001, Figure 3.2]. In addition, management within an ERAS pathway 
resulted in significantly fewer postoperative complications [RR (95% CI): 0.53 (0.41, 0.69); 
I²=0%; p<0.00001, Figure 3. 3]. Of the 452 patients, 4 died during the 30 day follow-up 
period, with one death (myocardial infarction) in the ERAS group and three (2 myocardial 
infarctions and 1 pulmonary embolism) in the traditional care group. The Forest plots in 
Figures 3.4 and 3.5, demonstrate that there were no statistically significant differences in 
readmission [RR (95% CI): 0.80 (0.32, 1.98); I²=9%; p=0.62] and mortality rates [RR (95% 
CI): 0.53 (0.09, 3.15); I²=0%; p=0.49]., The I2-statistic showed significant heterogeneity for 
the effect of ERAS on the length of hospital stay [ʖ ?A? ? ? ? ? ? ?ĚĨA? ? ?ƉA? ? ? ? ? ?/ ?A? ? ?A? ?&ŝŐƵƌĞ
3.2]. However, the results for complications, readmissions and mortality had no or very 
low heterogeneity (I2=0-9%).  
Study Traditional Care ERAS  
Anderson et al., 
2003 
PCA until pain control with oral 
analgesics 
Epidural for first 24-36h 
Delaney et al., 
2003 
No epidurals, PCA for all patients No epidurals, PCA for all 
patients 
Gatt et al., 2005 Epidurals for first 24-36h  Epidurals for first 24-36h 
Khoo et al., 2007 Epidurals (Median 3 days) Epidurals (Median 2 
days) 
Muller et al., 2009 Epidurals for 2 days after surgery Epidurals for 2 days after 
surgery 
Serclova et al., 
2009 
Epidurals according to discretion of 
anaesthetists  
Epidurals used for all 
patients 
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Figure 3.2: Forest plot of comparison: Length of Hospital Stay 
 
 
 
Figure 3.2: Forest plot of comparison: Length of Hospital Stay [ERAS=enhanced recovery after 
surgery; TC = traditional care]. ERAS was associated with 2.5 days lesser hospital stay compared 
with traditional care. 
 
 
Figure 3.3: Forest plot of comparison: Complications 
 
Figure 3.3: Forest plot of comparison: Complications [ERAS=enhanced recovery after surgery; TC 
= traditional care]. ERAS was associated with 47% reduction in risk of complications compared 
with traditional care 
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Figure 3.4: Forest plot of comparison: Readmission 
 
 
Figure 3.4: Forest plot of comparison: Complications [ERAS= enhanced recovery after surgery; TC 
= traditional care]. No difference in readmission rates were observed with ERAS compared with 
traditional care. 
 
 
Figure 3.5: Forest plot of comparison: Mortality 
 
Figure 3.5: Forest plot of comparison: Mortality [ERAS= enhanced recovery after surgery; TC = 
traditional care]. No difference in mortality rates were observed with ERAS compared with 
traditional care. 
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3.4 Discussion 
The results from the present meta-analysis suggest that the implementation of four or 
more elements of the ERAS pathway leads to a reduction in length of hospital stay by 
more than 2 days and an almost 50% reduction in complication rates in patients 
undergoing major open colonic/colorectal surgery. At the same time, no significant 
difference was noted in readmission rates or mortality between the groups. Although no 
firm conclusions could be made with regards to the latter two outcome measures, the 
present meta-analysis indicates that early discharge and ERAS protocols did not seem to 
increase the risk of readmission or mortality. However, these results are open to further 
scrutiny due to the following reasons. There was significant heterogeneity for the effect 
of ERAS on the length of hospital stay and hence, could potentially weaken the inferences 
drawn. The effect of using epidurals on the postoperative pain outcome was investigated 
in two studies using visual analogue scores (VAS) (Anderson et al., 2003, Gatt et al., 
2005). Anderson et al (Anderson et al., 2003) used epidurals only in the study group and 
patient controlled analgesia in the control group. Their results showed that postoperative 
pain did not differ significantly from preoperative levels in the ERAS group, but it was 
increased in the control group. However the pain scores were similar in both groups by 
day 7. This is in contrast to the study by Gatt and colleagues (Gatt et al., 2005) in which 
epidurals were used in both groups with no recordable differences in pain scores. 
Interpretation of the influence of epidurals on postoperative pain and other outcomes 
was further complicated in the study by Serclova and co-workers (Serclova et al., 2009) 
where the adoption of an epidural in the control arm was optional. When the rate of 
epidural failure (28%) was added to the fact that not all patients received an epidural, the 
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presence of an effective epidural in the control group became a random event. 
Postoperative pain was not studied as an outcome measure in the other studies which 
used epidurals in both groups (Gatt et al., 2005, Khoo et al., 2007, Muller et al., 2009, 
Serclova, 2009). Equally, a uniform method of reporting complications and their degree 
of severity was not followed in these studies. The rate of complications in the control 
arms varied widely from 45-75%, as was the reporting of specific complications, with 
wound morbidity varying between 0 and 33%. One study (Anderson et al., 2003) 
considered failures of treatment as a complication (e. g. ineffective epidural), whereas 
another study (Khoo et al., 2007) reported a relatively high incidence of what may 
otherwise be considered rare complications (e. g. 8% incidence of pressure sores). In such 
circumstances caution needs to be exercised in combining results from one trial to 
another. We have, therefore, included the number of patients with complications per 
group rather than the total number of complications per group, for the meta-analysis. 
The number of deaths (4 of 452 patients) was too small to detect significant differences 
in mortality and all of them occurred within the primary hospital stay. All these studies 
had a follow-up period of 30 days and therefore it is unlikely that any impact of 
complications or mortality, on the primary length of hospital stay would have been 
missed in the included RCTs. 
A potential confounding factor in the RCTs is that some studies (Serclova et al., 2009, 
Delaney et al., 2003) had included patients who underwent small bowel resections in the 
study population. In addition, in the study by Serclova et al (Serclova et al., 2009) the 
participants were between 18-70 years of age with ASA grades I and II, underwent open 
intestinal resections with or without stoma and had a significantly longer hospital stay in 
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both groups compared to other included studies [mean (range) 7.4 (5-11) days in ERAS 
group and 10.4 (7-22) days in the traditional care group]. This may have potentially 
reduced the readmission rate and led to significant bias in reporting the outcomes. The 
variation reported in outcomes from the different studies probably reflects the inherent 
differences in practice that exists between different surgical units and countries. 
However, despite all these differences between these studies, the ERAS groups 
consistently showed faster recovery. 
Another weakness of the RCTs included, and hence also of this meta-analysis, is the lack 
of information regarding compliance with protocols and the elements of ERAS pathway in 
the included studies and, hence, the significance of the contribution of the individual 
elements to outcome could not be ascertained. A recent study has shown that when 
instituting changes of treatment protocols of a more complex nature, such as the ERAS 
pathway, it is difficult to reach full compliance with all the elements of the pathway 
(Maessen et al., 2007). This weakness is an often under estimated factor as it is almost 
never reported or even looked for. This is true not only for studies of implementation of 
new protocols such as the present, but also in the general surgical literature. Another 
drawback is that because of the inherent difficulties, none of the included studies were 
blinded and the average Jadad score (Jadad et al., 1996) was 2.83. There was also a wide 
variation in the number of elements of the ERAS pathway incorporated in each study, 
though all of them may not be equally important. All studies included elements such as 
preoperative counselling, no routine use of NG tubes, enforced postoperative 
mobilization, early enteral feeding in the ERAS group. Other elements that were 
commonly used in these studies were preoperative feeding, no bowel preparation, 
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epidural analgesia, no routine use of drains and no systemic morphine use. The use of 
elements such as synbiotics, avoidance of fluid overload (fluid restriction), maintenance 
of perioperative high oxygen concentration, short length incisions and early removal of 
bladder catheter were less consistently applied.  
However, there are reasons to believe that including as many ERAS elements as possible 
in a clinical pathway may have resulted in a cumulative effect and contributed to 
enhanced recovery in this group of patients. Aggressive rehabilitation with early 
ambulation and feeding should stimulate the gastrointestinal tract and accelerate 
recovery of bowel function, whilst routine use of nasogastric tubes or systemic morphine 
would impair bowel function. The use of standard laxatives is still debatable, as the 
standard measure of return of bowel function would be the ability to tolerate oral 
feeding rather than just bowel movement. 
There is also growing evidence in the literature, about the contribution of individual 
elements comprising the ERAS pathway to a decrease in morbidity and facilitation of 
early discharge (Guenaga et al., 2009, Lobo et al., 2002a, Nelson et al., 2007, Rahbari et 
al., 2009, Awad et al., 2009a). A large consecutive series of 541 patients undergoing 
colorectal resections with a structured care program of planned early discharge within a 
fast track protocol also showed reduced readmission rates with no increase in the 
incidence of morbidity and mortality (Andersen et al., 2007). These results concur with 
other systematic reviews (Wind et al., 2006) and meta-analyses (Gouvas et al., 2009b, 
Eskicioglu et al., 2009b, Walter et al., 2009) on the ERAS pathway and the inclusion of a 
much larger number of patients (452) in the present meta-analysis, further strengthens 
the conclusions. The other less studied elements which form part of ERAS may have also 
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contributed to the outcome, but evidence is lacking as there are no robust studies 
supporting this hypothesis. These elements form part of the ERAS pathway based on 
common consensus opinions and derived from traditional care settings. Further 
prospective studies of ERAS pathway are needed with emphasis on strict protocol 
compliance to examine these individual elements, so that critical elements that 
contribute to the outcome, might be identified using a regression model. 
Evidence from the literature, supports the view that the ERAS pathway seems to reduce 
the overall healthcare cost (Kariv et al., 2007, Kehlet, 2005). From a health economics 
point of view, the data suggest that, with the decrease in complications and hospital stay 
and similar readmission rates, the cost of treatment per patient would be significantly 
lower for those treated within an ERAS pathway than those receiving traditional care, 
despite the need for dedicated staff to implement the pathway.  
This meta-analysis has shown that ERAS pathways help to reduce both hospital stay and 
complication rates. There is supportive evidence from the included studies that enhanced 
recovery programs should be considered as standard perioperative care. To further 
strengthen the evidence base and to develop a well-established clinical pathway, future 
RCTs of ERAS pathways applying stringent criteria, with presentation of data regarding 
protocol compliance, are recommended. 
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Chapter 4 
A meta-analysis of randomised controlled trials on preoperative oral carbohydrate 
treatment in elective surgery 
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4.1 Introduction 
 
Preoperative fasting and surgery cause metabolic-stress and insulin resistance, which is 
characterised by hyperglycaemia and decreased responsiveness of tissues (mainly 
skeletal muscle and liver) to the biological actions of insulin (Awad et al., 2009b). 
Development of insulin resistance is associated with increased morbidity (Sato et al., 
2010), mortality (Sato et al., 2010) and length of hospital stay (Thorell et al., 1999b). 
Measures to attenuate development of insulin resistance, such as preoperative oral 
treatment with complex carbohydrates may, therefore, be clinically beneficial. A number 
of studies have examined the effects of preoperative carbohydrate treatment on 
postoperative insulin resistance and glucose kinetics (Soop et al., 2001, Svanfeldt et al., 
2007), protein balance and body composition (Svanfeldt et al., 2007, Yuill et al., 2005), 
postprandial hormonal and metabolic responses (Awad et al., 2011a, Awad et al., 2010, 
Awad et al., 2011b), immune function (Melis et al., 2006), gene and protein expression 
(Awad et al., 2010, Wang et al., 2010), residual gastric volume (Awad et al., 2011a, Lobo 
et al., 2009), drink-related complications (Yuill et al., 2005, Kaska et al., 2010, Mathur et 
al., 2010) , patient well-being (Hausel et al., 2001, Hausel et al., 2005), and length of 
hospital stay (Yuill et al., 2005),(Mathur et al., 2010, Noblett et al., 2006b). Whilst the 
safety (Yuill et al., 2005, Mathur et al., 2010), and physiological benefits of preoperative 
carbohydrate treatment have been demonstrated, data regarding the effects on 
important clinical endpoints such as length of hospital stay are conflicting; with some 
studies demonstrating a reduction (Noblett et al., 2006b) and others no reduction (Yuill 
et al., 2005, Mathur et al., 2010), in length of stay. Reasons for these inconsistencies 
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include small numbers of participants and study of heterogeneous groups of patients 
undergoing surgical procedures of differing magnitudes (Li et al., 2012). Meta-analysis of 
studies on the effects of preoperative carbohydrate treatment on clinical endpoints has 
hitherto not been performed.  
The aims of the present meta-analysis were to determine the effects of preoperative 
carbohydrate treatment in patients undergoing elective surgery on: 1) length of hospital 
stay; 2) development of postoperative insulin resistance; 3) occurrence of drink-related 
(vomiting, aspiration and pneumonia) and postoperative complications; and 4) 
occurrence of postoperative nausea and vomiting.  
 
4.2 Materials and Methods  
 
4.2.1 Eligibility 
Inclusion criteria: Prospective studies that randomised adult patients undergoing elective 
ƐƵƌŐĞƌǇ ƚŽ ĞŝƚŚĞƌƉƌĞŽƉĞƌĂƚŝǀĞ ŽƌĂů ƚƌĞĂƚŵĞŶƚ ǁŝƚŚ ĐŽŵƉůĞǆ ĐĂƌďŽŚǇĚƌĂƚĞƐ ƵƐŝŶŐ A? ? ? Ő
oral carbohydrate in the preoperative morning serving of the drink or a control arm were 
included. The latter may have been either ingestion of an equivalent volume of placebo 
drink (containing no nutrients) or preoperative fasting. 
 
Exclusion criteria: Randomised controlled trials that administered intravenous 
carbohydrate, utilized <50 g oral carbohydrate in the preoperative morning serving of the 
drink, that did not compare preoperative carbohydrate treatment against a 
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placebo/preoperative fasting control arm, in which study outcomes were not measured, 
and those that included patients with diabetes mellitus were excluded. Additionally, non-
randomised, case-control, retrospective, healthy volunteer studies, and other studies 
that did not fulfill the inclusion criteria were also excluded.  
Type of Intervention: WƌĞŽƉĞƌĂƚŝǀĞĐĂƌďŽŚǇĚƌĂƚĞƚƌĞĂƚŵĞŶƚƵƐŝŶŐA? ? ?ŐŽƌĂůĐĂƌďŽŚǇĚƌĂƚĞ 
(with or without additional additives) compared with control. 
Outcomes: The primary outcome measure was the effect of preoperative carbohydrate 
treatment on length of primary hospital stay, (defined as number of postoperative days 
in hospital, until discharge). Secondary outcomes included the effects of preoperative 
carbohydrate treatment on development of postoperative insulin resistance, occurrence 
of drink-related (vomiting, aspiration or pneumonia) and postoperative complications, 
and occurrence of postoperative nausea and vomiting.  
Types of groups and subgroups of patients analysed:  
A priori subgroup analyses were performed to examine the effects of preoperative 
carbohydrate treatment on length of stay in: 1) all patients who received preoperative 
carbohydrate treatment; 2) patients undergoing major abdominal surgery; 3) operative 
ƉƌŽĐĞĚƵƌĞƐǁŝƚŚĂŶĞǆƉĞĐƚĞĚůĞŶŐƚŚŽĨƐƚĂǇA? ?ĚĂǇƐ  ?ĞŐ ?ůĂƉĂƌŽƐĐŽƉŝĐĐŚŽůĞĐǇƐƚĞĐƚŽŵǇ ?
hernia repair and thyroidectomy); and 4) orthopaedic surgery. 
4.2.2 Search strategy  
Studies published in all languages between January 1980 and April 2012 in Medline, 
Embase, Science Citation Index and Cochrane Library databases were searched using the 
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MeSH search terms preoperative, postoperative, protein, insulin resistance, insulin 
sensitivity, oral, loading, glucose, hospital stay, nausea, vomiting, pulmonary, 
complication, well-being, thirst, hunger, pain and anxiety. These results were combined 
with carbohydrate and surgery in combination with the Boolean operators AND, OR and 
NOT. Additionally, bibliographies of published randomised controlled trials were scanned 
for studies that were missed in the initial electronic search. Commercial companies that 
produced preoperative carbohydrate drinks were contacted for any unpublished data. 
Corresponding authors of the relevant publications were approached for additional or 
missing data when necessary.  
4.2.3 Data collection  
 
The randomised controlled trials identified were examined independently by two authors 
(K. Varadhan & S. Awad) and were considered as eligible for inclusion for meta-analysis if 
they met predefined inclusion criteria. Data collected included age of participants, type 
of surgery, presence of diabetes, American Society of Anaesthesiologists (ASA) grade, 
total quantity and timing of carbohydrate ingestion preoperatively, study reported 
outcomes, length of hospital stay, changes in insulin resistance, occurrence of pulmonary 
and surgical complications and postoperative nausea and vomiting. Outcomes measures 
were recorded either as intention to treat analysis or per protocol, as mentioned in the 
included RCTs.  
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4.2.4 Assessment of quality and risk of bias of included studies 
 
The quality of studies was assessed for patient selection, comparability of the two study 
groups, and outcome measures used. Each randomised controlled trial was assessed for 
method of randomisation, allocation concealment, blinding, protocol violation, 
description of withdrawals/dropouts. Any disagreement was resolved by consensus 
discussions with the other members of the review team. Graphic exploration with funnel 
plots was also used to evaluate publication bias.  
The overall quality of the evidence obtained from the included studies, for the outcome 
measures used in this meta-analysis was assessed comprehensively using GRADEpro® 
software, Cochrane Collaboration. Judgements of the quality of specific outcomes were 
based on presence or absence of the following variables in individual randomised 
controlled trials: limitations of study design and execution, inconsistency, indirectness 
and imprecision of results and risk of bias. Overall quality of the evidence for each 
outcome was a pooled result of the assessments in the above domains and was graded 
as very low, low, moderate or high. Strength of recommendations for either preoperative 
carbohydrate treatment or control was based on the combined results of the 
aforementioned systematic assessments.  
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4.2.5 Statistical analysis 
 
Two authors (KKV and SA) performed the statistical analysis using RevMan 5.1 software 
(The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) using 
standard methods recommended by the Cochrane Collaboration. Effect sizes for 
dichotomous outcomes were reported as risk ratio with 95% confidence intervals and 
continuous outcomes as mean differences. A random-effects model with the inverse 
variance method was used for pooled analyses. Differences were considered significant 
at p<0.05. Quantitative assessment of heterogeneity was calculated first using both 
 ‘ĨŝǆĞĚ ? ĂŶĚ  ‘ƌĂŶĚŽŵ ? ĞĨĨĞĐƚ ŵŽĚĞůƐ ĨŽƌ Ăůů ŽƵƚĐŽŵĞƐ ? dƚ ĨŽƌ ŚŽŵŽŐĞŶĞŝƚǇ ǁĂƐ ƚŚĞŶ
ĂƐƐĞƐƐĞĚƵƐŝŶŐʖ ?ĂŶĚƚŚĞ/ ?ƐƚĂƚŝƐƚŝĐǁŝƚŚǀĂůƵĞƐŽĨŽĨ/ ?ůĞƐƐƚŚĂŶŽƌĞƋƵĂůƚŽ ? ?A? ? ? ?A? ?
and 75%, representing low, moderate, and high heterogeneity, respectively. If the I2 test 
rejected the assumption of homogeneity of studies, then the random-effect analysis was 
reported. 
4.3 Results 
4.3.1 Eligible studies  
 
Twenty-one randomised controlled trials published between 1998 and 2012 fulfilled the 
inclusion criteria, leading to a total of 1685 patients (range 14 to 252 patients per study), 
733 in preoperative carbohydrate treatment group, 952 in control group (Table 4.1 and 
Figure 4.1). Characteristics of included studies are shown in Tables 4.1.  
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Figure 4.1: PRISMA DIAGRAM 
 
Figure 4.1: Selection of studies for the meta-analysis. Twenty one RCTs were 
considered eligible and were included for the meta-analysis. 
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Table 4.1: Characteristics of studies of preoperative carbohydrate treatment in patients 
undergoing elective surgery included in this meta-analysis.  
 
 Study Type of surgery 
Method of 
randomisation 
Allocation 
concealment 
Blinding 
Inclusion 
and 
exclusion 
criteria 
defined 
Dropouts 
and 
withdrawals 
described 
Nygren et 
al., 1998 
Open major 
colorectal surgery 
Not stated Not stated Not 
stated 
No Yes 
Hausel et 
al., 2001 
Laparoscopic 
cholecystectomy 
and open major 
colorectal surgery 
Not stated Not stated Double-
blind 
Yes Not stated 
Soop et al., 
2001 
Total hip 
replacement 
Drinks in 
random coded 
lots and given 
to 
consecutively 
enrolled 
patients 
Not stated Double-
blind 
Yes Yes 
Henriksen 
et al., 2003 
Open major 
colorectal surgery 
Block 
randomisation 
Sealed 
envelope 
method 
Not 
stated 
Yes Yes 
Bisgaard et 
al., 2004 
Laparoscopic 
cholecystectomy 
Block 
randomisation 
Random 
coded 
bottles 
Double-
blind 
Yes Yes 
Soop et al., 
2004 
Total hip 
replacement 
Drinks in 
random coded 
lots and given 
to 
consecutively 
enrolled 
Not stated Double-
blind 
Yes Yes 
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patients 
Hausel et 
al., 2005 
Laparoscopic 
cholecystectomy 
Computer 
generated 
randomisation 
Not stated Double-
blind 
Yes Yes 
Yuill et al., 
2005 
Major open 
abdominal surgery 
Not stated Not stated Double-
blind 
Yes Yes 
Melis et al., 
2006 
Orthopedic 
surgery 
Not stated Sealed 
envelope 
method 
Single-
blind 
Yes No 
Noblett et 
al., 2006 
Open major 
colorectal surgery 
Random 
number 
allocation 
Sealed 
envelope 
method 
Single-
blind 
Yes Yes 
Rapp-Kesek 
et al., 2007 
Cardiac surgery Not stated Not stated Not 
stated 
Yes No 
Jarvela et 
al., 2008 
Cardiac surgery Not stated Sealed 
envelope 
method 
Single-
blind 
Yes No 
Yagci et al., 
2008 
Laparoscopic 
cholecystectomy 
and thyroid 
surgery 
Not stated Not stated Single-
blind 
Yes No 
Lauwick et 
al., 2009 
Thyroid surgery Computer 
generated 
randomisation 
Not stated Double-
blind 
Yes Yes 
Awad et al., 
2010 
Laparoscopic 
cholecystectomy 
Computer 
generated 
randomisation 
Sequentially 
numbered 
bottles 
Double-
blind 
Yes Yes 
Kaska et al., 
2010 
Open major 
colorectal surgery 
Not stated Sealed 
envelope 
method 
Single-
blind 
Yes Not stated 
Lidder et 
al., 2010 
Open and 
laparoscopic 
major colorectal 
Computer 
generated 
Sealed 
envelope 
method 
Double-
blind 
Yes Yes 
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surgery 
Mathur et 
al., 2010 
Open major 
colorectal and 
liver surgery 
Block 
randomisation 
Sealed 
envelope 
method 
Double-
blind 
Yes Yes 
Wang et 
al., 2010 
Open major 
colorectal surgery 
Not stated Not stated Double-
blind 
Yes Yes 
Perrone et 
al., 2012 
Open/laparoscopic 
cholecystectomy 
and unilateral 
inguinal hernia 
repair 
Computer 
generated 
randomisation 
Not stated Double-
blind 
Yes Reasons for 
exclusions 
not stated 
Dock-
Nascimento 
et al., 2012 
Elective 
laparoscopic 
cholecystectomy 
Computer 
generated 
randomisation 
Not stated Not 
stated 
Yes Yes 
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 4.3.2 Characteristics of included studies   
 
 
Randomisation methods used were computer random number generator (Hausel et al., 
2005, Lauwick et al., 2009, Dock-Nascimento et al., 2012, Perrone et al., 2011), coded lots 
of study drinks (Soop et al., 2001, Soop et al., 2004, Lidder et al., 2010b), sealed 
envelope(Melis et al., 2006, Kaska et al., 2010, Mathur et al., 2010, Noblett et al., 2006b, 
Henriksen et al., 2003, Jarvela et al., 2008), and block randomisation(Mathur et al., 2010, 
Henriksen et al., 2003), were reported in fifteen studies and not reported in six (Yuill et 
al., 2005, Wang et al., 2010, Hausel et al., 2001, Nygren et al., 1998, Yagci et al, 2008, 
Rapp-Kesek et al, 2007).  
Allocation concealment was reported in nine studies (Melis et al., 2006, Kaska et al., 
2010, Mathur et al., 2010, Noblett et al., 2006b, Lidder et al., 2010a, Henriksen et al., 
2003, Jarvela et al., 2008, Bisgaard et al., 2004), using the sealed envelope method and 
not stated in the remaining studies. Twelve randomised controlled trials were described 
as double-blind (Soop et al., 2001, Yuill et al., 2005, Awad et al., 2010, Wang et al., 2010, 
Mathur et al., 2010, Hausel et al., 2001, Hausel et al., 2005, Lauwick et al., 2009, Perrone 
et al., 2011, Soop et al., 2004b, Lidder et al., 2010a, Bisgaard et al., 2004), five were 
single-blind(Melis et al., 2006, Kaska et al., 2010, Noblett et al., 2006b, Jarvela et al., 
2008, Yagci et al., 2008), and blinding was not stated in four (Dock-Nascimento et al., 
2012, Henriksen et al., 2003, Nygren et al., 1998a, Rapp-Kesek et al., 2007). Only two 
studies (Mathur et al., 2010, Dock-Nascimento et al., 2012), followed-up patients at one 
month post-hospital discharge, the remainder followed-up patients to hospital discharge.  
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Patient withdrawal and dropouts after randomisation were reported in fourteen studies 
(Soop et al., 2001, Yuill et al., 2005, Wang et al., 2010, Mathur et al., 2010, Hausel et al., 
2005, Noblett et al., 2006b, Lauwick et al., 2009, Dock-Nascimento et al., 2012, Perrone 
et al., 2011, Soop et al., 2004b, Henriksen et al., 2003, Nygren et al., 1998a, Bisgaard et 
al., 2004).  
Standard inclusion and exclusion criteria were defined in all but one study (Nygren et al., 
1998). Of the authors who were contacted (Svanfeldt et al., 2007, Yuill et al., 2005, Melis 
et al., 2006, Wang et al., 2010, Kaska et al., 2010, Mathur et al., 2010, Hausel et al., 2001, 
Noblett et al., 2006b, Lauwick et al., 2009, Perrone et al., 2011, Henriksen et al., 2003, 
Jarvela et al., 2008, Yagci et al., 2008, Bisgaard et al., 2004, Aronsson et al., 2009, Faria et 
al., 2009, Protic et al., 2010, Breuer et al., 2006, Nygren et al., 1999, Nygren et al., 1995),  
to provide additional data, all but two (Wang et al., 2010, Yagci et al., 2008), responded. 
The study published by Yuill et al included data on a subgroup of patients who were part 
of a larger multicentre commercial study (to date unpublished) sponsored by Numico 
Research (manufacturer of one of the commercially available preoperative carbohydrate 
beverages). For the purpose of this meta-analysis, data from this unpublished company-
sponsored study were combined with that from Yuill et al.  
The following studies were excluded from the meta-analysis for these reasons: 
observational design (Can et al., 2009, Gustafsson et al., 2008), studied healthy 
volunteers (Awad et al., 2011a, Awad et al., 2011b, Svanfeldt et al., 2005, Vermeulen et 
al., 2011)), included patients with diabetes mellitus (Breuer et al., 2006), utilised 
intravenous (Gustafsson et al., 2008) carbohydrate treatment (Nygren et al., 1998a, 
Thorell et al., 1996a)  or hypocaloric nutrition (Schricker et al., 2008); reported duplicate 
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data (Nygren et al., 1999); administered <50 g of oral carbohydrate in the pre-anaesthetic 
induction serving of the study drink (Aronsson et al., 2009, Faria et al., 2009, Protic et al., 
2010); administered preoperative carbohydrates for two weeks preoperatively 
(Okabayashi et al., 2011, Okabayashi et al., 2010) and did not include a placebo/fasted 
control group (Svanfeldt et al., 2007, Can et al., 2009).  
4.3.4 Patient characteristics 
 
The present meta-analysis included patients who underwent major open abdominal 
surgery, colorectal (Yuill et al., 2005, Kaska et al., 2010, Mathur et al., 2010, Hausel et al., 
2001, Noblett et al., 2006b, Henriksen et al., 2003, Nygren et al., 1998b), liver (Yuill et al., 
2005, Mathur et al., 2010), oesophago-gastric and pancreatic surgery (Yuill et al., 2005), 
laparoscopic/open cholecystectomy (Hausel et al., 2001, Hausel et al., 2005, Perrone et 
al., 2011, Lauwick et al., 2009), thyroid, inguinal hernia (Perrone et al., 2011), cardiac 
(Jarvela et al., 2008, Rapp-Kesek et al., 2007), and orthopaedic surgery (Soop et al., 2001, 
Soop et al., 2004b, Nygren et al., 1999). ASA grade (range I-III) were reported in thirteen 
studies (Awad et al., 2010, Wang et al., 2010, Kaska et al., 2010, Mathur et al., 2010, 
Hausel et al., 2001, Hausel et al., 2005, Noblett et al., 2006b, Lauwick et al., 2009, Dock-
Nascimento et al., 2012, Perrone et al., 2011, Soop et al., 2004b, Henriksen et al., 2003, 
Yagci et al., 2008). The age of participants within each group, were reported as mean ± 
standard deviation/standard error in fifteen studies (Soop et al., 2001, Awad et al., 2010, 
Melis et al., 2006, Kaska et al., 2010, Hausel et al., 2005, Noblett et al., 2006b, Soop et al., 
2004b, Henriksen et al., 2003, Jarvela et al., 2008, Nygren et al., 1998a, Yagci et al., 2008, 
Rapp-Kesek et al., 2007) and median (range) in the remaining six studies (Yuill et al., 
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2005, Wang et al., 2010, Mathur et al., 2010, Hausel et al., 2001, Bisgaard et al., 2004). 
The calculated overall mean ± standard deviation age from the former group of studies 
was 55.1 ± 11.2 and 54.0 ± 10.0 years for preoperative carbohydrate treatment and 
placebo/fasted groups, respectively. Amongst studies included in this meta-analysis, 
study groups were well-matched with no differences in baseline body mass index 
between study groups at randomisation. The quality assessment for each outcome 
(Tables 4.2 and 4.3) showed some risk of bias and imprecision for both outcomes when 
all the studies were included for analysis. Confounding variables such as selection of 
patients based on body mass index, ASA grade, inclusion of patients undergoing 
laparoscopic cholecystectomy and major open colorectal resections within the same 
study, variations in doses and timing of administration of preoperative carbohydrate 
treatment, administration of other nutrients preoperatively in addition to carbohydrates 
and type of surgery performed may have contributed to the heterogeneity of results. The 
subgroup analyses eliminated some of these confounders and improved the quality of 
evidence within individual subgroups. Therefore, the quality of evidence across all 
outcomes ranged from low to moderate (Tables 4.2 and 4.3). 
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Table 4.2: Quality of evidence of included RCTs 
 
Study 
Risk of bias 
In
co
n
si
st
e
n
cy
 
In
d
ir
e
ct
n
e
ss
 
Im
p
re
ci
si
o
n
 
 
Other considerations 
 
Nygren et al., 
1998 
No No No Yes 
Wide confidence interval for length of stay; excluded patients who 
developed post-operative complications. Hyperinsulinaemic-
euglycaemic clamp performed on postoperative day 1. 
Hausel et al., 2001 Selection bias* No No Yes 
*Combination of laparoscopic cholecystectomy and open major 
colorectal surgery in same study. Low event rates. 
Hyperinsulinaemic-euglycaemic clamp performed on postoperative 
day 1. 
Soop et al., 2001 Selection bias* No No Yes 
*Included patients with body mass index 18-28 kg/m2, not 
intention to treat analysis. Low event rates. 
Henriksen et al., 
2003 
No No No No Not intention to treat analysis. 
Bisgaard et al., 
2004 
Selection bias* No No No 
 ?ǆĐůƵĚĞĚƉĂƚŝĞŶƚƐ^ŐƌĂĚĞA?///ĂŶĚƚŚŽƐĞǁŚŽĚĞǀĞůŽƉĞĚ
surgical complications. Not intention to treat analysis. 
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Soop et al., 2004 Selection bias* No No Yes 
*Included patients with body mass index 18-28 kg/m2, not 
intention to treat analysis. Hyperinsulinaemic-euglycaemic clamp 
performed on postoperative day 3. Low event rates. 
Hausel et al., 2005 No No No Yes 
Not intention to treat analysis, planned discharge at 24 hours 
postoperatively. Low event rates. 
Yuill et al., 2005 
Reporting 
bias* 
No No No 
*Study did not report outcomes of patients enrolled at other 
centers that were participating in a multicenter commercial trial.  
Melis et al., 2006 Selection bias* No Yes No 
*Excluded patients with body mass index >30 kg/m2. 
Assessed surgery induced immunosuppression as the primary 
outcome. 
Noblett et al., 
2006 
No No No Yes 
Groups who were randomised to preoperative fasting or water 
ingestion were combined in the analyses. 
Rapp-Kesek et al., 
2007 
Selection bias* No Yes  No 
*Only studied patients aged >65 years. Both study groups received 
intraoperative glucose infusions. Used Homeostasis Model 
Assessment-Insulin Resistance to determine perioperative changes 
in insulin sensitivity. 
Jarvela et al., 2008 No No No No Both study groups received postoperative insulin infusions to 
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maintain glycemic control. 
Yagci et al., 2008 Selection bias* No No No  ?ǆĐůƵĚĞĚƉĂƚŝĞŶƚƐ^ŐƌĂĚĞA?/// ? 
Lauwick et al., 
2009 
Selection bias* Yes** Yes Yes 
*Women aged 19- ? ?ǇĞĂƌƐǁŝƚŚĂďŽĚǇŵĂƐƐŝŶĚĞǆA? ? ?ŬŐ ?ŵ2 were 
enrolled. Excluded patients with history of motion sickness or 
postoperative nausea and vomiting. **Study drink administered to 
control group drink was not iso-volumetric with active comparator. 
Not intention to treat analysis. Did not utilise visual analogue scale 
questionnaires to measure postoperative nausea and vomiting. 
Awad et al., 2010 Selection bias* No No No 
*Only studied patients undergoing inpatient laparoscopic 
cholecystectomy for uncomplicated gallstone disease.  
Kaska et al., 2010 Selection bias* No Yes No 
*Age between 35-75 years and body mass index 20-30 kg/m2 were 
included. Used the Qualitative Insulin Sensitivity Check Index to 
determine perioperative changes in insulin sensitivity. 
Lidder et al., 2010 No No No No 
Studied groups included patients undergoing both open and 
laparoscopic surgery. Used Homeostasis Model Assessment-Insulin 
Resistance and insulin tolerance tests, to determine perioperative 
changes in insulin sensitivity. 
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Mathur et al., 
2010 
No No No Yes 
Used Homeostasis Model Assessment-Insulin Resistance to 
determine perioperative changes in insulin sensitivity. 
Wang et al., 2010 
Selection bias* No No No 
*Excluded patients aged <25 or >75 years and those with >10% 
weight loss in past 6 months. Used Homeostasis Model 
Assessment-Insulin Resistance to determine perioperative changes 
in insulin sensitivity. 
Perrone et al., 
2012 
Selection bias* No No No 
 ?ǆĐůƵĚĞĚƉĂƚŝĞŶƚƐ^ŐƌĂĚĞA?/// ?ďŽĚǇŵĂƐƐŝŶĚĞǆAN ? ? ?ƉĂƚŝĞŶƚƐ
had intraoperative complications or surgery >3 hours. Used 
Homeostasis Model Assessment-Insulin Resistance(Matthews et 
al., 1985) to determine perioperative changes in insulin sensitivity. 
Study groups were not well-matched for insulin resistance at 
baseline. 
Dock-Nascimento 
et al., 2012 
Selection bias* No No No 
 ?ǆĐůƵĚĞĚƉĂƚŝĞŶƚƐŽĨĂŐĞAM ? ?ŽƌAN ? ?ǇĞĂƌƐ ?^ŐƌĂĚĞA?/// ?ŽƵƚƐŝĚĞ
body mass index range 18-30 kg/m2 and patients had surgery >2 
hours. Used Homeostasis Model Assessment-Insulin Resistance to 
determine perioperative changes in insulin sensitivity. 
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 Table 4.3: Quality assessment Summary of Findings 
Participants 
(studies) 
Follow up  
Risk of 
bias 
Inconsistency Indirectness Imprecision Publication 
bias 
Overall quality 
of evidence 
Study event rates (%) Relative 
effect 
(95% CI) 
Anticipated absolute effects 
With 
Control 
With Preop 
carbohydrates versus 
standard/placebo 
Risk with 
Control 
Risk difference with Preop 
carbohydrates versus 
standard/placebo (95% CI) 
Complications - All studies  
878 
(9 studies) 
serious1 no serious 
inconsistency2 
no serious 
indirectness 
serious3 undetected ْْٚٚ 
LOW1,2,3 
due to risk of 
bias, 
imprecision 
68/523  
(13%) 
60/355  
(16.9%) 
RR 0.88  
(0.5 to 
1.53) 
Study population 
130 per 
1000 
16 fewer per 1000 
(from 65 fewer to 69 
more) 
Length of stay - All studies  
1198 
(12 studies) 
serious2 no serious 
inconsistency 
no serious 
indirectness 
serious2,3 undetected ْْٚٚ 
LOW2,3 
due to risk of 
bias, 
imprecision 
689 509 The mean length of stay - all studies in the 
intervention groups was 0.19 lower 
(0.46 lower to 0.08 higher) 
Length of stay - Major Abdominal Surgery  
762 
(7 studies) 
serious1 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
undetected ْْْٚ 
MODERATE1 
due to risk of 
bias 
443 319 The mean length of stay - major abdominal 
surgery in the intervention groups was 1.08 
lower (1.87 to 0.29 lower) 
Length of stay - Operative procedures with expected LOS <3 days  
406 
(3 studies) 
serious4 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
undetected ْْْٚ 
MODERATE4 
due to risk of 
bias 
232 174 The mean length of stay - operative 
procedures with expected los <3 days in the 
intervention groups was 0 higher 
(0.03 lower to 0.03 higher) 
Length of stay - Orthopaedic Surgery  
30 
(2 studies) 
serious2 no serious 
inconsistency 
no serious 
indirectness 
no serious 
imprecision 
undetected ْْْٚ 
MODERATE2 
due to risk of 
bias 
14 16 The mean length of stay - orthopaedic surgery 
in the intervention groups was 
0.48 higher 
(0.23 to 0.73 higher) 
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4.3.5: Length of hospital stay  
 
Data on length of hospital stay were available in twelve studies with a total of 1198 
patients (preoperative carbohydrate treatment: 509 and control: 689 patients). Length of 
stay data were reported as actual length of hospital stay in eight studies (Soop et al., 
2001),(Yuill et al., 2005),(Kaska et al., 2010, Mathur et al., 2010),(Hausel et al., 
2005),(Dock-Nascimento et al., 2012, Perrone et al., 2011, Soop et al., 2004b), as time to 
 ‘ĨŝƚŶĞƐƐƚŽĚŝƐĐŚĂƌŐĞ ?ŝŶƚǁŽƐƚƵĚŝĞƐ (Mathur et al., 2010, Noblett et al., 2006b) and were 
not reported in the original publications of three studies (Hausel et al., 2001),(Henriksen 
et al., 2003, Nygren et al., 1998a). Five studies (Yuill et al., 2005, Kaska et al., 2010, 
Mathur et al., 2010, Noblett et al., 2006b, Perrone et al., 2011) reported median 
(interquartile range or range) length of stay, and the original authors were contacted to 
provide data as mean ± standard deviation.  
To enable comparison between study groups, data from the placebo and fasted groups 
were combined and a new mean ± standard deviation calculated. Amongst all studies (Fig 
4.2) that utilised preoperative carbohydrate treatment, there were no differences in 
length of stay between preoperative carbohydrate treatment and control patients [mean 
difference, inverse variance, random effects model, 95% confidence interval [-0.19 days, 
(-0.46 to -0.08), I2 = 83%, p=0.16] (Fig 4.2).  
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However, subgroup analysis of studies (N=7, Figure 2) that included patients who 
received preoperative carbohydrate treatment prior to major open abdominal surgery, 
with 319 preoperative carbohydrate treatment and 443 control, demonstrated significant 
reduction in length of stay for the preoperative carbohydrate treatment group [mean 
difference, inverse variance, random effects model, 95% confidence interval [-1.08 days, 
(-1.87 to -0.29), I2 = 60%, p=0.007]. No differences were demonstrated in studies (N=4, 
Figure 4.2) that included patients undergoing surgical procedures with expected length of 
ƐƚĂǇA? ?ĚĂǇƐ ?ŵĞĂŶĚŝĨĨĞƌĞŶĐĞ ?ŝŶǀĞƌƐĞǀĂƌŝĂŶĐĞ ? random effects model, 95% confidence 
interval [0.00, (- 0.03 to 0.03), I2 = 0%, p=0.970]. Conversely, in two small studies of 30 
patients undergoing orthopaedic surgery, there was a significant reduction in length of 
stay for the control group [mean difference, inverse variance, random effects model, 95% 
confidence interval [-0.48, (-0.23 to -0.73), I2 = 0%, p<0.0002]. 
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Figure 4.2: Length of Hospital Stay 
 
Figure 4.2: Forest plot of the effect of preoperative oral carbohydrate treatment on 
length of hospital stay in patients undergoing elective surgery. Abbreviations: CI  W 
confidence interval; IV  W inverse variance. 
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4.3.6 Insulin resistance 
 
The effects of preoperative carbohydrate treatment on the development of 
postoperative insulin resistance are shown in Table 4. Three studies utilised the 
hyperinsulinaemic-euglycaemic clamp technique to measure relative changes in insulin 
sensitivity(Soop et al., 2001),(Soop et al., 2004b, Nygren et al., 1998a) and demonstrated 
significant reduction in development of postoperative insulin resistance in preoperative 
carbohydrate treatment patients when compared with control.  
Three further studies (Mathur et al., 2010, Dock-Nascimento et al., 2012, Perrone et al., 
2011) utilised Homeostasis Model Assessment-Insulin Resistance [HOMA-IR] calculations 
to determine changes in perioperative insulin resistance; with two demonstrating a 
reduction in postoperative HOMA-IR values between preoperative carbohydrate treated 
and control patients (Table 4.4). Finally, a study (Lidder et al., 2010) which utilised the 
Qualitative Insulin Sensitivity Check Index [QUICKI], to derive a crude estimate of changes 
in perioperative insulin sensitivity, demonstrated significant reduction in the 
postoperative insulin resistance index in the preoperative carbohydrate treatment group. 
141 
 
Table 4.4: Effect of preoperative carbohydrate treatment on development of postoperative insulin resistance.  
&ŽƌƐƚƵĚŝĞƐƚŚĂƚƵƚŝůŝǌĞĚƚŚĞ ‘ŐŽůĚ-ƐƚĂŶĚĂƌĚ ?ƚĞĐŚŶŝƋƵĞĨŽƌŵĞĂƐƵƌŝŶŐŝŶƐƵůŝŶƐĞŶƐŝƚŝǀŝƚǇ ?ŚǇƉĞƌŝŶƐƵůŝŶĂĞŵŝĐ-euglycaemic clamp], data presented are 
mean ± standard deviation. A greater reduction in insulin sensitivity implies greater development of insulin resistance.  
 
Study  
 
Method to determine insulin 
sensitivity 
Mean ± standard deviation 
% relative change in insulin 
sensitivity measured by 
glucose infusion rate 
Mean ± standard deviation 
% relative change in insulin 
sensitivity measured by 
glucose disposal rate 
p-value 
Nygren et al., 
1999 
Hyperinsulinaemic-euglycaemic 
clamp 
Not available 
Preoperative carbohydrate 
treatment: -26 ± 8% 
Control: -49 ± 6% 
p<0.05 
Soop et al., 2001 
Hyperinsulinaemic-euglycaemic 
clamp 
Preoperative carbohydrate 
treatment: -18 ± 6% 
Control: -43 ± 9% 
Preoperative carbohydrate 
treatment: -19 ± 6% 
Control: -37 ± 9% 
 
p<0.05 
Soop et al., 2004 
Hyperinsulinaemic-euglycaemic 
clamp 
Preoperative carbohydrate 
treatment: -36 ± 10% 
Control: -49 ± 7% 
Not available p>0.05 
 
Rapp-Kesek et al., 
2007 
Homeostasis Model 
Assessment-Insulin Resistance 
There were no significant differences in the ratios of 
homeostasis model assessment-insulin resistance at baseline 
Not stated 
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and postoperative days 1, 2 and 6 
Lidder et al., 2010 
Homeostasis Model 
Assessment-Insulin Resistance 
homeostasis model assessment-insulin resistance was lower 
in group receiving pre- and post-operative supplement than 
in group receiving pre and post-operative placebo 
p=0.011 
Mathur et al., 
2010 
Homeostasis Model 
Assessment-Insulin Resistance 
No significant differences in homeostasis model assessment-
insulin resistance between groups at baseline. Homeostasis 
model assessment-insulin resistance significantly higher than 
baseline in placebo group on days 1, 5 and 7 but not 
significantly different in preoperative carbohydrate 
treatment patients postoperatively 
p>0.05 
Wang et al., 2010 
Homeostasis Model 
Assessment-Insulin Resistance 
Median levels of homeostasis model assessment-insulin 
resistance increased significantly by the end of surgery in all 
three study groups (oral carbohydrate treatment, placebo, 
fasting) but they were significantly lower in the oral 
carbohydrate treated group  
p<0·001 
Perrone et al., 
2012 
Homeostasis Model 
Assessment-Insulin Resistance 
The insulin resistance alterations before and after surgery 
were found to be significantly higher in the control group 
then the group that received the carbohydrate/whey protein 
study drink 
p<0.05 
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Dock-Nascimento 
et al., 2012 
Homeostasis Model 
Assessment-Insulin Resistance 
Postoperative homeostasis model assessment-insulin 
resistance was greater in control patients compared with the 
other three study groups (placebo drink, carbohydrate drink, 
carbohydrate-glutamine drink) 
p=0.01 
Kaska et al., 2010 Qualitative Insulin Sensitivity 
Check Index 
No significance difference between preoperative 
carbohydrate treatment and control. QUICKI significantly 
lower postoperatively in preoperative carbohydrate 
treatment group compared to fasted group. 
p<0.05 
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4.3.7 Pulmonary and surgical complications  
 
No studies reported occurrence of drink-related pulmonary complications in 
preoperative carbohydrate treatment patients or those who received placebo. Nine 
studies that fulfilled the inclusion criteria provided data on the occurrence of 
postoperative complications (Figure 4.3). With 355 preoperative carbohydrate and 
523 control patients, no differences were noted between the groups (Figure 3) in the 
occurrence of postoperative complications [risk ratio, Mantel-Haenszel, random 
effects model, 95% confidence interval (0.88, [0.50 to 1.53], I2 = 41%, p=0.64). 
However, few of the included studies reported occurrence of complications after 
hospital discharge (i.e. prolonged follow-up) and therefore the presented data 
reflects the effects of PCT on the occurrence of in-hospital complications.  
 
Figure 4.3: Forest plot of the effect of preoperative oral carbohydrate treatment on 
development of surgical complications in patients undergoing elective surgery. 
Abbreviations: CI- confidence interval; IV- inverse variance. No differences in complications 
were noted between CHO and control. 
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4.3.7 Postoperative nausea and vomiting  
 
Data on postoperative nausea and vomiting were reported in five studies (Yuill et al., 
2005),(Hausel et al., 2005, Lauwick et al., 2009),(Henriksen et al., 2003, Jarvela et al., 
2008). Nausea was determined by means of visual analogue scale questionnaires. 
Three studies demonstrated no differences in the occurrence of postoperative 
nausea and vomiting between preoperative carbohydrate treatment and control 
groups (Yuill et al., 2005),(Lauwick et al., 2009, Henriksen et al., 2003), one study 
reported fewer(Hausel et al., 2005) and one study reported more (Jarvela et al., 
2008)25 instances of postoperative nausea and vomiting in preoperative 
carbohydrate treated patients. However, only two studies (Hausel et al., 
2005),(Lauwick et al., 2009) reported data on the use of anti-emetics.  
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4.4 Discussion 
 
Principal findings 
This meta-analysis of 21 randomised controlled trials evaluating the effects of 
preoperative carbohydrate treatment on patients undergoing elective surgery 
demonstrated a significant reduction in length of stay amongst patients undergoing 
major open abdominal surgery. Preoperative carbohydrate treatment was safe (no 
occurrence of drink-related complications), associated with reduced development of 
postoperative insulin resistance but the latter was not associated with any effect on 
surgical complications.  
Strengths of the meta-analysis 
This is the first meta-analysis to examine the effects of preoperative carbohydrate 
treatment on clinical outcomes in 1685 patients undergoing elective surgery. The 
only subgroup of studies that included sufficient numbers of patients (N=762) to 
demonstrate a potential difference in length of hospital stay were those of patients 
undergoing major abdominal surgery. Therefore, for the primary outcome of the 
effect of preoperative carbohydrate treatment on length of stay, data from this 
subgroup of patients were of clinical importance and comprised the largest grouping 
of patients presently available in the literature. To maintain homogeneity of 
interventions, the studies that prescribed <50 g of carbohydrates were excluded 
from the analysis. A separate subgroup analysis based on the surgical procedures, 
identified the true effect of preoperative carbohydrate drinks on length of stay, 
especially those undergoing major abdominal surgery that would otherwise be 
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confounded by other surgical procedures of lesser magnitude. Assessment of the 
quality of individual studies and the reported outcomes using Cochrane methodology 
and grading the evidence presented using GRADEpro®, further strengthens the 
methodology.  
Limitations of the meta-analysis 
The main limitation of this meta-analysis was the relatively weak design of many of 
the included studies whose quality, as assessed by GRADEpro®, was rated as low to 
moderate. There were small numbers and significant heterogeneity in the design and 
magnitude of surgery in many studies of preoperative carbohydrate treatment that 
precluded their inclusion in this meta-analysis. The definitions of outcomes such as 
complications and reporting of events varied between studies. Similarly, insulin 
resistance were measured using different methods in the included studies, making it 
difficult to arrive at a common consensus, though most studies reported attenuation 
of postoperative insulin resistance in carbohydrate treated patients. Moreover, not 
all outcomes were reported by the included studies. Therefore this meta-analysis 
included studies that used preoperative carbohydrates and reported at least one 
outcome of interest. The aforementioned weaknesses limited the numbers of studies 
eligible for inclusion in the assessment of the primary outcome of length of hospital 
stay.  
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Meaning of the study/Health policy implications 
For the primary outcome, difference in length of hospital stay, the studies of major 
open abdominal surgery demonstrated a reduction in length of hospital stay by one 
day. This is likely due, in part, to improved recovery after surgery since no differences 
in complication rates were demonstrated between the carbohydrate treated and 
control groups. This improved recovery could be explained by the metabolic effects 
of preoperative carbohydrate treatment, namely, an attenuated postoperative 
insulin resistance response leading to marked effects on several key aspects of 
metabolism. For glucose metabolism, development of insulin resistance reduces 
glucose uptake in peripheral insulin-sensitive cells such as skeletal muscle, this 
occurring secondary to decreased activation of specific glucose transporting proteins 
such as glucose transporter-4 (GLUT-4)(Thorell et al., 1999a). The latter was recently 
shown due to a defect in a key intracellular signalling pathway involving 
phosphatidyl-inositol-3-kinase in muscle (Wang et al., 2010). Simultaneously with the 
effects on glucose metabolism, preoperative carbohydrate treatment results in 
decreased protein catabolism in the body (Svanfeldt et al., 2007) and improved 
activation of anabolic signals (tyrosine kinase) in muscle (Wang et al., 2010). The 
aforementioned changes may be responsible, in part, for observed reduced loss of 
lean body mass postoperatively (Yuill et al., 2005). The combination of reduced 
substrate supply and loss of muscle mass may explain the finding of substantial 
reductions in muscle force that persist for weeks following elective surgery in 
preoperative fasted patients compared to patient given preoperative carbohydrate 
treatment (Henriksen et al., 2003). The two small orthopaedic studies included a 
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total of 30 patients and were underpowered to inform an effect of preoperative 
carbohydrate treatment on length of hospital stay. Similarly, three further studies 
(Dock-Nascimento et al., 2012, Perrone et al., 2011, Hausel et al., 2005) that included 
patients undergoing day surgery and procedures with an expected length of hospital 
stay of one day, would not have been expected to demonstrate measurable 
differences in length of stay between preoperative carbohydrate treated and control 
patients. Furthermore, the main mechanisms underlying any differences in length of 
stay between preoperative carbohydrate treatment and control groups are thought 
related to either improved recovery and/or reduction in complications, both 
associated with changes in insulin resistance. However, laparoscopic and minor 
surgery are associated with minimal development of insulin resistance and low 
complication rates, therefore, an intervention such as preoperative carbohydrate 
treatment would not be expected to improve clinical outcomes in this group of 
patients. Any beneficial effects of preoperative carbohydrate treatment in such 
patient groups would primarily be related to improving preoperative well-being 
(Hausel et al., 2001, Bisgaard et al., 2004). 
Preoperative carbohydrate treatment reduced development of postoperative insulin 
resistance when the gold-standard hyperinsulinaemic-euglycaemic clamp was 
utilised to measure insulin sensitivity. These findings were akin to previous data from 
studies that utilised intravenous glucose treatment to effect a similar degree of 
insulin release (Nygren et al., 1998) and strongly support the notion that 
preoperative carbohydrate treatment does reduce the development of early 
postoperative insulin resistance (Awad et al., 2009). Studies that measure changes in 
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perioperative insulin resistance utilising methods that use basal insulin and glucose 
concentrations (i.e. HOMA-IR and QUICKI) yielded conflicting data which should be 
interpreted with caution. HOMA-IR and QUICKI values are derived from formulae of 
basal concentrations of insulin and glucose, a situation that arises when insulin is not 
active. Indeed, measurement of insulin sensitivity relies on quantifying insulin 
stimulated glucose uptake in peripheral tissues; the latter only seen with higher 
concentrations of insulin (seen post-prandially and in the hyperinsulinaemic-
euglycaemic clamp). Utilising HOMA as a surrogate marker for the 
hyperinsulinaemic-euglycaemic clamp would not be appropriate, therefore, since the 
two modalities measure different parameters that are not comparable. Furthermore, 
the clinical effects of insulin resistance have traditionally been demonstrated utilising 
the hyperinsulinaemic-euglycaemic clamp (Sato et al., 2010, Soop et al., 2001, 
Svanfeldt et al., 2005, Nygren et al., 1998a). Whilst there exists evidence that a 
reduction in insulin resistance may lead to reduced postoperative complications(Sato 
et al., 2010), this was not confirmed by the present meta-analysis, which 
demonstrated no differences in the occurrence of postoperative complications 
following preoperative carbohydrate treatment, despite the reduction in 
postoperative insulin resistance. 
The data on well-being presented in this meta-analysis were conflicting. Two studies 
of patients undergoing laparoscopic cholecystectomy (Hausel et al., 2001, Bisgaard et 
al., 2004) demonstrated improved preoperative well-being compared to placebo, 
whilst this was not confirmed a third in patients undergoing thyroid surgery (Lauwick 
et al., 2009). The reasons underlying these conflicting data remain unknown but may 
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include the use of differing methods to measure changes in well-being and differing 
magnitudes of surgical procedures.  
The traditional practice of overnight fasting has definitively been shown to be 
unnecessary and numerous anaesthesia societies have now changed their guidelines 
to permit more liberal fluid intakes (Maltby, 2006) up to 2 h prior to induction of 
anaesthesia. Findings from the present meta-analysis indicated preoperative 
carbohydrate treatment was not associated with an increase in drink-related 
complications; confirming the safety of utilising oral complex carbohydrate drinks of 
appropriate osmolality preoperatively. Numerous countries have already updated 
their preoperative guidelines to recommended preoperative carbohydrate treatment 
due to its perceived beneficial effects on insulin resistance and well-being (Smith et 
al., 2011b). This meta-analysis also suggests that, in addition to the aforementioned 
benefits, faster recovery (decreased length of hospital stay) in patients undergoing 
open major abdominal surgery may also be expected. Preoperative carbohydrate 
treatment, as part of a multimodal enhanced recovery protocol, is recommended by 
the Enhanced Recovery After Surgery (ERAS®) group. When employing several 
components of the Enhanced Recovery After Surgery recommendations, a recent 
meta-analysis demonstrated a reduction in length of stay of 2.5 days (Varadhan et 
al., 2010), in keeping with recent data that suggest the beneficial effects on reduced 
recovery time and complication rates accrued in an almost stepwise fashion with 
increased compliance and utilisation of Enhanced Recovery After Surgery 
components (Gustafsson et al., 2011). Interestingly, in the latter study (Gustafsson et 
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al., 2011) the components that affected outcomes were preoperative carbohydrate 
treatment and fluid overload.  
Future research 
As the quality of evidence presented in this meta-analysis was weak, further well-
designed randomised studies are required to specifically examine the effects of 
preoperative carbohydrate treatment on postoperative recovery and determine 
which patient groups are likely to benefit most. Such studies should be conducted in 
patient groups where expected postoperative length of stay is of sufficient length to 
enable differences in the effects of preoperative carbohydrate treatment on 
metabolism and subsequent function to be detected. In addition, such studies should 
be performed whilst controlling for other aspects of perioperative care known to 
influence length of stay (Gustafsson et al., 2011). On the other hand, future studies 
ŽĨ ƉĂƚŝĞŶƚƐ ƵŶĚĞƌŐŽŝŶŐ  ‘ŵŝŶŽƌ ? ƐƵƌŐĞƌǇ ƐŚŽƵůĚ ĨŽĐƵƐ ŽŶ ĂŶǇ ƉŽƚĞŶƚŝĂů ĞĨĨĞĐƚƐ ŽĨ
preoperative carbohydrate treatment on perioperative well-being. This would be of 
interest given recent data on the central regulatory effects of glucose and insulin on 
the serotonin system(Orosco and Gerozissis, 2001). There presently exists limited 
data on the effects of preoperative carbohydrate treatment in patients who are 
obese (body mass index >30 kg/m2 ? ?^ŐƌĂĚĞA?/// ?ŚĂǀĞĚŝĂďĞƚĞƐ ?ŽƌĂƌĞƵŶĚĞƌŐŽŝŶŐ
emergency surgery. However, further randomised trials of preoperative 
carbohydrate treatment as the only intervention may be difficult to undertake, as 
this intervention is now incorporated into enhanced recovery after surgery protocols. 
Any beneficial effects of preoperative carbohydrate treatment demonstrated in 
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these trials may be difficult to isolate from those caused by other interventions 
within the enhanced recovery protocols (such as use of neuroaxial blockade).  
In summary, this meta-analysis suggests that use of preoperative carbohydrate 
treatment in patients undergoing major abdominal surgery may be associated with 
shortened length of hospital stay and attenuation of insulin resistance. However, the 
quality of evidence was low to moderate necessitating further well-designed 
randomised trials.  
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Chapter 5 
The mechanistic basis of metabolic response to surgery and the development of 
postoperative insulin resistance in patients having major abdominal surgery 
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5.1 Background & Aims 
Postoperative insulin resistance (POIR) is a hallmark feature in patients having major 
abdominal surgery (Thorell et al., 1999b). Surgical stress may induce changes in 
metabolic pathways that perturb glucose homeostasis in the perioperative period, 
resulting in stress hyperglycaemia which contributes to increased postoperative 
morbidity, length of stay and prolonged recovery (Thorell et al., 1999b, van den 
Berghe et al., 2001, Jackson et al., 2012). Similarly, studies in burns injury (Gore et 
al., 2001), trauma (Laird et al., 2004, Sung et al., 2005, Jeschke et al., 2004), and 
critically ill patients (Bochicchio et al., 2005, Pittas et al., 2004) also show a causal 
relationship between hyperglycaemia and increased morbidity and mortality. 
Conversely, maintenance of glycaemia with insulin therapy is associated with 
reduction of length of stay and decreased risk of complications in this group of 
patients (Van den Berghe et al., 2006, Finfer et al., 2009). However, the molecular 
mechanisms underlying these postoperative changes in carbohydrate oxidation and 
insulin resistance is less clear.  
POIR develops within hours of surgery and into the first postoperative day (Thorell et 
al., 1999a). The effects of metabolic response to surgery has been shown to peak in 
the first 24-48 hours following surgery and last for several days postoperatively 
before returning to basal conditions (Thorell et al., 1999b).  
Skeletal muscle becomes refractory to insulin action during stress and contributes to 
peripheral insulin resistance. Skeletal muscle constitutes a primary site for insulin 
dependent glucose uptake (Zurlo et al., 1990) and along with liver, plays an 
important role in the development of POIR during stress states. 
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In previous studies using a rodent-endotoxaemia model of clinical endotoxaemia, it 
was noted that inhibition of PI3K/Akt1 signaling, and activation of the Forkhead Box 
O (FOXO) family of transcription factors that lie downstream of PI3K/Akt1, occurred 
concomitantly with induction of muscle atrophy programme and the impairment of 
muscle carbohydrate oxidation (Crossland et al., 2008). Importantly, these events 
were accompanied by marked upregulation of FOXO gene targets muscle atrophy F-
box (MAFbx), RING finger 1 (MuRF1) and pyruvate dehydrogenase kinase-4 (PDK4), 
which strongly suggests a role for Akt/FOXO signaling in the simultaneous induction 
of muscle atrophy and impairment of muscle carbohydrate oxidation during 
endotoxaemia. Impaired Akt/FOXO signaling has also been implicated in muscle 
insulin resistance, through FOXO-mediated upregulation of isoform PDK4. PDK4 
phosphorylates and inactivates pyruvate dehydrogenase complex (PDC), the rate-
limiting step in carbohydrate oxidation. Thus, increased PDK4 expression may lead to 
the development of POIR in patients having major abdominal surgery. 
Furthermore, a study investigating the changes in anabolic and catabolic pathways in 
skeletal muscle of critically ill patients has demonstrated a key role of muscle pro-
inflammatory cytokines, changes in PI3K/Akt signalling pathway, cathepsin, PDK4 and 
muscle ubiquitin ligases, MAFBx and MURF1 in the molecular regulation of muscle 
mass and carbohydrate metabolism (Constantin et al., 2011). Both, IL-6 and TNF-ɲ
mRNA expression were higher in patients than controls (6.5 fold & 2 fold, 
respectively). Also, the magnitude of phosphorylation of signalling proteins thought 
to control translation initiation of protein synthesis such as Akt, GSK3 and 
mTOR/p70s6k, was reduced with the simultaneous up-regulation of muscle protein 
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breakdown pathways (Ubiquitin proteasome complex and Cathepsin-L) compared to 
controls. Both, PDK4 mRNA and protein expression were raised (2-fold and 2.7 fold 
respectively), indicating inhibition of muscle carbohydrate oxidation occurs 
concomitantly with protein breakdown in these patients.  
As detailed in Chapter 1 of this thesis, evidence from studies involving surgical 
patients suggests a possible role of inflammation in the development of 
postoperative insulin resistance. For example, Witasp et al demonstrated a 
significantly increased expression of IL-6, IL-6 receptor and TNF, in skeletal muscle of 
patients having surgery postoperatively (Witasp et al., 2009b). The inflammation 
induced by surgical stress may be associated with impairment of the gut epithelial 
barrier due to disruption of tight junctions and increased para-cellular penetration of 
luminal macromolecules, including of bacterial antigens, thereby resulting in an 
exaggerated inflammatory response (Hollander., 1999; Clayburgh et al., 2004). 
Therefore, we contend whether inflammation associated with surgical trauma is 
responsible for the concomitant activation of muscle insulin resistance and protein 
breakdown, and whether this can be linked to impaired Akt signalling and FOXO 
mediated up-regulation of its downstream targets, namely PDK4 and MafBx. 
Gastrointestinal surgery mediated increases in gut permeability and expression of IL-
6 and PDK4 mRNAs in quadriceps muscle may underpin the post-operative increase 
in whole-body insulin resistance in humans. An improved understanding of the 
mechanisms involved in the development of POIR and surgical stress induced 
changes in carbohydrate metabolism are of substantial interest, to determine future 
therapeutic interventional targets to attenuate the surgical stress response and POIR.  
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Thus, the aim of this study was to investigate the mechanistic basis of metabolic 
response to surgery and the development of postoperative insulin resistance in 
patients having major abdominal surgery.  
 
5.2 Methods 
5.2.1 Experimental design and sample collection 
Fifteen patients undergoing major elective open gastrointestinal surgery were 
included prospectively, after obtaining a written informed consent and ethics 
approval. Patients who were undergoing emergency surgery, suffering from chronic 
illness, (e.g. diabetes), disseminated malignant disease, on medications known to 
affect glucose metabolism, on statins, on long term antibiotics or anti-inflammatory 
drugs (e.g. NSAIDS, Steroids), immunosuppressive agents, on full therapeutic dose of 
anticoagulants, or anti-platelet therapy, suffering from bleeding diathesis were 
excluded from the study.  
Fig 5.1: Time course of sample collection from patients undergoing major surgery  
        
 
D7-14 Days                                                        Start of surgery                                       End of surgery                        2
nd
postoperative 
day   
GTT & 
51
Cr-EDTA tests (Preop)                                 GTT & 51Cr-EDTA tests (2nd POD) 
       - Blood samples;                      - Muscle Biopsy;            GTT  W Glucose Tolerance Test;  
                51
Cr-EDTA ʹ Chromium EDTA test for gut permeability 
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The following investigations were performed in patients having major abdominal 
surgery (Fig. 5.1):  
(1) Arterialised-venous blood samples were obtained at three time-points; pre-
assessment visit, during surgery and on the second postoperative day and were 
analysed for plasma concentrations of insulin, cortisol, lactate and free fatty acids  
(2) An Oral Glucose Tolerance Test (GTT) was performed at the pre-assessment visit 
and on the 2nd postoperative day (Chapter 1). Glucose was measured using 
(HemoCue glucose analyser; HemoCue Ltd, Ängelholm, Sweden). 
(3) A 51Cr-EDTA gut permeability test using an oral preparation containing 1.8 MBq of 
51 chromium labelled ethylene-diamine-tetra-acetate (51Cr-EDTA), (Department of 
Medical Physics, University of Nottingham, U.K.) in 100 mL of water was performed 
during the screening visit and on the 2nd postoperative day. A 24 hour urine sample 
was collected and a small samƉůĞ ŽĨ ƵƌŝŶĞ ǁĂƐ ĐŽƵŶƚĞĚ ĨŽƌ ƌĂĚŝŽĂĐƚŝǀŝƚǇ ďǇ Ă ɶ -
scintillation counter in triplicate (IGE Millennium VG camera with Hawkeye CT and 
Wallac Wizard 3 automatic gamma counter). Results were expressed as the 
percentage urinary excretion of the orally administered dose of 51Cr-EDTA. 
(4) Muscle biopsies of approximately 100 mg, were taken from rectus abdominis and 
vastus lateralis muscles at the beginning and at the end of surgery. The samples were 
immediately snap-frozen in liquid nitrogen. The specimens obtained at the end of 
surgery were taken from the contralateral side to avoid false measurements due to 
local tissue injury. The samples were analysed for the following: 
Muscle mRNA expression: Interleukin-6 (IL-6), Tumour Necrosis Factor- ɲ  ?dE&-ɲ ? ?
Protein Kinase-B (Akt1), Insulin Receptor Substrate-1 (IRS-1), Forkheadbox-0 (FOXO), 
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Ubiquitin ligases (MAFbx and MURF1), and Pyruvate Dehydrogenase Kinase-4 
(PDK4). 
x Muscle protein expression: IL-6, MAFbx, FOXO, PDK4 and P70s6k. 
x Muscle Pyruvate Dehydrogenase Complex (PDC) activity and metabolites: 
glycogen, lactate 
x Mitochondrial ATP production rates (MAPR). 
5.2.2 Statistics 
Within subject comparisons of responses to surgical stress over time will eliminate 
inter-individual variability. Existing gene expression data from healthy volunteer 
studies in our department indicates that with P<0.01 and an analysis power of 90%, a 
true difference in the mean response of matched pairs that equates with a doubling 
of mRNA expressions was detected, using 13 subjects. In the present study fifteen 
patients were included to allow for 2 dropouts. Data are presented as means ± S.E.M. 
ĂŶĚ ĐŽŵƉĂƌŝƐŽŶƐ ǁĞƌĞ ƉĞƌĨŽƌŵĞĚ ƵƐŝŶŐ ^ƚƵĚĞŶƚ ?Ɛ ƵŶƉĂŝƌĞĚ t test. Real-time PCR 
results were analysed by one-way analysis of variance (ANOVA). Differences were 
considered statistically significant when P < 0.05. 
 
5.3 Results 
Fifteen patients [49 (range 22-70) years, BMI 26 (range 18-38) kg/m2] undergoing 
major elective open abdominal surgery were included in the study. Seven of these 
patients were operated for pancreatic cancer and eight were for benign disease, such 
as chronic pancreatitis and incisional hernia. Mean time elapsed between biopsies 
was 223 min (range 110-390). The average white cell count was 8.98 (5.4  W 14.0).  
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5.2: mRNA expression in Rectus Abdominis and Vastus Lateralis Muscle, in patients 
having major abdominal surgery 
 
mRNA expression changes in both rectus and vastus muscle is shown as fold-change 
from muscle biopsies taken at the start of surgery (pre-surgery) to those taken at the 
end of surgery, where the pre-surgery results were set as one. The values in the 
legend represent the statistical difference of gene expression between the two 
muscle groups. (*represents significance from pre-surgery (p<0.05).  
Biopsies from rectus muscle at the start and end of surgery, showed a significant 
fold-change in gene expression changes for TNF-ɲ  ? ? ? ? ?-fold), FOXO1 (10.5-fold), 
MafBx (11.5-fold), Cathepsin (7.5-fold) and PDK4 (7.8-fold) (Figure 2). Whereas, in 
the vastus muscle, the fold change for mRNAs were significant for TNF-ɲ  ? ?-fold), 
FOXO1 (2.3 fold), MafBx (6.4-fold), and PDK4 (3.5-fold) (Fig. 2).  
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5.3 Ratio of gene expression (Rectus Abdominis / Vastus Lateralis Muscle) in patients 
having major abdominal surgery 
 
 
The data from the present study showed marked alterations in gene expression in 
skeletal muscle during major abdominal surgery. The ratio of mRNA expression 
changes in both rectus and vastus muscle is shown as fold-change from muscle 
biopsies taken at the start of surgery (pre-surgery) to those taken at the end of 
surgery. The magnitude of response in the rectus muscle (being the site of the 
maximal injury due to abdominal surgery) was greater for most genes studied, when 
compared with gene expression from the vastus muscle. However, the pattern of 
gene expression was similar across all genes in both groups of muscles. Cathepsin-L, 
FOXO1, and IL-6 mRNA expressions were significantly higher in the rectus when 
compared with vastus muscle (Fig. 5.2). (*represents significance from pre-surgery; 
P<0.05). Muscle mRNA expressions of the two pro-inflammatory cytokines, IL-6 and 
TNF-ɲ ?ǁĂƐŐƌĞĂƚĞƌĂƚƚŚĞĞŶĚŽĨƐƵƌŐĞƌǇĐŽŵƉĂƌĞĚǁŝƚŚƉƌĞ-surgery. Specifically, in 
the rectus, IL-6 mRNA expression was about 3000-fold higher. 
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Figure 5.4: IL-6 mRNA expression in vastus muscle in patients having major abdominal 
surgery 
 
 
The IL-6 mRNA expression in vastus, showed a highly significant fold change in IL-6 
mRNA post-surgery (**P<0.01). 
Thus, the gene expression data in patients undergoing major abdominal surgery, 
shows that there was increased expression of mRNA involved in inflammation (IL-6, 
TNF-ɲ ? ? ŵƵƐĐůĞcarbohydrate oxidation (PDK4) and protein breakdown (FOXO1, 
MafBx, Cathepsin-L) postoperatively. 
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Figure 5.5: Protein expression in Rectus Abdominis muscle in patients having major 
abdominal surgery 
 
 
Figure 5.5 shows, fold-change in the relative optical density of IL-6, MafBx and PDK4, 
ratio of phosphorylated p70s6k to total p70s6k, ratio of phosphorylated to total 
FOXO1 proteins in patients undergoing major abdominal surgery, quantified by 
Western blotting. Blank staple represents protein expression at start of surgery and 
filled staple represents protein expression at end of surgery. (*, **, *** refers to 
significance level of P<0.05, P<0.01, P< 0.001). 
Major abdominal surgery resulted in a significant fold-change in protein expression 
for IL-6 (5.9±2.23), PDK4 (4.49±1.85), P70s6k (14.9±3.8), phosphorylated P70s6k 
(15.7±6.7), FOXO1 (11.21±4.08), and phosphorylated FOXO1 (7.82±3.28).  
The corresponding western blots for MAFbx, phosphorylated FOXO1, FOXO1, 
phosphorylated p70s6k, p70S6k, PDK4 and IL-6 in rectus muscle biopsies obtained at 
the beginning (Pre) and end of surgery (Post) from patients undergoing major 
abdominal surgery.  
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Figure 5.6: Protein expression in Vastus Lateralis muscle in patients having major 
abdominal surgery 
 
 
                                    
 
 
 
 
No significant fold-change were noted in the relative optical density in vastus muscle 
for IL-6, MAFbx and PDK4, phosphorylated 70s6k, total p70s6k, phosphorylated and 
total FOXO1 proteins in patients undergoing major abdominal surgery quantified by 
Western blotting. Pre-surgery represents protein expression at start of surgery and 
post-surgery represents protein expression at end of surgery. 
Figure 5.7, also shows typical Western blots for MAFbx, pFOXO1, FOXO1, Pp70s6k, 
p70S6k, PDK4 and IL-6 in vastus muscle biopsies. The values at the beginning (Pre) 
and end of surgery (Post) from patients undergoing major abdominal surgery was not 
significant (n = 15).  
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Figure 5.7: Gut permeability in patients having major abdominal surgery 
 
 
 
Gut permeability test was performed using the 51Cr-EDTA method at the time of 
screening and 24 hours postoperatively in patients undergoing major abdominal 
surgery. The figure shows a significant increase in gut permeability following surgery. 
Gut permeability (% urinary excretion of 51Cr-EDTA): Pre surgery: 4.79 ± 0.82; Post-
surgery: 7.30 ± 1.03; (* refers to significance level of P<0.05).  
 
 
* 
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Figure 5.8: Plasma Cytokines in patients having major abdominal surgery 
 
 
 
Figure 5.8 shows the concentration of plasma IL-6 and TNF-ɲ ĚƵƌŝŶŐ ƚŚĞ ǀŽůƵŶƚĞĞƌ
screening visit, pre-operatively (pre-op), at end of surgery (post op) and 24 hours 
after surgery (24 hr). There was a significant increase in both plasma IL-6 and TNF-ɲ
postoperatively, which remained elevated after 24 hours post-surgery, secondary to 
the surgical stress response. (*, **, *** refers to significance level of P<0.05, P<0.01, 
P< 0.001). 
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Figure 5.9: Plasma Insulin levels in patients having major abdominal surgery 
 
 
Plasma insulin concentration was significantly lower at the end of surgery 
compared with preoperative levels (screening: 14.2±2.2 versus post-surgery: 
10.6±2.1, P<0.05). No significant differences for serum concentration of insulin 
were noted between measurements taken at the start of surgery, end of surgery 
and 24 hours postoperatively. (* refers significance value of P< 0.05). 
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Figure 5.10: Plasma Cortisol in patients having major abdominal surgery 
 
 
Plasma cortisol concentrations were significantly increased at the end of surgery 
compared with preoperative levels (mean difference ± standard error: 5.617±1.2; 
*p<0.05). This suggests that following surgery, the counter-regulatory hormonal 
response is induced secondary to the trauma of surgery, leading to an increase in 
cortisol levels. However, cortisol concentrations seem to decrease to near- baseline 
levels (pre-surgery levels) at 24 hours, suggesting that the degree of inflammation is 
seem to subside with time, postoperatively and is considerably less when compared 
with levels seen at the end of surgery. 
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Figure 5.11: Plasma Lactate in patients having major abdominal surgery 
 
Plasma lactate concentration increased from 1.26±0.13 mmol/l at the start of surgery 
to 1.82±0.22 mmol/l at the end of surgery, *P<0.05. 
Figure 5.12: Free fatty acids in patients having major abdominal surgery 
 
Following surgery, plasma FFA levels increased from pre-surgery (0.56 ± 0.11) versus 
post-surgery (0.72±0.09) P<0.01. FFA levels declined from post-surgery to 24 hours 
post-surgery (0.39±0.45) P<0.05). 
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Figure 5.13: Muscle Glycogen in patients having major abdominal surgery 
 
Patients having major abdominal surgery showed a significant decrease in rectus 
muscle glycogen concentration post-surgery [mean ± S.E.M): (306.93 ± 20.5 versus 
213.64 ± 20.8); p<0.003].  
Figure 5.14: Vastus- Pyruvate Dehydrogenase Activity in patients having major 
abdominal surgery 
 
The activation status of pyruvate dehydrogenase is shown in figure 5.14, as 
measured by the assay of the rate of acetyl CoA production from pyruvate in muscle 
homogenates. The results show a significant decrease in pyruvate dehydrogenase 
complex activity, post-surgery, (PDC activity measured in mmol/acetylCoA min/kg 
wet muscle @ 37°C; p<0.036). 
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Figure 5.15: Mitochondrial ATP production rate in patients having major abdominal 
surgery 
 
In patients having major abdominal surgery, a significant decline of mitochondrial 
ATP production rates of approximately 50% was observed when Glutamate, 
Glutamate+Malate, Palmitoyl-carnitine +Malate, Pyruvate+ Malate were used as 
substrates.  
Mitochondrial ATP production rates were suppressed post-surgery for the substrate 
combinations of glutamate/succinate (19.21 ± 3.99nM/min/ml pre-operatively vs. 
10.55 ± 2.33nM/min/ml post-operatively, p<0.05), palmitoyl carnitine/malate (9.76 ± 
2.51nM/min/ml vs. 4.81 ± 1.03nM/min/ml, p<0.05), succinate (3.08 ± 
0.76nM/min/ml vs. 2.28 ± 0.91nM/min/ml, p<0.05) and glutamate/malate (12.74 ± 
2.88nM/min/ml vs. 6.75 ± 2.22nM/min/ml, p<0.05). 
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Figure 5.16: Glucose Tolerance Test in patients having major abdominal surgery 
 
A glucose tolerance test was performed in all patients at the time of screening 
(preoperative) and at 24 hours after surgery (postoperative). The test showed an 
increase in both fasting and postprandial glucose levels postoperatively. When 
compared with the preoperative levels, these results were highly significant, 
confirming the development of postoperative insulin resistance after major 
abdominal surgery. 
174 
 
5.4 Discussion 
Postoperative muscle insulin resistance is a hallmark feature of patients having major 
abdominal surgery. The results from the study in patients having major abdominal 
surgery, suggest that surgical stress induced inflammatory response, was associated 
with inhibition of Pyruvate Dehydrogenase Complex (PDC) controlled carbohydrate 
oxidation secondary to raised PDK4 and may be an important causative factor in the 
development of POIR. Furthermore, surgical stress induced up-regulation of protein 
breakdown pathways by FOXO mediated up-regulation of ubiquitin ligase, MAFbx 
mRNA and MAFbx protein, as well as Cathepsin-L mRNA. The present data suggest a 
common signalling pathway involving Akt/FOXO and PDK4, which may be involved in 
the impairment of carbohydrate oxidation and muscle protein breakdown, in patients 
undergoing major abdominal surgery (Fig 5.17). 
Fig 5.17: Mechanistic basis of postoperative muscle insulin resistance 
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Surgery induces a systemic inflammatory response which attracts macrophages, 
neutrophils at the site of injury and generates important mediators including 
cytokines such as IL-6 and TNF-ɲ ?ǁŚŝĐŚĐĂŶĂĐƚůŽĐĂůůǇŽŶƚŚĞǁŽƵŶĚĂŶĚĂůƐŽƚĂƌŐĞƚ
distant organs such as gut, liver and skeletal muscle (Hill and Hill, 1998). In keeping 
with activation of inflammatory response following surgery, both the cytokines IL-6 
and TNF-ɲ ŵZE ǁĞƌĞ ĨŽƵŶĚ ƚŽ ďĞ ƵƉ-regulated in our study (p<0.05). There was 
also a significant increase in plasma IL-6 and TNF-ɲ ?ƉŽƐƚŽƉĞƌĂƚŝǀĞůǇĐŽŵƉĂƌĞĚǁŝƚŚ
pre-operative concentrations. It has been reported that cytokines and counter-
regulatory hormones work synergistically to mediate the metabolic response to 
trauma or sepsis (Watters et al., 1986). The inflammatory response induced by 
cytokines is reported to affect IRS-1 binding (Rui et al., 2001) and decrease Akt1 
signalling (Medina et al., 2005, Latres et al., 2005). These events could lead to 
decreased phosphorylation of FOXO family of transcription factors and up-regulation 
of FOXO gene targets such as MAFbx and PDK4 (Sandri et al., 2004, Crossland et al., 
2008).  
The present study in patients undergoing major abdominal surgery showed a 
significant increase in gut permeability following surgery (% urinary excretion of 51Cr-
EDTA): Pre surgery: 4.79 ± 0.82; Post-surgery: 7.30 ± 1.03; p<0.02. The amino acid, 
glutamine is a main fuel for the enterocytes and is important to maintain the gut-
barrier function. In acute stress states, glutamine deficiency causes gut mucosal 
atrophy and breakdown of the gut mucosal barrier. It has also been reported that 
disruption of intestinal tight junctions or increased para-cellular permeability can 
occur due to an intestinal disease, an initial injury or an inflammatory mediated 
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insult, allowing entry of luminal antigens, thereby triggering an exaggerated immune 
response (Clayburgh et al., 2004, Hollander, 1999). The translocated bacteria or their 
products in the portal or systemic circulation may induce a cytokine response via 
activation of macrophages in either the liver or mesenteric lymph nodes and may 
influence the ongoing metabolic processes (Deitch et al., 1994, Meakins, 1990). In 
keeping with this, an increased risk of septic complications possibly due to changes in 
the intestinal mucosal barrier, intestinal permeability and bacterial translocation 
have been demonstrated in patients secondary to major abdominal surgery, severe 
acute pancreatitis, burns, critical illness and major trauma (Chin et al., 2007, 
Costantini et al., 2009, Qiao et al., 2009, Qiao et al., 2006, Takesue et al., 2002, Zhang 
and Jiang, 2009). 
Impaired PI3K/Akt1/FOXO signalling and the resultant up-regulation of PDK4 are 
considered to be the key regulators of induction of insulin resistance. The protein 
kinase-B, Akt1 is central to the insulin signalling mechanism in which its activation 
regulates protein synthesis and its inactivation allows the expression of atrogin-1 
(MAFbx), via up-regulation of FOXO. Stimulation of skeletal muscle with insulin-like 
growth factor (IGF-1) leads to up-regulation of Akt1 and activation of protein 
synthesis via mTOR/p70S6k, while inactivating the repressors of protein synthesis 4E-
BP1 and GSK3 (Nader, 2005). 
The mRNA expression data shows Akt1 was not significantly up-regulated at the end 
of surgery (Figure 5.2). Therefore, it is possible that following surgery, Akt1 was in a 
predominantly dephosphorylated/inactive state, and the likely factor to cause Akt1 
dysregulation and thereby FOXO signalling is TNF-ɲ (Medina et al., 2005), which 
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enables FOXO1 to up-regulate PDK4. In the present study, major abdominal surgery 
resulted in both, FOXO1 and PDK4 mRNA up-regulation postoperatively (10.5-fold 
and 7.8fold respectively; p<0.05). This was also associated with a significant fold-
change (p<0.05), in protein expression for FOXO1 (11.21±4.08), PFOXO1 (7.82±3.28) 
and PDK4 (4.49±1.85). 
An increased expression of FOXO mRNA was likely to be responsible for the up-
regulation of the ubiquitin ligase, MAFbx (11.5-fold in rectus, 6.5 Wfold in vastus), 
which is involved in atrophy signalling. It has also been reported that TNF-ɲ
stimulates MAFbx expression via a p38 MAPK dependent mechanism in skeletal 
muscle (Li et al., 2005). FoxO1, in addition to activation of the ubiquitin ligases, could 
also enhance muscle atrophy through inhibition of myogenesis resulting from 
enhanced myostatin expression (Allen and Unterman, 2007). In our study, there was 
no significant upregulation of Myostatin in both rectus and vastus muscle, 
postoperatively (Figure 5.2). However, there was a significant increase in protein 
expression for phosphorylated p70S6k and total p70S6k (P70s6k: 14.9±3.8), 
phosphorylated P70s6k: 15.7±6.7; p<0.05). However, the ratio of phosphorylated to 
total p70s6k was not found to be significant, suggesting that there was no effect on 
protein synthesis in the immediate postoperative period (Figure 5.6). 
A likely factor causing inhibition of the pyruvate dehydrogenase complex (PDC) is the 
FOXO1 mediated up-regulation of PDK4. PDC activity determines the glucose flux in 
the mitochondria and thus controls the rate-limiting step in carbohydrate oxidation, 
the oxidative decarboxylation of pyruvate to acetyl-CoA to be used in the tri-
carboxylic acid (TCA) cycle in the mitochondria subsequently, where reducing 
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equivalents are produced for use in the electron transport chain to generate ATP. 
Inhibiting the activity of PDC by phosphorylation of the complex prevents the 
conversion of carbohydrate-derived pyruvate into acetyl-CoA (Harris et al., 2001). 
The study showed a reduced muscle PDC activity at the end of surgery compared 
with pre-surgery levels (p<0.05), confirming that surgical stress induced increase in 
PDK4 decreased PDC activity (5.15) and resulted in decreased mitochondrial ATP 
production (Figure 5.16). 
Evidence from other studies also shows that inflammation plays an important role in 
muscle carbohydrate metabolism in surgical patients. A study in patients undergoing 
major gastrointestinal surgery highlighted the involvement of local inflammatory 
mediators in surgical stress (Witasp et al., 2009a). The study showed an increased 
expression of genes encoding inflammation such as IL-6 and TNF-ɲ ? ǁŚŝůƐƚ ƚŚĞ
changes in expression of genes encoding molecules involved in insulin signalling and 
glucose transport such as insulin receptor substrate 1 (IRS1), phosphoinositide-3-
kinase (PI3K) and GLUT4 were less marked. Similar gene expression changes for IL-6 
were noted in epicardial and subcutaneous adipose tissue in patients undergoing 
cardiac surgery (Kremen et al., 2006) and in skeletal muscle of patients undergoing 
open cholecystectomy and hernia repair (Thorell et al., 1996b), which also reported a 
significant linear relationship between the reduction in relative insulin sensitivity and 
the concomitant plasma levels of IL-6, with only minor increments in the levels of 
stress hormones postoperatively. Other studies have also reported that cytokines 
also influence skeletal muscle catabolism both directly by modulating protein 
synthesis and degradation and indirectly, through inhibition of the regulatory action 
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of anabolic hormones (Vary, 1998) and activation of hypothalamic-pituitary-adrenal 
axis (Navarra et al., 1991). Thus it was established from the present study and the 
evidence from the aforementioned studies that the transcriptional regulation of 
MAFbx and PDK4 via FOXO1 is intrinsically linked to the inflammatory state and 
cellular metabolic status via a co-ordinated pathway of signalling events. 
Evidence from this present study highlighted important cellular events in 
carbohydrate metabolism that may lead to postoperative muscle insulin resistance 
and hyperglycaemia. Patients having major abdominal surgery had increased plasma 
concentrations of free fatty acids, lactate and cortisol, postoperatively, possibly as a 
consequence of the metabolic response to surgery and increased catecholamine 
activity, which results in an increased turnover of free fatty acid and glycerol from 
adipose tissue. Cortisol, along with other counter-regulatory hormones such as 
catecholamines, glucagon and growth hormone, can raise blood glucose by enhanced 
glycogenolysis and gluconeogenesis (Rizza et al., 1982, Nosadini et al., 1983). In 
keeping with this finding, there was also a significant decrease in rectus muscle 
glycogen concentration post-surgery [mean ± SD): (306.9 ± 79.6 versus 213.6 ± 80.5; 
p<0.003] and an increased lactate production which was significantly raised 
postoperatively (1.26±0.13 mmol at the start of surgery to 1.82±0.22 mmol at the 
end of surgery, P<0.05), possibly from muscle glycogenolysis and increased 
metabolism in the hypoxic injured tissues. Evidence show that increased lactate 
production in the acute inflammatory state is subsequently utilized by the liver for 
ŐůƵĐŽŶĞŽŐĞŶĞƐŝƐŝŶƚŚĞ ‘ŽƌŝĐǇĐůĞ ? ?ĨŽƌŵĂŝŶƚĂŝŶŝŶŐƚŚĞĞŶĞƌŐǇƐƵƉƉůǇŝŶƚŚĞƚƌĂƵŵĂ
(Shaw and Wolfe, 1989), in patients with burns (Wilmore et al., 1980, Frayn, 1985).  
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Evidence from studies in patients undergoing surgery, shows a significantly higher 
plasma concentrations of glucose (Brandi et al., 1990, Crowe et al., 1984), 
noradrenaline and glucagon whilst the levels for insulin, growth hormone, cortisol 
and adrenaline were unaltered (Thorell et al., 1994). Postoperative hyperglycaemia 
was associated with increased insulin requirements to maintain euglycaemia (Brandi 
et al., 1990) and a raise in counter-regulatory hormones, whole body protein 
oxidation and energy expenditure (Brandi et al., 1990). It was noted that glucose 
utilisation was significantly depressed during and after surgery along with 
suppression of insulin secretion during operation, increased plasma cortisol levels 
and an increased urinary catecholamine excretion (Wright et al., 1974). Other studies 
investigating serum insulin changes in surgical patients, have reported a lower insulin 
levels at the start of surgery compared with intraoperative and postoperative periods 
(Crowe et al., 1984, Nygren et al., 1998b, Aarimaa et al., 1974), and impaired insulin 
response both intra-operatively (Wright et al., 1974, Barton, 1985) and soon after 
surgery (Stenberg et al., 1984, Aarimaa et al., 1974). Brandi et al, also reported an 
impaired whole-body glucose disposal by 33-60%, in patients 6 -8 hours after 
undergoing major abdominal surgery whilst the hepatic glucose production at 
baseline was less suppressed by insulin, which was associated with increased cortisol, 
lactate and total lipolysis (plasma free fatty acid and glycerol levels) (Brandi et al., 
1993).  
Thus it is clear that the antagonistic actions of counter-regulatory hormones such as 
glucagon, cortisol and catecholamines, impair the metabolic actions of insulin and 
may contribute to the development of insulin resistance in the immediate 
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postoperative period (Krentz, 1996). The evidence from the aforementioned studies 
shows that a failure of cellular glucose utilisation along with the changes in insulin 
response, is an important event in the metabolic response to injury that may lead to 
the stress induced hyperglycaemia, noticed in patients undergoing major abdominal 
surgery.  
In conclusion, the results of the present study in surgical patients showed an 
increased plasma IL-6, as well as a marked up-regulation of muscle IL-6, PDK4 mRNA 
expression and a decrease in PDC activity. This was associated with impaired glucose 
tolerance and increased gut permeability postoperatively. Furthermore, plasma 
concentrations of free fatty acids, cortisol and lactate were increased along with a 
decrease in muscle glycogen concentration postoperatively. However, no significant 
changes in insulin concentration were observed during surgery. Interestingly, the 
aforementioned changes in the carbohydrate oxidation were also associated with a 
decrease in pyruvate mediated mitochondrial ATP production in the immediate 
postoperative period. This is the first study that has shown the changes in molecular 
mechanisms underlying the development of postoperative insulin resistance in 
patients having major abdominal surgery. The findings also support the intrinsic link 
between the metabolic response to surgery and inflammation that leads to inhibition 
of carbohydrate oxidation in patients having major abdominal surgery.  
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Chapter 6 
 
Randomised control trial of Preoperative carbohydrate and Dichloroacetate on 
skeletal muscle insulin resistance following major abdominal surgery 
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6.1 Introduction 
The study in patients undergoing major abdominal surgery described in the previous 
chapter, demonstrated that surgical stress and inflammation contribute to the 
development of POIR. Surgical stress resulted in a marked up-regulation of muscle 
interleukin-6 and pyruvate dehydrogenase kinase isoform-4 (PDK4) mRNA and 
protein expression which occurred concomitantly with a decreased muscle pyruvate 
dehydrogenase complex activity. Furthermore, we have also shown that increased 
muscle PDK4 expression inhibits the activity of pyruvate dehydrogenase complex 
(PDC), which represents the rate-limiting step for muscle carbohydrate (CHO) 
oxidation. Importantly, these alterations in molecular signalling secondary to surgical 
stress were associated with impaired glucose tolerance, decreased mitochondrial ATP 
production, increased gut permeability, increased free circulating fatty acids, and 
decreased muscle glycogen levels postoperatively. Impaired PI3K/Akt1/FOXO 
signaling and the resultant up-regulation of PDK4 are considered to be the key 
regulators of insulin resistance (Murton et al., 2008, Kim et al., 2006, Stitt et al., 
2004). 
6.1.1 Preoperative carbohydrate treatment (CHO) 
Elective surgical procedures have been traditionally performed after an overnight 
fast. This period of fasting extends beyond 12 hours, whilst awaiting surgery. 
Provision of CHO has been shown to improve patient comfort before surgery, reduce 
anxiety and thirst before surgery (Hausel et al., 2001). Perioperative interventions 
such reduced preoperative fasting times, preoperative oral carbohydrate (CHO), 
minimally invasive incisions and early enteral feeding postoperatively, may help 
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minimise the surgical stress response and attenuate the development of POIR, in 
surgical patients (Lassen et al., 2009a). A study in patients having open 
cholecystectomy reported that pre-operative carbohydrate (CHO) feeding with an 
infusion of 300 g glucose instead of an overnight fast, reduces POIR by 50%, similar to 
a level seen in patients having a relatively minor surgery such as a hernia repair 
(Ljungqvist et al., 1994). This was supported by the findings that there is an up-
regulation of skeletal muscle PDK4 mRNA expression after 48 hours of starvation, 
associated with a 42% reduction in insulin sensitivity and provision of carbohydrate 
derived pyruvate down-regulates PDK4 (Nygren et al., 1998a). This suggests that 
muscle PDK4 would be a prime target in carbohydrate oxidation and that CHO 
favours oxidative glucose disposal in skeletal muscle by its effect on PDK4. 
Wang et al investigated whether altered insulin dependent activation of the PI3K/PKB 
signalling pathway would contribute to the development of POIR, in surgical patients 
(Wang et al., 2010). POIR and subjective wellbeing was significantly better in the CHO 
group than in the fasting/placebo group. At the end of surgery, muscle protein-
tyrosine kinase activities, as well as PI3K and PKB levels were significantly increased in 
the CHO group. Even in diabetic patients, CHO was shown to reduce preoperative 
thirst, anxiety, postoperative nausea and vomiting and to also improve insulin 
sensitivity (Hendry et al., 2008, Ramos et al., 2008). It has also been reported that 
CHO is safe, alters immune and catabolic response to surgery and it did not alter 
gastric pH, content or gastric emptying, and there was no increased risk of aspiration 
during anaesthesia in surgical patients (Ljungqvist and Soreide, 2003).  
These findings are supported by the results from the systematic review and meta-
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analysis of RCTs of the effect of CHO in patients undergoing major abdominal surgery 
presented in chapter 4, which showed a reduced length of stay [mean difference, 
95% confidence interval: 1.08 (1.87 to 0.29); I2 < 60%, p < 0.007]. CHO reduced 
postoperative insulin resistance with no effect on in-hospital complications over 
control (risk ratio, 95% confidence interval, 0.88 (0.50 - 1.53), I2 = 41%; p <0.640). 
Therefore, attenuating POIR with CHO and increasing coupling of glycolysis to glucose 
oxidation seems a promising strategy in elective surgical patients.  
6.1.2 Dichloroacetate 
 
Dichloroacetate, a halogenated carboxylic acid has been shown to increase PDC 
activity by inhibiting PDK4 in animals (Whitehouse and Randle, 1973) as well as 
humans (Timmons et al., 1998a, Constantin-Teodosiu et al., 2012, Constantin-
Teodosiu et al., 1999). DCA is reported to promote muscle (Constantin-Teodosiu et 
al., 1999) and liver oxidative glucose disposal (Shangraw et al., 1998) and leads to 
decreased blood glucose (Stacpoole et al., 1978). Inhibition of PDK4 and activation of 
PDC, shifts the metabolism of pyruvate from glycolysis towards the oxidative 
pathway in the mitochondria, resulting in increased carbohydrate oxidation and 
mitochondrial ATP production. DCA has been shown to be a more potent 
pharmacological inhibitor of PDK4 than pyruvate (Bowker-Kinley et al., 1998, 
Stacpoole and Greene, 1992). Previous human studies utilizing DCA in patients with 
lactic acidosis (Stacpoole et al., 1983) and healthy volunteers during exercise (Carraro 
et al., 1989) have shown reduced blood lactate accumulations, reduced reliance on 
non-oxidative production of ATP in muscle by decreased glycogen breakdown, 
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following exercise and a better match between pyruvate production and oxidation 
(Timmons et al., 1998a).  
6.2 Hypothesis and aims 
 
The study in patients undergoing major abdominal surgery showed that surgical 
stress and inflammation contributes to the development of POIR secondary to 
changes in insulin signalling, with a marked up-regulation of PDK4. The decrease in 
PDC activity resulted in impaired carbohydrate oxidation and decreased 
mitochondrial ATP production, making PDK4 an important metabolic target to 
attenuate the development of POIR. Moreover, the evidence from the 
aforementioned studies shows that both CHO and DCA given to patients 
preoperatively could lead to improvements in POIR and reduction in surgical stress 
induced hyperglycaemia in the postoperative period, possibly by inhibiting PDK4.  
Therefore, maximising the contribution from oxidative ATP regeneration by 
activation of PDC using DCA or by enhancing glucose uptake using preoperative 
strategies such as oral carbohydrate drinks, may potentially attenuate the 
development of postoperative muscle insulin resistance.  
Specifically, by addressing the alterations in FOXO gene targets namely PDK4 and 
PDC, that is primarily responsible for development of POIR, the aim was to 
investigate whether, increasing preoperative PDC activity and flux using DCA infusion 
improved POIR over and above that seen with CHO ingestion alone. 
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Whilst the impact of CHO on attenuating the development of POIR has been studied 
in surgical patients, the effect of DCA on POIR in patients having surgery has not been 
investigated previously. Moreover, it would be interesting to study whether DCA 
could act synergistically with CHO in improving oxidative glucose disposal and 
mitochondrial ATP production in patients having major abdominal surgery previously. 
6.3. Methods  
 
6.3.1 Study design and ethics 
  
Twenty adult patients undergoing major open elective gastrointestinal surgery were 
randomised using a computer-generated central randomisation in this open-labelled 
study into 2 groups of 10 each, to receive one of the following preoperative 
interventions, Group (1): CHO and Group (2): CHO and DCA. The approval for this 
randomised controlled, open-labelled trial was obtained from the Cambridgeshire 
Research Ethics Committee and NHS Ethics Committee and was performed in 
accordance with the Declaration of Helsinki. 
Patients who expressed an interest to take part in the study were invited to a 
subsequent screening visit and an informed consent was obtained. Data regarding 
ƚŚĞ ƉĂƌƚŝĐŝƉĂŶƚƐ ? ĚĞŵŽŐƌĂƉŚŝĐƐ ?general health, clinical diagnosis and the type of 
surgical procedure were collected. About 15mls of blood were taken for plasma 
glucose, insulin and cortisol. Patients were then provided with a glucose drink and 
further blood tests were done at regular intervals for 3 hours following the drink to 
check for glucose and insulin levels during the Glucose Tolerance Test (GTT). 
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6.3.2 Inclusion criteria & Exclusion criteria 
 
All patients over 18 years of age who were undergoing major elective open 
abdominal surgery and provide a written informed consent to participate in the study 
were included. Patients who were undergoing emergency surgery, suffering from 
chronic illness, (e.g. diabetes) or other debilitating diseases, on long term anti-
inflammatory drugs, (e.g. NSAIDS, Steroids, immunosuppressant), on long term 
antibiotics, on statins, on full therapeutic dose of anticoagulants, or aspirin >325 
mg/day, clopidrogel >75 mg/day, suffering from bleeding diathesis, pregnant or 
breastfeeding and who were unable to give consent were excluded. 
6.3.3 Preoperative Interventions 
 
Preoperative carbohydrate drinks (CHO) group: Patients who were randomised to 
CHO group CHO (n=10) ingested 800ml PreOp (Nutricia Clinical Care, 12.5 g CHO/100 
ml) the night before and 400ml in the morning of surgery, about 3 hours before the 
ŝŶĚƵĐƚŝŽŶŽĨĂŶĂĞƐƚŚĞƐŝĂ ? ?EƵƚƌŝĐŝĂƉƌĞKƉ ?ŝƐĂĨŽŽĚĨŽƌƐƉĞĐŝĂůŵĞĚŝĐĂůƉƵƌƉŽƐĞƐĨŽƌ
the preoperative dietary management of surgical patients, produced by N.V.Nutricia, 
in The Netherlands. It is a 0.5kcal/ml, clear, non-carbonated, lemon flavoured iso-
osmolar carbohydrate drink, containing sweeteners. There are no special risks 
associated with the drink being ingested 4 hours before surgery, as studies indicate a 
mean gastric emptying time of CHO within this range and is now part of standard 
care in patients having major surgery in some centres. 
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Dichloroacetate group (DCA): The patients in the DCA with CHO group received the 
CHO drinks as well as an intravenous infusion of DCA (50mg/kg body weight) over 45 
min, one- two hours before the induction of anaesthesia. Dichloroacetate was 
ŵĂŶƵĨĂĐƚƵƌĞĚ ďǇ  ‘ůĨĂ ĞƐĂƌ ? ? h< ? ǁŝƚŚ ƚŚĞ ĂĐƚŝǀĞ ĐŽŵƉŽƵŶĚ ĂƐ  ‘^ŽĚŝƵŵ
ĚŝĐŚůŽƌŽĂĐĞƚĂƚĞ ?  ?^EƵŵďĞƌ ? ? ? ?-56-1), which has been identified to be used for 
research and development purposes (ref: SU24). This product is commercially 
available in the EU, (EINECS number: 218-461-3). This is an open-labelled study and 
therefore, no attempts were made to blind the product from the users. 
Dichloroacetate was dispensed on the day of surgery from the sterile production unit, 
EŽƚƚŝŶŐŚĂŵhŶŝǀĞƌƐŝƚǇ,ŽƐƉŝƚĂůƐ ?YƵĞĞŶ ?ƐDĞĚŝĐĂůĞŶƚƌĞĂŵƉƵƐ ?ĂĨƚĞƌƉĂƐƐŝŶŐƚŚĞ
ƋƵĂůŝƚǇ ĐŽŶƚƌŽů ŵĞĂƐƵƌĞƐ ? ĂŶĚ ŝŶĨƵƐĞĚ ŝŶƚƌĂǀĞŶŽƵƐůǇ ďĂƐĞĚ ŽŶ ŝŶĚŝǀŝĚƵĂů ƉĂƚŝĞŶƚ ?Ɛ
body weight. 
The description of interventions used in this study is presented in fig. 6.1. 
Figure 6.1: Time course of sample collection from patients undergoing major 
surgery 
Screening           Preoperative                                      During the operation                               2ndpost operative 
day      
 
 
D7-14 Days         Night before     2 hr before surgery        Start of surgery                                    End of surgery                   Day 2 
Postop.                    
GTT                                                                                                                                                                  GTT       
                 
       - Blood samples     - Preoperative carbohydrates                - Muscle Biopsy                 - Surgery 
GTT ± Glucose Tolerance Test, at screening visit and on 2ndpost operative day   
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6.3.4 Blood tests 
 
Following an overnight fast, patients had an oral glucose tolerance test (GTT) at the 
screening visit (about 1-2 weeks before surgery) and on the second postoperative day 
as described in chapter 2. Insulin resistance was quantified using homeostatic model 
assessment of insulin resistance (HOMA-IR) using plasma glucose and insulin levels. 
Analysis of plasma insulin, glucose and cortisol were performed at screening, during 
surgery and on the 2nd postoperative day.  
6.3.5 Muscle biopsy 
 
A total of four small samples of muscle tissue was taken according to a standard 
protocol, at the start and the end of the operation as follows: one sample was taken 
from rectus abdominus muscle in the abdomen and one sample from a single incision 
(about 1cm) placed on outer part of thigh (vastus lateralis muscle) at the beginning 
and also at the end of operation under general anaesthesia. Another muscle biopsy 
from the thigh was taken under local anaesthesia on the second postoperative day 
for analysis of mRNA and proteins involved in the insulin signaling pathway, as 
described in chapter 2. It was ensured that the collection of samples did not alter the 
course of the operation or compromise patienƚƐ ? ƐĂĨĞƚǇ ǁŚŝůƐƚ ƵŶĚĞƌŐŽŝŶŐ ƐƵƌŐĞƌǇ ?
The patients had the standard postoperative care, including diet and physiotherapy, 
as any other patient having elective major abdominal surgery. The study was 
conducted at the Division of Gastrointestinal Surgery, QueĞŶ ?Ɛ DĞĚŝĐĂů ĞŶƚƌĞ ĂŶĚ
the School of Biomedical Sciences, University of Nottingham.  
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6.3.6 Primary endpoint 
 
The relative change in insulin sensitivity calculated using the HOMA-IR method, 
between preoperative and postoperative levels, in patients undergoing major 
abdominal surgery.  
6.3.7 Secondary endpoints 
 
1. The relative change in mRNA expressions for genes involved in muscle insulin 
signaling namely, Akt1, FOXO1, PDK4, and muscle cytokines, IL-6, and TNF-ɲŝŶǀĂƐƚƵƐ
and rectus muscles of patients, before and after undergoing major abdominal surgery 
following the preoperative interventions. 2. Mitochondrial ATP production rates in 
patients undergoing major abdominal surgery. 
6.3.8 Sample size justification 
 
Sample size was estimated from a two-sample means test with a 95% degree of 
confidence for two groups with comparable standard deviations and a 2-fold mean 
ĚŝĨĨĞƌĞŶĐĞĂŶĚǁŝƚŚƚŚĞɲĂŶĚɴǀĂůƵĞƐĨŝǆĞĚĂƚ ? ? ? ?ĂŶĚ ? ? ? ?ƉŽǁĞƌ ? ? ? ? ?ƌĞƐƉĞĐƚŝǀĞůǇ ?
Within each group the preoperative level of expression was given a value of 1, and 
fold changes in mRNA and protein expression after surgery and postoperative were 
calculated, relative to pre-surgery. Comparison of gene and protein data between 
and within groups was carried out by Mann-Whitney U and Wilcoxon t-tests, 
respectively. Insulin sensitivity data were analysed by Student's independent t-test. 
Data are presented as mean ± SEM. Differences were considered significant at P < 
0.05.  
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6.4 Results 
 
Twenty patients participated in the trial. However, two patients, one patient from 
each group discontinued participation and accounted for two drop-outs following 
recruitment. The mean (SE) age and body mass index of the patients in the CHO 
group were 59 (4.6) years and 27.2 (1.5) kg/m2 respectively. The corresponding 
values for the DCA group were 58 (4.5) and 29 (3.5) kg/m2 respectively. These 
differences were not statistically significant. All patients complied with the protocol 
for ingestion of CHO drinks, and no patient had any drink related complications. 
Similarly the DCA group had DCA infusion about 2.8 ± 0.6 hours before 
commencement of surgery. The mean time between the muscle biopsies taken at the 
beginning and end of surgery were 269 (range: 130  W 380) minutes in the CHO group 
and in the DCA 284 (range: 143  W 352) minutes. 
6.4.1 Gene expression in Rectus Abdominis and Vastus Lateralis Muscle 
 
In this section, the changes in gene expression results for both groups are presented 
across all time points. The gene expression level from vastus muscle taken before 
start of surgery for the CHO group was taken as the baseline-value, which was set as 
one. For both groups (CHO & DCA), the columns in the graphs represent fold-change 
in gene expression for individual time-points, from the base-line value.  
The muscle biopsies were taken from rectus and vastus, at the start of surgery (pre-
op), at the end of surgery (post op) and also on the second postoperative day (48 
hours postop).  
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Figure 6.2: CHO group - Gene expression in Rectus Abdominis in patients having 
major abdominal surgery 
 
 
 
 
 
 
 
 
Figure 6.3: CHO group - Gene expression in Vastus Lateralis in patients having 
major abdominal surgery 
 
 
 
 
 
 
 
 
Figures 6.2 and 6.3 show the gene expression changes before and after surgery in 
patients undergoing major abdominal surgery for the CHO group, in the rectus and 
vastus muscle groups respectively. 
The gene expression changes in the vastus muscle before the start of surgery in the 
CHO group was considered as the baseline value. The figures shows that mean fold-
change for all the genes measured before and after surgery. CHO treatment did not 
significantly alter the gene expressions of PDK4, FOXO1, MYOSTATIN, TRIM63 
(Ubiquitin ligase  W up-regulation causes protein breakdown) and TNF, in both rectus 
and vastus muscles when compared to pre-surgery levels, in patients undergoing 
major abdominal surgery.  
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Figure 6.4: DCA group - Gene expression in Rectus abdominis in patients having 
major abdominal surgery 
 
 
 
 
 
 
 
 
Figure 6.5: DCA group - Gene expression in Vastus Lateralis in patients having major 
abdominal surgery 
 
 
 
 
 
 
 
Figures 6.4 and 6.5 show the fold-changes in gene expression in rectus and vastus 
muscle for the DCA group respectively, at the start of surgery, end of surgery and 48 
hours after surgery. The gene expression changes in the vastus muscle before the 
start of surgery in the CHO group was considered as the baseline value. The gene 
expressions in the DCA group are represented as fold changes from this baseline 
value. Mean fold-change for all the genes measured were not significant across all 
time-points for the DCA group, in both rectus and vastus. The results suggest that 
DCA treatment did not significantly alter the gene expression of PDK4, FOXO1, 
MYOSTATIN, TRIM63 (Ubiquitin ligase  W up-regulation causes protein breakdown) 
and TNF, when compared with pre-surgery levels in patients having major abdominal 
surgery.  
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Figure 6.6: DCA vs CHO group - Gene expression in Rectus Abdominis in patients 
having major abdominal surgery 
 
Figure 6.7: DCA vs CHO group - Gene expression in Vastus Lateralis in patients 
having major abdominal surgery 
 
Figures 6.6 and 6.7: Gene expression changes for the both the CHO and DCA groups 
in the rectus and vastus muscle groups respectively, in patients undergoing major 
abdominal surgery. The gene expression changes in the vastus muscle before the 
start of surgery in the CHO group was considered as the baseline value. 
The results show that mean fold-change for all the genes measured were not 
significant across all time-points measured, for both CHO and DCA groups. The 
results suggest that both CHO and DCA treatments resulted in no significant changes 
in gene expressions of those involved in the development of muscle insulin 
resistance and protein breakdown such as PDK4, FOXO1, MYOSTATIN, TRIM63 
(Ubiquitin ligase - upregulation causes protein breakdown) and TNF, postoperatively, 
when compared with the levels at the start of surgery in the CHO group.  
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6.4.2 Metabolic assays 
 
Figure 6.8: Plasma Insulin levels in CHO and DCA group in patients having major 
abdominal surgery 
 
The above figure shows plasma insulin concentrations (mU/L) for CHO and DCA 
groups at screening, during surgery and 48 hours post-surgery. Insulin 
concentrations between both groups were not significant at screening visit and 
during surgery. However, The CHO group had a significantly higher insulin 
concentrations in the postoperative period (48 hours after surgery) compared 
with DCA (p<0.05), suggesting higher insulin concentrations were needed in the 
CHO group compared with the DCA group to maintain euglycaemia.  
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Figure 6.9: Plasma Glucose levels in CHO and DCA group in patients having major 
abdominal surgery 
 
 
Figure 6.9 shows plasma glucose concentrations (mmol/L) for CHO and DCA 
groups groups at screening, during surgery and 48 hours post-surgery. Plasma 
glucose concentrations were not significant between both groups at any given 
time-point. However, the glucose concentrations were significantly higher during 
surgery than preoperative or postoperative levels in both CHO and DCA groups 
(p<0.05).  
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Figure 6.10: Plasma Cortisol levels in CHO and DCA group in patients having major 
abdominal surgery 
 
 
 
Figure 6.10 shows plasma cortisol concentrations (ng/ml) for CHO and DCA 
groups. Plasma cortisol concentrations were not significant between both groups 
at any given time-point. There were no significant changes in either group 
following surgery compared with preoperative levels, suggesting that provision of 
both CHO and DCA did not have a significant effect on cortisol levels, despite 
changes in insulin and glucose concentrations at the same time points. 
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Figure 6.11: HOMA-IR values in CHO and DCA group in patients having major 
abdominal surgery 
 
 
Figure 6.11: The Homeostatic Model Assessment (Homa-IR) was used to quantify 
insulin resistance in patients undergoing major abdominal surgery. It is reported 
to correlate with the hyperinsulinaemic-euglycaemic clamp method 
(r=0.88)(Matthews et al., 1985).  
The formula for HOMA-IR: (Glucose X Insulin) divided by 22.5. Normal: <3; 
Moderate insulin resistance: 3-5; Severe insulin resistance: > 5.  
HOMA-IR quantified using fasting values of plasma glucose and insulin at the 
following time points: screening, at the start of surgery, post-surgery and 48 hours 
after surgery. The results show that no significant differences were noted 
between the CHO and DCA groups. The HOMA-IR values (ranging from 1.5  W 4), for 
both groups reflect that both groups maintained preoperative insulin sensitivity in 
the postoperative period, after CHO and DCA. 
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Figure 6.12 Glucose Tolerance Test group in patients having major abdominal 
surgery 
 
 
Figure 6.12 shows the glucose tolerance test (GTT), performed preoperatively at 
screening visit and 48 hours postoperatively in both CHO and DCA groups. The 
values in x-axis represented as pre-fast indicates values before the glucose drink 
and pre-120 indicates 2 hours after glucose drink, during the GTT. No significant 
differences for fasting or post-prandial glucose concentrations were noted 
between CHO and DCA groups. This suggests that surgical stress did not 
contribute to a significant increase in postoperative plasma glucose 
concentrations, following either CHO or DCA. 
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Figure 6.13 Mitochondrial ATP Production Rate group in patients having major 
abdominal surgery 
 
 
Mitochondrial ATP production rates, in patients undergoing major abdominal 
surgery, measured at the start of surgery and at the end of surgery from the 
vastus muscle for both CHO and DCA groups. MAPR were quantified using 
pyruvate as a substrate and data normalised for mitochondrial content using 
citrate synthase activity. Differences between groups * p=0.05, ***p<0.001. 
DCA increased mitochondrial CHO oxidation above that achieved by CHO alone, 
which waned by 48hr post-surgery. MAPR (µmol ATP/min/mmol acetyl-CoA); CHO 
vs DCA: Using pyruvate as substrate [pre-surgery 6663 ± 1015 vs 10516 ± 1488]; 
[post-surgery 7415 ± 2804 vs 5031 ± 556]. Nevertheless, this was associated with a 
trend for improved POIR 48 hours post-surgery relative to CHO. The values for 
DCA were significantly raised compared with CHO for Glutamate+Succinate and 
Glutamate+Malate. 
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6.5 Discussion 
 
The present randomised study in patients undergoing major abdominal surgery, 
has demonstrated that both preoperative CHO and DCA attenuated the 
development of POIR. The results show that preoperative administration of CHO 
and DCA was not associated with an increased expression of genes involved in the 
development of POIR, in contrast to our earlier study in surgical patients, which 
showed that surgical patients was associated a marked degree of POIR, with 
increased PDK4 mRNA expression and decreased PDC activity (chapter 5). 
In this present study, the important molecular targets responsible for POIR, such 
as FOXO and PDK4, did not show marked increase in fold-change in mRNA 
expression between preoperative and postoperative levels for both CHO and DCA 
(fig 6.7). This suggests that factors responsible for increase in POIR such as the 
surgical stress and inflammation were modulated as a result of treatment with 
CHO and DCA, resulting in a better maintenance of insulin sensitivity 
postoperatively. However, no significant differences were noted between the two 
treatment groups, in causing attenuation of POIR in surgical patients.  
Serum insulin and blood glucose concentrations were not significantly different 
between groups at any point, but a strong trend for blood glucose to be lower in 
DCA 48 hours post-surgery was noted (fig 6.8 and fig 6.9). Interestingly the insulin 
requirements in the CHO group were significantly higher to suppress the plasma 
glucose concentrations to that of DCA group, 48 hours after surgery. However, 
plasma cortisol concentrations were not different between the two groups at the 
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same time points (6.9), suggesting attenuation of the surgical stress response to a 
certain degree, in contrast to our earlier study showing increased plasma cortisol 
concentrations postoperatively (chapter 5). This was reflected in the finding that 
there was better maintenance of insulin sensitivity in the HOMA-IR values, ranging 
from 1.5  W 4 (fig 6.10). Similarly, expression of pro-inflammatory cytokine, TNF-ɲ
mRNA and genes involved in protein breakdown, Cathepsin and Trim63, were not 
up-regulated following surgery (fig 6.7), suggesting a trend towards increased 
anabolism with the use of CHO and DCA.  
The results are in line with a study which investigated the effects of CHO on 
metabolic stress response in patients having elective abdominal surgery, showed 
CHO resulted in lower fasting glucose, HOMA-IR index, cortisol and IL-6 in the 
immediate postoperative period. These reductions were independent of age, sex, 
body mass index and major abdominal surgery (Vigano et al., 2012).  
The effect of starvation and the protective effects of preoperative feeding have 
been investigated in many studies (Awad et al., 2009b, Svanfeldt et al., 2005, Faria 
et al., 2009). A study in patients having cholecystectomy showed that 
preoperative CHO compared with placebo drink, showed muscle PDK4 mRNA and 
protein expression was 4-fold lower in the carbohydrate group. Moreover, the 
study also showed improved activities of mitochondrial membrane complexes (I, II 
and IV), 4 h after ingestion of CHO (Awad et al., 2010). Faria et al, reported that 
plasma glucose, lactate, insulin, lactate/pyruvate ratio to be significantly higher in 
patients who had placebo drink than those who had CHO, preoperatively (Faria et 
al., 2009). A study in healthy volunteers on the effects of starvation and refeeding 
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showed increased mRNA expression of PDK4 by 4-fold and 42% decrease in insulin 
sensitivity, independent of the phosphorylation status of FOXO1 during fasting 
(Tsintzas et al., 2006). Studies have also shown that CHO treatment results in less 
postoperative losses of nitrogen and protein (Svanfeldt et al., 2007, Crowe et al., 
1984), a better-maintained lean mass (Yuill et al., 2005), muscle strength 
(Henriksen et al., 2003, Noblett et al., 2006b) and accelerated recovery (Nygren et 
al., 2001).  
There have been no studies to date that investigated DCA infusion in surgical 
patients and had shown improvements in carbohydrate oxidation and attenuation 
in POIR. The present study, whilst demonstrating better maintenance of insulin 
sensitivity in the postoperative period using CHO, has also shown that CHO 
ingestion preoperatively results in improved pyruvate flux into the mitochondria 
during the intraoperative period. This is probably because the effect of DCA is 
more pronounced during the first few hours after infusion, where CHO entry is 
facilitated into tissues, including mitochondria, reflected by lower insulin levels at 
the end of operation and during the immediate postoperative period. Studies in 
animals and human volunteers using contracting ischemic human muscle and in 
subjects performing leg extensor exercises have shown that DCA infusion 
improved substrate availability for aerobic ATP production and resulted in 
increased resting PDH activation, less phosphocreatine utilisation and decreased 
glycogen breakdown (Timmons et al., 1998b, Timmons et al., 1996, Timmons et 
al., 1998a, Timmons et al., 1998c). 
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Muscle mitochondrial function was quantified by assaying ATP production during 
the utilization of a number of different substrates. Both CHO and DCA groups 
demonstrated better maintenance of mitochondrial ATP production. Importantly, 
comparison between the groups showed that DCA increased preoperative 
pyruvate mediated mitochondrial ATP production rates (MAPR) above CHO alone, 
which was not evident 48 hours post-surgery. MAPR was higher in the DCA group, 
when Glutamate+Malate and Glutamate+Succinate were used as substrates for 
mitochondrial oxidation (Fig 6.13). Though, based on a relatively heterogenous 
group of patients, using gene expression data and changes in plasma insulin, 
glucose and cortisol levels we have comprehensively demonstrated increased 
glucose oxidation towards a glycolytic pathway and increased mitochondrial ATP 
production, which has not been studied in surgical patients previously. 
In summary, the present study in patients having major abdominal surgery 
supports our hypothesis that administration of either CHO or CHO with DCA, 
attenuates the impairment of CHO oxidation and the development of POIR, 
induced by surgical stress. Furthermore, DCA increased mitochondrial CHO 
oxidation above that achieved by CHO alone, which waned by 48hours post-
surgery.  
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General discussion 
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7.1 Research objectives & Aims 
 
Patients undergoing major abdominal surgery respond to surgical trauma 
postoperatively with a series of cellular and molecular events which contributes to 
the development of POIR. The nature of the underlying disease, type of surgery, the 
magnitude of the surgical procedure and the metabolic response to surgery could 
have a negative impact on patient recovery. The resultant stress-induced 
hyperglycaemia is reported to be associated with increased postoperative 
morbidity and delayed recovery (Thorell et al., 1999b, van den Berghe et al., 2001, 
Jackson et al., 2012). ERAS protocols attempt to attenuate the surgical stress 
through a series of perioperative interventions, including reduced preoperative 
fasting and ingestion of oral carbohydrate drinks preoperatively. However, the 
underlying molecular mechanisms contributing to the development of 
postoperative insulin resistance in patients having major abdominal surgery and the 
mechanisms by which the preoperative interventions attenuate surgical stress are 
not well defined. 
The present thesis examined the molecular mechanisms of the metabolic response 
to surgical trauma which contributes to the development of POIR. Thus the overall 
aims were as follows: 
(1) To examine the evidence behind the principles of the ERAS pathway and the 
effect of preoperative carbohydrate loading on postoperative outcomes, in patients 
undergoing major abdominal surgery using a systematic and meta-analytical 
approach  
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(2) To study the molecular basis of the metabolic response to surgery underlying 
the development of postoperative muscle insulin resistance with particular 
emphasis on changes in insulin signalling and mitochondrial function. Specifically, to 
investigate whether alterations in the insulin mediated, Akt/FOXO and PDK4 
signalling pathway underlies the development of insulin resistance following 
surgical stress and whether these changes in the signalling mechanisms were 
associated with increased inflammatory gene expression in skeletal muscle and  
(3) To study the effect of interventional strategies such as preoperative 
carbohydrate loading, in attenuating the development of POIR in patients 
undergoing major abdominal surgery. 
 
7.2 Study outcomes 
 
ERAS pathway was reported to attenuate the stress response to surgery and enable 
patient recovery. The objective of the meta-analysis presented in chapter 3, was to 
study the differences in outcomes in patients undergoing major elective open 
colorectal surgery within an ERAS pathway and those treated with conventional 
perioperative care. The randomized controlled trials comparing ERAS with 
conventional perioperative care were selected and assessed for methodology quality 
using standard methods recommended by the Cochrane Collaboration. The outcome 
measures studied were length of hospital stay, complication rates, readmission rates 
and mortality. Six randomized controlled trials with 452 patients that satisfied the 
eligibility criteria were included for the meta-analysis. The number of individual ERAS 
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interventions used in the studies ranged from 4-12, with a mean of 9. The length of 
hospital stay [weighted mean difference (95% confidence interval): -2.55 (-3.24, -1.85)] 
was significantly reduced by 2.5 days and complication rates were reduced by 47% 
[relative risk (95% confidence interval): 0.53 (0.44, 0.64)] were significantly reduced in 
the enhanced recovery group. There was no statistically significant difference in 
readmission and mortality rates. Implementing ERAS protocols in patients having 
major elective colorectal surgery resulted in reduced length of hospital stay and 
complication rates after major elective open colorectal surgery without compromising 
patient safety. The common perioperative interventions used in the studies were 
preoperative carbohydrates, avoidance of bowel preparation, epidural analgesia, early 
postoperative mobilisation, early postoperative feeding and avoidance of opiate 
analgesia. The beneficial effects of these interventions were well reported previously 
and might have contributed to the reduced risk of complications postoperatively. 
Differences in implementation of interventions and reduced compliance contributed 
to the heterogeneity of the results in individual studies. For example, not all patients 
used epidural analgesia in some studies (Anderson et al., 2003, Serclova, 2009). 
However, the beneficial effects of reduced complications and length of stay in this 
group of patients was probably, a result of the cumulative effect of interventions such 
as preoperative feeding and early enteral nutrition which might have resulted in 
patients having surgery in a metabolically fed state and consequent attenuation of the 
stress response.  
This view was confirmed in the meta-analysis of RCTs on preoperative oral 
carbohydrate treatment in elective surgery (chapter 4). This study included twenty-
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one RCTs, consisting of 1685 patients (733 in CHO group and 952 in control group). 
The studies were categorised according to the type of surgery as those having major 
abdominal surgery, studies in which operative procedures with expected length of stay 
less than or equal to 2 days, and those having orthopaedic surgery and a subgroup 
analysis was performed. The outcome measures were length of stay, development of 
POIR, complications, nausea and vomiting. No overall difference in length of stay was 
noted for analysis of all studies or subgroups of patients undergoing surgery with an 
expeĐƚĞĚ ŚŽƐƉŝƚĂů ƐƚĂǇ A? ? ĚĂǇƐ Žƌ ŽƌƚŚŽƉĂĞĚŝĐ ƉƌŽĐĞĚƵƌĞƐ ? ,ŽǁĞǀĞƌ ? ƉĂƚŝĞŶƚƐ
undergoing major abdominal surgery following CHO had reduced length of stay [mean 
difference, 95% confidence interval: -1.08 (-1.87 to -0.29); I2=60%, p=0.007]. CHO 
reduced postoperative insulin resistance with no effects on in-hospital complications 
over control (risk ratio, 95% confidence interval, 0.88 (0.50-1.53), I2=41%; p=0.640). 
There was significant heterogeneity amongst studies and therefore quality of evidence 
was low to moderate. Three studies included utilised the hyperinsulinaemic-
euglycaemic clamp technique to measure relative changes in insulin sensitivity and 
demonstrated significant reduction in development of POIR in CHO group compared 
with control (Soop et al., 2001, Soop et al., 2004a, Nygren et al., 1998a). Others used 
the HOMA-IR method and showed a reduction in postoperative HOMA-IR values 
between CHO and control.(Mathur et al., 2010, Dock-Nascimento et al., 2012, Perrone 
et al., 2011). However, the quality of evidence for these outcomes ranged from low to 
moderate.  
In general, the results from both the studies on ERAS protocols and preoperative CHO 
in surgical patients showed beneficial postoperative outcomes. The quality of studies 
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reflected the variations in clinical practices in different centres and differences in 
implementation of strict quality control measures when conducting randomised 
studies involving surgical patients. However, they show in common that surgical stress 
can be attenuated by simple preoperative interventions and that reduction of POIR in 
surgical patients leads to better postoperative clinical outcomes. Hence, it seemed 
important to understand the molecular mechanisms underlying the beneficial effects 
of these interventions to validate and optimise perioperative care in patients having 
surgery. Therefore, prospective studies were undertaken in patients having major 
abdominal surgery to investigate the mechanistic basis of metabolic response to 
surgery and the mechanisms underlying the development of POIR in surgical patients 
(Chapters 5 and 6). 
The study in patients undergoing major abdominal surgery, described in chapter 5, 
suggested that surgical stress induced inflammatory response, was associated with 
inhibition of Pyruvate Dehydrogenase Complex (PDC) controlled carbohydrate 
oxidation through the Akt/FOXO mediated upregulation of PDK4 and may be an 
important mechanism in the development of POIR. PDC activity determines the 
pyruvate flux in to the mitochondria for ATP production and thus, controls the rate-
limiting step in carbohydrate oxidation, the oxidative decarboxylation of pyruvate to 
acetyl-CoA to be used in the tri-carboxylic acid (TCA) cycle. The mRNA expression data 
showed significant up-regulation of genes, FOXO1 and PDK4 mRNA up-regulation 
postoperatively. This was also associated with a significant fold-change (p<0.05), in 
protein expression for FOXO1 (11.21±4.08), PFOXO1 (7.82±3.28) and PDK4 
(4.49±1.85). An increased expression of FOXO mRNA was likely to be responsible for 
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the up-regulation of the ubiquitin ligase, MAFbx (11.5-fold in rectus, 6.5 Wfold in 
vastus), which is involved in atrophy signalling.  
Akt is an important mediator of the protein synthesis pathway via GSKɴŝŶŚŝďŝƚŝŽŶĂŶĚ
regulation of 43S pre-initiation complex and by mTOR activation. However, in the 
present study (chapter 5), Akt was not significantly upregulated. The FOXO family of 
transcription factors are phosphorylated by Akt, which renders them inactive. 
However, the study showed that surgical stress induced significant up-regulation of 
mRNA expressions of FOXO, which is a transcriptional activator of its downstream 
target, MAFbx, the ubiquitin ligase, involved in the ubiquitin-proteosome mediated 
protein degradation pathways. Since FOXO transcription factors are known to regulate 
PDK4 by transcriptional activation, it is probable that a common signalling pathway 
involving Akt/FOXO and PDK4, may be involved in the impairment of carbohydrate 
oxidation and muscle protein breakdown, in patients undergoing major abdominal 
surgery.  
The principal trigger which induces the aforementioned changes in Akt/FOXO 
signalling, could be the surgical stress induced inflammatory response, mediated by 
cytokines which is reported to affect IRS-1 binding (Rui et al., 2001) and inhibit Akt1 
signalling (Medina et al., 2005, Latres et al., 2005), and in turn leads to decreased 
phosphorylation of FOXO family of transcription factors and up-regulation of FOXO 
gene targets such as MAFbx and PDK4 (Sandri et al., 2004, Crossland et al., 2008). In 
keeping with this, after the initiation of inflammatory response following surgery, both 
the cytokines IL-6 and TNF-ɲŵZEǁĞƌĞĨŽƵŶĚƚŽďĞƵƉ-regulated (p<0.05). Plasma 
concentrations of IL-6 and TNF-ɲ were also found to be significantly increased 
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postoperatively. Moreover, another important finding of this study, which might have 
contributed to the inflammatory response, is the significant increase in gut 
permeability following surgery (% urinary excretion of 51Cr-EDTA): Pre surgery: 4.79 ± 
0.82; Post-surgery: 7.30 ± 1.03; p<0.02. Increased gut permeability may enable 
bacterial translocation, which may exaggerate the inflammatory process, especially in 
patients having major abdominal surgery. Evidence shows that disruption of intestinal 
tight junctions or increased para-cellular permeability due to an intestinal disease, 
injury or an inflammatory mediated insult, may allow entry of luminal antigens, 
thereby triggering an exaggerated immune response (Clayburgh et al., 2004, 
Hollander, 1999). The translocated bacteria or their products in the portal or systemic 
circulation may induce a cytokine response via activation of macrophages in either the 
liver or mesenteric lymph nodes and may influence the ongoing metabolic processes 
(Deitch et al., 1994, Meakins, 1990). However, the presence of bacteremia was not 
tested in the study and therefore, whether surgical stress resulted in bacterial 
translocation could not be ascertained, despite the study confirming increased gut 
permeability following surgery. In summary, the studies have demonstrated that PDK4 
plays a significant role in causing POIR (Chapter 5). Thus it can be inferred that 
impaired PI3K/Akt1/FOXO signalling and the resultant up-regulation of PDK4 leads to 
the inhibition of PDC activity and impaired carbohydrate oxidation that may contribute 
to POIR in patients having major abdominal surgery.  
From the meta-analysis of RCTs comparing CHO with placebo drinks or control 
(Chapter 4), we showed that preoperative carbohydrate drinks in patients undergoing 
major surgery was associated with improved postoperative outcomes of length of stay 
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and reduction in POIR. Therefore, a logical approach would be to study the effect of 
CHO on the aforementioned changes in metabolic signalling pathways and POIR. It was 
hypothesised that CHO and the drug, DCA which is known to increase PDC activity by 
inhibiting PDK4, will attenuate the impairment of carbohydrate oxidation secondary to 
surgical stress. The aim of the study described in Chapter 6, was to establish whether 
preoperative oral carbohydrate treatment (CHO) combined with an intravenous 
infusion of dichloroacetate (DCA), will maintain the substrate-specific, postoperative 
MAPR and attenuate the surgical stress response and whether by increasing 
preoperative PDC activity and flux using DCA infusion will improve POIR over and 
above that seen with CHO ingestion alone. The results showed that administration of 
either CHO or CHO with DCA, attenuates the impairment of CHO oxidation and the 
increased expression of mRNA of important molecular targets responsible for POIR, 
such as FOXO and PDK4, was not evident following either CHO or DCA treatment 
preoperatively. The results showed no significant differences in mRNA expression 
between preoperative and postoperative levels for both CHO and DCA. However, a 
major limitation of this study is that comparisons with a control group with no CHO or 
DCA could not be performed due to issues with recruitment and analysis. Therefore, 
the results were presented for the CHO and DCA group only, limiting the validity of any 
conclusions about effects of CHO alone on the metabolic responses.  
The study also showed plasma concentrations of glucose were found to be lower in 
DCA group 48 hours post-surgery. Interestingly the insulin requirements in the CHO 
group were significantly higher to suppress the plasma glucose concentrations to that 
of DCA group, 48 hours after surgery. However, this finding did not correlate with 
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increased cortisol as would be expected following surgical stress. The concentrations 
of the counter-regulatory hormone were not different between the two groups, at 
these time points. There was also a better maintenance of insulin sensitivity as noted 
with the measurements of HOMA-IR in both CHO and DCA.  
Both CHO and DCA group showed maintenance of muscle mitochondrial function, 
when quantified by assaying ATP production during the utilization of a number of 
different substrates for mitochondrial oxidation. Importantly, comparison between the 
groups showed that DCA increased preoperative pyruvate mediated mitochondrial 
ATP production rates above CHO alone, which was not evident 48 hours post-surgery. 
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7.3 Future work and limitations 
 
The current thesis examined the mechanistic basis of metabolic response to surgery 
and the development of postoperative insulin resistance in patients having major 
abdominal surgery. The studies highlight that surgical stress contributes to POIR, 
secondary to decreased carbohydrate oxidation and also resulted in impaired 
mitochondrial function. The results from the observational study in patients having 
major abdominal surgery (Chapter 5) have shown both, flux through PDC, and 
mitochondrial ATP production were significantly reduced postoperatively. Although, 
the results proved the hypothesis that surgical stress induced increase in PDK4 and 
inhibition of PDC activity contributes to the development of POIR, certain important 
mechanisms that link surgical stress with POIR remains to be ascertained.  
Mitochondrial ATP production (MAPR) is a marker of mitochondrial function, whereby 
mitochondria generates energy in the form of ATP, through oxidation of three 
different energy sources namely carbohydrates, fats and proteins. In the setting of 
surgical stress a decrease in PDC activity secondary to increased PDK4 may contribute 
to reduced pyruvate flux into the tri-carboxylic acid cycle. However, the results 
showed that MAPR was significantly depressed for all the substrates used for ATP 
synthesis. This suggests an overall impairment in mitochondrial function, and not only 
when pyruvate was used as a substrate. Therefore it is difficult to establish whether 
increased PDK4 and decreased PDC contributed to the overall impairment in 
mitochondrial function or whether other mechanisms may be involved, for example, 
oxidative stress which contributes to mitochondrial dysfunction.  
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It was shown that pro-inflammatory cytokines in plasma as well as muscle (mRNA and 
proteins) was increased following surgery. The origin of the cytokines that mediates 
the inflammatory response in surgical patients is not clear. Biopsies were taken from 
both the abdominal rectus and the vastus muscles in the thigh, which showed similar 
response in mRNA expression of IL-6 and TNF-ɲ ?ĂůďĞŝƚƚŽĂůĞƐƐĞƌĚĞŐƌĞĞŝŶƚŚĞǀĂƐƚƵƐ ?
The surgical trauma to the abdomen wall in itself could be a significant trigger in 
initiating the inflammatory response and release of cytokines. In addition, bowel 
handling during the surgical procedure could also result in translocation of gut bacteria 
into the circulation. Nevertheless, it can be reasonably assumed that the surgical 
trauma would result in a greater inflammatory response than increased gut 
permeability and triggered the stress response. 
Finally, a glucose tolerance test and HOMA-IR, were used as a surrogate marker of 
POIR. Performing a hyperinsulinaemic-euglycaemic clamp study, to assess POIR in 
surgical patients was considered to be difficult due to clinical constraints involved in 
the postoperative period, for example, intensive care, pain, patient compliance etc. 
However, since the commencement of this research work, other studies that followed 
have shown that it is feasible in most patients. Therefore future work should use the 
clamp technique as a gold-standard for confirming insulin resistance in clinical settings. 
Future work could also focus on including patients who may be insulin-resistant, 
preoperatively in whom there is an increased risk of postoperative morbidity (for 
example, in diabetics) and study the effects of CHO and DCA on POIR in this group. 
Providing there are significant benefits associated with DCA, future studies using CHO 
and DCA can include specific subsets of patients in different clinical settings, including 
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sepsis, obesity and cancer. It would also be interesting to study the effects of DCA in 
the emergency surgical setting, where provision of CHO would not be feasible and DCA 
infusion can be administered preoperatively. 
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8.1 MAPR analysis (Mitochondrial ATP Production Rate) 
This test allows the analysis mitochondrial ability to utilise different substrates in its 
production of ATP.  
Principle 
The monitoring reagent contains firefly luciferase which emits light at a magnitude 
proportional to the amount of ATP present. Measuring values over time allows data 
to be generated for the respiration rates of mitochondria utilising different 
substrates.  
After a period of time ATP is dispensed into the cuvettes, as a result the 
luminescence should show a marked jump in magnitude. This jump is due solely to 
the known amount of ATP (in picomoles) dispensed. This result can be used as a 
calibrator in order to work out the change in ATP/min from the change in mV/min. 
(mV are the units of the machine). 
Having worked out the rates of ATP production in each cuvette, this data can be 
interpreted further by using citrate synthase activity (for example) as a marker for 
mitochondrial quantity. (x picomoles ATP produced / x units of citrate synthase 
activity, for example). 
Preparation of mitochondria from muscle tissue ʹ Differential Centrifugation 
Using a minimum of 30mgs of tissue (100mgs max, 60-80 optimum). 
All of the following should be performed on ice/ in a pre-cooled centrifuge (~4oC) 
 ? Cut away any visible connective tissue with a clean, sharp blade and proceed to 
finely dice the sample to make homogenisation easier. Weigh the sample and make a 
note. 
 ? Transfer the sample to a cooled glass homogenisation vessel and add (20 x 
weight (mgs))µl of homogenisation buffer. (KCl 100mM, KH2PO4¬ 50mM, Tris 50mM, 
MgCl2 5mM, EDTA 1mM, ATP 1.8mM) 
 ? Homogenise with pestle homogeniser for 3 minutes on ice, and transfer crude 
ŚŽŵŽŐĞŶĂƚĞƚŽĂ ?ŵů ‘ŵƵƐĐůĞĞǆƚƌĂĐƚŝŽŶƚƵďĞ ? ?ŽƌĞquivalent).  
 ? In a correctly balanced centrifuge, spin the homogenate for 3mins, 650G (RCF) 
 ? Transfer supernatant to a clean tube and discard the cell debris. 
 ? Spin the supernatant for 3mins @ 15000G  
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 ? A small brownish pellet should form which contains the desired mitochondria. 
Remove and discard the supernatant and pipette half of the original buffer volume 
(homogenisation buffer), and re-suspend the pellet via gentle agitation with the 
pipette. 
 ? Spin for 3mins @ 15000G. This is to wash the pellet. 
 ? The pellet will reform. After discarding the supernatant, pipette 1/10th of the 
original buffer volume (though no less than 100µl) of resuspension buffer (pH 7.2, 
Human Serum Albumin (essentially FFA free) 0.5mg/ml, sucrose 240mM, 
monopotassium phosphate 15mM, magenesium acetate tetrahydrate 2mM, EDTA 
0.5mM) 
The resulting mitochondrial suspension must NOT be frozen if MAPR analysis is 
required  W this must be performed immediately after the preparation. It can be 
frozen at -20oC for later enzyme complex analysis. 
 
Method 
Having isolated mitochondria from tissue extracts the following cuvette compositions 
should be made. Each cuvette tests a different substrate (or blank) and should be 
made in duplicate for accuracy. 
On the BioOrbit Luminometer, each cuvette: 
800µl ATP monitoring reagent. (Lyophilized ATP monitoring reagent, (containing 
firefly luciferase, D-luciferine 0.1g/L, L-luciferine 4mg/L, bovine serum albumin 1g/L, 
and Na2P2O7 1µM) dissolved in pH 7, sucrose 0.19M, monopotassium phosphate 
19mM, magnesium acetate tetrahydrate 2.5mM, EDTA 0.7mM) 
140µl substrate (test each of the combinations below)  
Glutamate 16.4mM/ Succinate 15mM 
1. Palmitoyl-L-Carnitine 5µM/ Malate 1.5mM (with Human Serum Albumin 
0.14mg/ml) 
2. Pyruvate 50mM/ Malate 22mM 
3. Succinate 2.5mM 
4. Glutamate 32.75mM/ Malate 22mM 
50µl of 12mM ADP; 10µl diluted (in resuspension solution) mitochondrial 
suspension. (diluted 300X  W overall dilution in cuvette: 30000X), Read the cuvettes in 
the luminometer. 
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8.2 Muscle Acetyl CoA Analysis 
 
Following PDC extraction protocol 
 
GOT 
[14C] aspartate + ketoglutarate ÅÆ [14C] oxaloacetate + glutamate 
 
               Citrate Synthase 
[14C] oxaloacetate + acetyl coA ÅÆ [14C] citrate + coA 
 CoA is cleared by NEM, leaving detectable [14C] citrate 
 
1. Prepare [14C]oxaloacetate ʹ quantities here give 600µl (30 samples) 
 
Prepare Master Mix 
 
20µl HEPES/KOH 0.5M pH 7.4 
 30µl EDTA 11mM pH 7.4 
  ? ?A?ůɲ-ketoglutarate (FRESH  W 4.5mg/ml)  W on D52 shelf 
 100µl [14C] aspartate 40µM 
 10µl GOT 1:15 - 10µl stock/ 190µl H2O 
 
Gently vortex master mix, incubate at room temperature for 10 minutes 
 
Add 20µl PCA 1M, (stop transamination), vortex gently 
 
Incubate for 5 minutes at room temperature, and then leave on ice 
 
Add 40µl ice cold KOH 0.6M, vortex, leave on ice for 5 minutes 
 
Add 360µl EDTA 11mM pH 7.4, vortex gently 
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2. Formation of [14C]citrate 
 
Add 20µl of sample to each tube (for rat studies) 
 
Add 30µl NEM 
 
Add 20µl of [14C] oxaloacetate solution to each tube 
 
Add 10µl CS 1:10 (2mgs/ml) to each tube to start the reaction. Do this every ten 
seconds with a vortex in between 
 
Incubate for 20 minutes at room temperature 
 
Make Transamination Mix  W this removes un-reacted [14C] oxaloacetate by 
converting it back to [14C] aspartate 
 100µl GOT (6.5mg/ml) 
 900µl potassium glutamate 178mM 
 200µl H2O 
 
Add 30µl transamination mix, to the tubes every ten seconds 
Incubate for 20 minutes at room temperature 
Make ion exchange resin (1 part resin H+/ 2.5 parts H2O)  W this will be used to 
separate [14C] aspartate from [14C] citrate 
Add 1ml of resin to each tube, whilst the resin is continuously vortexing 
Vortex twice and leave to sediment 
Remove 500µl of liquid into scintillation vial 
Add 5ml of scintillation fluid and vortex 
DĞĂƐƵƌĞɴ-radioactivity in scintillation counter  
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8.3 Glycogen Assay 
 
A. Chemicals: 
-Triethanolamine 
-KOH 
-Mg(CH3COO)2 x 4H2O 
-EDTA Na2 x 2H2O 
-HK (Bakers yeast)  Sigma   H-4502 200 U (lyophilized) 
-Amyloglucosidase  Boehringer  208 469 2 g 
-Glu-6-P dehydrogenase Sigma    G-5885 200 U (lyophilized) 
 
B. Muscle solubilisation and glycogen hydrolysis: 
-G5 0.1 M NaOH 
-G6 0.1 M HCl 
Check that 1 vol of G5 neutralises 1 vol of G6. If not, write down the neutralisation 
ratio. 
-G7  -0.2 M citric acid form   8.40 g 
-0.2 M Na2HPO4      5.68 g 
Up to 200 ml solution, pH 5.0 with NaOH 5M 
-Amyloglucosidase 200 mg/ml G7  
Mix G7 and G6 in a ratio of 1:3 if G6 neutralises G5 in a 1:1 ratio. If not, adjust the 
ratio between G7 and G6 such as 4 volume of mix G7+G6 neutralises 1 volume of G5. 
-Solubilise 0.5-2.0 mg powder in 100 Pl G5  
  2.01-3.0 mg powder in 120 Pl G5 
  3.01-4.0 mg powder in 160 Pl G5 
and so on, by heating at 80 qC for 10 min. 
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NB Make sure that the muscle is well solubilised in NaOH before heating at 80 qC. 
You do that by hard mixing. Muscle will become a greenish clear solution after 
incubation. 
-Spin briefly (2-3 s) the samples to condense down.  
-Cool the samples to the room temperature. 
-For every 80 Pl G5 add 320 Pl of neutralisation mix (80 Pl G6 and 240 Pl G7) and 10 
Pl amyloglucosidase. 
-Incubate at room temperature for 60 min. 
-After 60 min incubation you can either, spin the samples and transfer the 
supernatant to new test tubes. Equally, you can freeze the samples and spin them at 
a later date. 
C. Glucosyl units assay: 
(2) Glu 6-P + NAD Æ P-gluconolactone + NADH  Glu-6-PDH 
(1) Glu + ATP Æ Glu 6-P + ADP     HK 
The increase in NADH is measures at 366 nm where H=3.4 Pmol/cm2 
G1 Reagent buffer: 
Triethanolamine  100 mM  7 g/100 ml 
KOH               40 mM   0.8 g/100 ml 
Mg(CH3COO)2 x 4H2O 30 mM   2.4 g/100 ml 
EDTA Na2 x 2H2O              1 mM   0.14 g/100 ml 
Adjust to pH 8.2 with further KOH. 
-Add 200 Pl water to each of HK and Glu 6 PDH vials. Mix 1:1. Keep the mix on ice. 
-To 80 Pl G1 add 5 Pl ATP 45 mM (27.72 mg/ml), 5 Pl DTT 60 mM (9.36mg/ml), 10 Pl 
NAD 30 mM (19.92 mg/ml) and 150 Pl H2O. Add 25-50 Pl sample. Mix. 
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Measure absorbance at 344 nm for 3-4 min (blank). Start the reaction by adding 2 Pl 
of a mixture of Glu 6PDH and HK. Record the absorbance for 10 min. 
Calculations:  
mmol glucosyl units/kg dry muscle=(' abs * extraction factor (L/Kg)*variation in 
volume during the glucosyl units assay*dilution factor)/(sample volume*extinction 
coefficient).  
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8.4 Lactate assay 
 
I. Preparing the solution: 
PCA  W 0.5 MOL 
EDTA 1 mMol 
300 µl ŽĨƚŚŝƐŵŝǆƚƵƌĞŝŶĞĂĐŚĞƉƉĞŶĚŽƌĨ ?Ɛ ?ŽŶĞĨŽƌĞĂĐŚƐĂŵƉůĞ ? 
Add 100µL of whole blood and shake vigorously. Put it on ice-bath as soon as possible 
for 5 minutes. 
Spin for 2 minutes (22000G) 
Take 300µl of supernatant and transfer to new test tubes (on ice). 
Add 50µl of 2.2 mol Bicarbonate 
Gently Vortex and leave on ice for 5 minutes 
Centrifuge again after 5 minutes (1 minute on high speed  W 22000G) 
Take supernatant and transfer to new eppendorf test tubes and store @ -80®C. 
 
II. ANALYSIS 
Have a minimum of 600µl final volume in the cuvette. 
The assay is carried out at pH 10; at this pH beef heart LDH is more stable than the 
skeletal enzyme (See Beohringer notes). 2-Amino-2methyl-1-propanol buffer with a pKa 
of 9.9 is suitable buffer. 
1. 2-Amino-2-methyl-1-propanol buffer 1M pH 10.0 = 8.9 g ( if liquid 9.5ml)/100 ml 
solution. Set pH 10.0 with HCL 6M. Make aliquots (10mls). Store at : -20®C 
2. Tris 20 mM pH 8.0 = 0.24 g/100 ml. Set pH with HCL 1M. Store at @ -20®C 
3. Hydrazine 1M. Mix 5 ml of the 20 M stock solution to 100 ml solution. Store @ room 
temperature. 
4. NAD+ 100mM = 70mg/ml water. Make aliquots (50 µl). Store at @ -20®C 
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5. Lactate Dehydrogenase (LDH) stock (beef heart) Boehringer 106984 (50 mg/10ml or 5 
mg/ml or 250 U/mg or 1250 U/ml). Dilute stock to 550 U/ml with Tris 20 mM containing 
0.02% albumin = @2.3 times dilution. Store @ 4®C. 
6. L-Lactate standard 500µM: 
Disolve 6 mg Na lactate in deionised water then makeup to 100ml solution.  
Make 100µl aliquots. Store at @ -20®C. 
Lactate 500 µM stock   1 3 5 8 10 15 20 
Lactate concentration (cuvette) µM 
Reagent buffer    600 600 600 600 600 600 600 
DI Water                 19 17 15 12 10 5 0
  
 
7. Reagent buffer: 
2-Amino-2,methyl-1-propanol buffer 1M pH 10.0           10.00 ml 
Hydrazine 1M            5.00 ml 
NAD+ 100 mM           0.05 ml  
Add deionised water up to 100 ml solution. 
 
To 600 µl reagent buffer add 10µl DI water and 10µl samples.  
Mix well and after 5 minutes read the initial fluorescence (F1) @ Ex-340 nm/Em-460 nm 
of each cuvette @ 30 second intervals.  
Add 5µl of LDH beef heart 550 U/ml to each cuvette @ 30 second intervals. 
Wait for @ 30 minutes. Keep the cuvettes at dark. Read F2 @ 30 second intervals. 
 
 
